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Synthetic biology aims to make the realisation of novel biological phenomena 
easier, faster and more precise through the design and engineering of biological 
components. This can be attempted using “top-down” approaches, by engineering 
the genomes of extant organisms to make them behave in new ways. Alternatively, 
it can be performed in a “bottom-up” fashion, by designing the characteristics of 
individual molecules and combining them in increasingly complex systems. The 
latter allows for the design of entirely new behaviours through the construction and 
assembly of components that are not observed in nature. Important design targets 
for this bottom-up approach are components that temporally and spatially control 
the expression of genes, that is, transcription factors. These are the targets of the 
work presented in this thesis. 
Transcription factors are ubiquitous and highly diverse. They are also the first point 
of control for the production of all other cellular components, both natural and 
designed. In prokaryotes, transcriptional control can be achieved by actively 
recruiting RNA polymerase to a gene of interest via protein-protein interactions or 
preventing RNA polymerase from binding to DNA by assembling oligomers at a 
promoter. Therefore, in their simplest forms, both transcriptional activators and 
repressors require (1) the ability to bind to DNA and (2) the ability to bind to other 
proteins. By combining protein domains that perform these functions, entirely 
artificial transcription factors can be generated. In the past, this has been achieved 
by combining naturally occurring protein domains. However, advances in rational 
protein design mean we can now design these domains de novo.  
Herein, a set of de novo tetrameric coiled coil-based protein-protein interaction 
domains is rationally designed and characterised in vitro. These coiled coils are 
then used to direct protein-protein interactions in E. coli, demonstrated through the 
design of semi-artificial transcription factors, which can themselves be controlled 
at the transcriptional level. In the future, these constitutively interacting domains 
could be made even more useful through the incorporation of dynamic behaviours, 
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Chapter 1: Introduction 
1.1 Synthetic biology 
Synthetic biology aims to make the design of biological components and 
behaviours readily achievable and routine. The remit of synthetic biology is broad, 
encompassing the design of previously unseen biological molecules, the 
engineering of a cell’s metabolome and the construction of orchestrated 
communities of organisms 1-3. What these seemingly disparate ventures have in 
common is the desire (1) to generate useful products with real world applications, 
and (2) to use these products as tools to expand our understanding of both natural 
and synthetic systems.  
Synthetic biology products can be considered as falling roughly into two categories 
(Figure 1-1) 4,5. The first includes all products that have been derived or modified 
from naturally occurring components, including proteins or whole cells. The second 
covers products that have been designed de novo (from scratch). While the latter 
may aim to recreate natural structures or functions, the use of components with a 
non-natural origin allows the innate complexity that is present in most naturally 
occurring components to be minimised. Approaches taken in this category include 
de novo protein design, xenobiology and protocell design 3,6,7. 
Naturally, there is overlap between the two categories. For example, natural 
proteins can be fused to de novo proteins to make semi-synthetic products, and 
proteins with non-natural structures or functions can be made using only the 20 
canonical amino acids. Additionally, de novo components can be introduced into a 
naturally occurring organism to augment biology by bestowing novel behaviours 
on that organism.  
1.1.1 Engineering approaches 
Approaches that involve the modification of naturally occurring biological parts, 
from proteins to whole cells, fall under the remit of “top-down” synthetic biology 5. 
Genetic engineering can be used to alter the properties and functions of well-




characterised natural components. DNA sequencing and synthesis and genome 
editing technologies like CRISPR/Cas9 have greatly facilitated these endeavours.  
Key examples of whole-cell engineering include ambitious projects such as: the 
chemical synthesis and transplantation of an entire bacterial genome to make 
JCVI-syn1.0, a version of Mycoplasma mycoides 8, as well as a minimal version of 
this genome 9; recoding the genome of Escherichia coli to generate strains that 
use a reduced set of codons, freeing up the remaining codons for the introduction 
of non-standard amino acids 10,11; and the Yeast 2.0 project, which aims to 
synthesise a version the genome of Saccharomyces cerevisiae 12-14. Such projects 
have accelerated the development of tools for DNA synthesis, assembly and 
editing.  
 
Figure 1-1 Summary of synthetic biology approaches. Left, top-down 
engineering approaches that involve modifying naturally occurring parts, 
including protein engineering, genetic circuit design, genome engineering 
and the engineering of microbial communities. Right, bottom-up de novo 
design approaches that involve using natural and non-natural building blocks 
to make new components and systems, including protein design, DNA 
nanotechnology, xenobiology and protocell biology.  




Other examples of biological engineering involve smaller genetic changes that still 
have profound effects on the behaviour of organisms. This includes metabolic 
engineering 2 and the design of synthetic genetic circuits 15. In metabolic 
engineering, existing enzymatic pathways, and the mechanisms that regulate 
them, are modified to increase their productivity or alter their activity. This can 
involve: altering the substrate specificity of metabolic pathways, such that 
organisms can utilise alternate feedstocks 16-19; redirecting enzymatic pathways to 
synthesise different products 20; increasing the productivity of metabolic pathways 
21; and introducing heterologous pathways into industrially relevant hosts 22,23. 
Conversely, in synthetic genetic circuit (SGC) design, biological parts are 
combined in new pathways to make circuits that impart various computer-like 
behaviours on living things, including multi-stable switching 24, logic-gating 25, 
enumeration 26, temporal oscillation 27 and light detection 28. 
Finally, naturally occurring proteins can be modified to alter their function. For 
example, inducible transcription factors can be modified to respond to new ligands 
29 and enzymes can be engineered to have altered substrate specificity 30.  Proteins 
can also be modified to have altered properties such as increased thermal stability 
31,32 or to be simpler by using a reduced amino acid palette 33. These engineered 
parts provide insight into protein sequence-to-structure relationships and also 
generate new components that can be used in metabolic engineering and SGC 
design.  
1.1.2 De novo approaches: biology from scratch 
The de novo design of biological components is a “bottom-up” approach to 
synthetic biology. Individual non-natural components, once realised, could be 
combined in increasingly complex systems until, in theory, something resembling 
a living cell is produced 4.  
These de novo components can also be implemented inside existing organisms. 
This approach offers benefits over simply using naturally occurring biomolecules 
for the following reasons: (1) designed components, such as proteins, can be made 
much simpler than natural ones; (2) de novo components can be designed for 
orthogonality (i.e. with limited cross-interaction with natural hosts or systems); (3) 
designed components should be well understood so should respond predictably to 
modifications to the component or its environment; and (4) de novo components 
could be designed to perform activities that are not observed in nature.  




Nucleic acids have been the focus of extensive study in synthetic biology and 
nanotechnology due to the simple Watson-Crick base pairing that dictates DNA 
and RNA interactions. As well as being vital to their biological functions these 
simple rules that dictate interactions between nucleic acids have been exploited in 
DNA origami and DNA nanotechnology to introduce new structures and functions 
into DNA 34-37. Furthermore, xeno nucleic acids (XNAs) have been able to 
reproduce both natural and artificial functions of nucleic acids, and have been used 
to encode heritable genetic information 38, as catalysts 39 and in nanotechnology 40.  
Further key advances in biomolecular design have occurred in the area of protein 
design. New protein structures and functions that have not been observed in nature 
can be designed using rational and computational approaches 41-44. Using just the 
20 proteinogenic amino acids means designed proteins can be readily introduced 
into organisms. However, the use of non-standard amino acids expands the 
chemical functionality of proteins greatly. For example, the site-specific 
incorporation of fluorescent amino acids has been an especially useful tool for the 
study of protein structure and function 45,46. The development of codon suppression 
technologies, where mRNA codons, tRNAs and aminoacyl-tRNA synthetases are 
co-opted to incorporate non-standard amino acids during in vivo ribosomal 
synthesis 47-49, has facilitated the design of proteins that contain multiple non-
standard amino acids 50. At the extreme of this are foldamers, non-biological 
polymers that adopt specific structures but are made primarily of non-proteinogenic 
monomers, such as the α-branched amino acid 2-aminoisobutyric acid 51. 
However, such polymers can generally only be made using synthetic methods.  
While a truly de novo living cell is certainly a long way from being delivered, 
rationally designed components still represent useful tools for modifying the 
behaviour of existing organisms. SGC design is an area that could particularly 
benefit from the introduction of new components. Currently, most of the parts used 
in SGC design are taken from nature and, while nature contains a wealth of the 
types of component used in SGC design (e.g. transcription factors, promoters, 
reporter genes), only a small number of these are adequately characterised to be 
routinely used. There have been efforts to broaden the array of available parts by 
mining components, such as transcription factors, from natural genomes 52. 
However, such parts must be characterised before they can be reliably 
implemented in SGCs. Therefore, it would be desirable to be able to routinely 
design components for specific tasks in SGCs as they arise. Transcription factors 




represent a particularly useful design target given that they are powerful regulators 
of other cellular components.  
1.2 Transcriptional regulation 
Transcription is the process whereby specific sections of DNA are copied into 
separate RNA molecules by an RNA polymerase (RNAP). The RNA molecules can 
then go on to perform various cellular functions. For example, messenger RNAs 
(mRNAs) are translated into proteins by the ribosome. The correct spatial and 
temporal regulation of transcription is vital for the survival of an organism. 
Additional components, transcription factors, allow an organism to up- or down-
regulate expression of specific genes in response to internal or external cues, 
altering the organism’s behaviour accordingly.  
Transcription in both eukaryotes and prokaryotes involves three steps – initiation, 
elongation and termination – all of which can be targets for regulating the 
expression level of a gene. However, the focus here will be mechanisms for the 
control of transcription initiation in bacteria.  
1.2.1 Bacterial transcription  
1.2.1.1 Bacterial promoters and RNA polymerase 
In prokaryotes, all transcription is performed by a single type of RNAP. Each RNAP 
holoenzyme is made up of a number of different subunits; E. coli has a subunit 
composition of α2ββ′ωσ (Figure 1-2) 53,54. The RNAP core enzyme (α2ββ′ω in E. 
coli) is a processive DNA-dependent RNA polymerase that synthesises RNA in a 
5′ to 3′ direction.  
The RNAP holoenzyme binds bacterial promoters at various regions, including the 
critical -10 and -35 boxes 55. The -10 boxes are generally AT-rich to aid DNA 
melting during initiation. The exact sequences of the -10 and -35 regions influence 
the rate of transcription initiation by affecting the rate of strand unwinding and the 
strength of RNAP binding. Bacterial promoters may contain additional Upstream 
(UP) elements, AT-rich regions 40-60 bp upstream of the transcription start site 
that are also contacted by components of RNAP 55. Finally, bacterial promoters 
may also contain other sequence elements including binding sites for transcription 
factors.  




The active site of RNAP is made up of the β and β′ subunits, which form a “crab 
claw” shape 56. A number of channels exist between the core of the claw and the 
protein surface: the primary channel, which accommodates downstream double-
stranded (ds) DNA and the nascent RNA-DNA hybrid; the secondary channel, 
which allows nucleotide triphosphate entry; and the RNA exit channel. Catalysis 
occurs in the primary channel, at the base of the claw, and requires two Mg2+ ions 
coordinated via evolutionarily conserved residues 57.  
A dimer of α subunits is located on the outside base of the claw 58. Through 
interactions with the β and β′ subunits via their N-terminal domains (α-NTDs), the 
dimer has a role in initiating RNAP assembly 59,60. The α subunits can also interact 
with promoter UP elements via their C-terminal domains (α-CTDs). This has a role 
in activating transcription initiation 61-64. The α-CTDs also interact with transcription 
factors such as the catabolite activator protein (CAP) 65. The α-NTDs and α-CTDs 
are joined by flexible linkers 66,67.  
The ω subunit interacts predominantly with the β′ subunit 68 and has various roles 
including maintaining the structure and function of this subunit and in the assembly 
of the RNAP core enzyme 69-71.  
Finally, the σ subunit, or σ factor, is responsible for promoter selection and is 
required for transcription initiation 72. Unlike the other RNAP subunits, there are 
multiple different σ factors, which are active under different conditions; in E. coli 
there are seven σ factors 73. The various σ factors have different promoter 
specificities and the RNAP holoenzyme is directed to specific genes depending on 
 
Figure 1-2 Schematic of E. coli RNA polymerase holoenzyme. The β and β′ 
subunits make up the active site; the α dimer facilitates RNAP assembly and 
contacts Upstream elements to activate transcription initiation; the ω subunit 
stabilises the β′ subunit; the σ subunit is responsible for promoter selection 
and binds the -10 and -35 boxes of the promoter (a σ70 family σ factor is 
shown). +1 is the transcription start site.  




the identity of its σ factor. The σ factors can be classified into two groups depending 
on their structure: the σ70 family, named for the E. coli “housekeeping” σ factor 74; 
and the σ54 family 75. The σ70 family members bind promoter DNA at the -10 and -
35 hexamers via the σ2 and σ4 domains, respectively 74,76,77. Conversely, the σ54 
family members bind to a different type of promoter with conserved -12 and -24 
regions 75.   
1.2.1.2 The stages of transcription: initiation, elongation and termination 
In all domains of life, transcription proceeds along three main steps as outlined 
briefly below 77,78. The first step, initiation, is further split into a number of sub-steps 
(Figure 1-3) 79. Initially, the RNAP holoenzyme binds to DNA non-specifically and 
undergoes promoter search 80,81. On encountering a suitable promoter, RNAP 
binds tightly to the DNA via the σ subunit to form the closed promoter complex, 
RPc. Additional contacts may be made to the DNA UP elements by the α subunits 
61-63. Regions of σ also bind to the active site and to the RNA exit channel, occluding 
them both 82. The complex then undergoes isomerisation to form the open 
promoter complex, RPo. This involves stabilisation of the unwound state of the AT-
rich -10 box by the σ2 domain. This leads to the formation of an open transcription 
bubble of 12-15 nucleotides (nt), which extends past the transcription start site (+1) 
83. Further conformational changes also remove σ from the active site, which is 
then occupied by single-stranded (ss) DNA. The RPo complex then performs 
multiple rounds of abortive initiation where short RNA molecules are repeatedly 
synthesised 84. Here, RNAP is bound to upstream promoter DNA while also pulling 
downstream DNA into the enzyme active site, resulting in DNA scrunching. The 
strain from the scrunched DNA and the continued occlusion of the RNA exit 
channel result in the dissociation of the abortive transcripts. Eventually, a long 
enough RNA molecule is made (11-15 nt) to expel σ from the RNA exit channel 82. 
Further conformational changes occur in σ that weaken its affinity for both DNA 
and the RNAP core enzyme and it ultimately dissociates, forming a highly 
processive elongation complex (EC) that escapes the promoter and continues 
transcription elongation 77. The RNAP core enzyme then progresses along the 
DNA. Elongation does not proceed at a uniform rate and the EC may pause. This 
can be a point of transcriptional control 85,86. 
Transcription is completed by termination. In bacteria, two methods exist for 
termination at the end of genes 86. The first, Rho-dependent termination, involves 
an ATP-dependent helicase, Rho 87,88. This binds to rut sites in the nascent RNA 




and then translocates along the RNA towards RNAP until it reaches a release site, 
whereupon RNAP is dissociated from the RNA. The second type of termination, 
Rho-independent or intrinsic termination, involves inverted repeats in the transcript 
that form an RNA hairpin loop, followed by a poly-U stretch 89,90. The loop causes 
RNAP to pause and the weakly associated A:U hybrid falls apart, releasing RNAP.  
1.2.1.3 Control mechanisms: alternative σ factors and transcription factors 
Organisms can alter their transcriptional profiles to adapt to changing 
environmental conditions. Bacteria can achieve this in many ways, including 
through the use of alternative σ factors and transcription factors.  
As introduced above, σ factors are the part of the RNAP holoenzyme responsible 
for promoter selection. In E. coli the housekeeping σ factor, σ70, is the predominant 
σ factor active during logarithmic growth 73. However, under different 
 
Figure 1-3 Stages of transcription initiation with the bacterial RNAP 
holoenzyme. Figure adapted from reference 77.  




circumstances, such as stress conditions, six alternative σ factors may become 
dominant 73. The different σ factors are responsible for regulating the expression 
of multiple genes, which are expressed from related promoters 91. This allows for 
widespread transcriptional changes using a relatively simple shared mechanism. 
For example, σ32 is the heat shock σ factor, which becomes active at elevated 
temperatures and helps the cell recover from the potential heat damage 92-94. In the 
σ32 mRNA, the start codon is occluded within a stem and loop structure 95. Elevated 
temperatures melt this RNA secondary structure allowing σ32 to be translated, 
leading to an increase in the level of this protein, which can then compete with the 
other σ factors for RNAP-binding 96,97. The σ32 RNAP holoenzyme then initiates 
transcription at relevant promoters, leading to an increase in the expression of 
chaperones, proteases and other proteins that help the cell recover on returning to 
its optimal growth temperature 98.  
The engineering of σ factors has been proposed as a means of generating new, 
orthogonal transcriptional regulators for synthetic biology 99. For example, σ factors 
from Bacillus subtilis can be used for orthogonal gene expression in E. coli 100. 
Additionally, mining of bacterial genomes for simple, two-domain σ sigma factors 
yielded a set of 20 σ factors with associated promoters that did not show any cross 
talk with each other 101. The DNA binding domains of these σ factors could also be 
mixed and matched to generate new σ factors with new DNA-binding 
specificities 101.  
Beyond alternative σ factors, bacteria possess a number of transcription factors 
that act to increase or decrease the expression level of a given gene above or 
below the basal level set by the σ factor and its binding to the -10 and -35 boxes. 
These transcription factors are classed as activators and repressors, respectively 
and they largely act at the various sub-steps of initiation. E. coli is predicted to have 
300-350 different transcriptional regulators 102. Many of these, such as CAP, 
regulate multiple genes while a small number act at a single promoter 103,104. The 
latter group includes the model bacterial transcription factor, the Lac repressor. 
Transcription factors are themselves usually controllable, for example via small-
molecule binding 105. This allows an organism to sense features of its environment, 
such as metabolite availability, and change its transcriptional profile accordingly.  
CAP is a transcriptional activator that acts at two different classes of promoter, 
class I and class II, in which the CAP-binding sites are located at different positions 
106. CAP uses a different mode of action at each class of promoter. In class I 




promoters, CAP binds the DNA upstream of the -10 and -35 boxes and contacts 
the α-CTD of RNAP 65. The additional contacts stabilise RNAP at the promoter in 
the closed conformation. In class II promoters, CAP binds the DNA at a site 
overlapping the -35 box and makes more extensive interactions with RNAP, 
binding the α-CTD, the α-NTD and the σ factor 107,108. As well as initially stabilising 
RNAP at the promoter in the closed promoter complex, this also promotes 
isomerisation of RNAP to form the open promoter complex 106. CAP is involved in 
the regulation of almost 200 genes and it is itself regulated by cyclic AMP (cAMP), 
only binding its specific DNA sites when complexed with cAMP 103,106. Thus, via 
CAP, the availability of nutrients has a large effect on the metabolic profile of 
bacteria. 
This recruitment/stabilisation method for transcription activation has been relatively 
simple to mimic with artificial systems. For example, introducing a protein-protein 
interaction between the α or the ω subunit of RNAP and a heterologous DNA-
binding domain leads to an increase in expression of genes whose promoters 
contain the corresponding DNA sequence as the mutant RNAP is recruited to and 
stabilised at those promoters 109,110. The recruitment/stabilisation method has also 
been used where the DNA-binding domain and RNAP are linked via a designed 
protein-protein interaction domain 111. In these systems, the strength of activation 
corresponds to the strength of the protein-protein interaction.  
Other methods for activating transcription in prokaryotes include distorting non-
optimal promoters such that RNAP can bind to them more efficiently. For example 
the MerR family of activators bind at promoters with non-optimal -10 to -35 spacers, 
reconfiguring them so that RNAP can bind 112. However, such modes of 
transcription activation are likely to be much more difficult to recreate. 
The Lac repressor, LacI, is a transcriptional repressor that regulates transcription 
of the genes in the lac operon only 113. Repression is caused by LacI binding an 
operator that overlaps the RNAP binding site 114. This prevents RNAP from 
accessing the DNA, thus preventing the formation of the closed promoter complex 
and subsequent transcription initiation. However, LacI in fact binds two operators 
simultaneously 114. This leads to DNA looping, which may occlude RNAP binding 
further and also increases the local concentration of LacI at the promoter 115,116. 
Overall, this increases the achievable level of repression. LacI also responds to 
small molecules: binding of allolactose prevents LacI from binding strongly to 
operator DNA 117,118. The LexA repressor also acts by blocking the formation of the 




closed promoter complex and has a binding site that overlaps the -35 box 119. Other 
methods for decreasing the level of transcription involve inhibiting open promoter 
complex formation 120 or inhibiting promoter escape after open promoter complex 
formation 121. 
The mechanism of promoter occlusion has also been relatively simple to mimic. 
For example, a transcription activator-like effector designed to bind to the lac 
operon O1 sequence has been found to repress transcription more strongly than 
wild type LacI when only the O1 operator is present 122.  
1.2.2 Artificial transcription factors 
As introduced above, nature contains a wealth of transcription factors that operate 
via multiple different mechanisms. However, it is desirable to expand the toolkit of 
transcriptional regulators beyond those that exist in nature by making new, artificial 
transcription factors. This is because, as outlined in Section 1.1.2, such 
components can be simpler, more predictable, more orthogonal to natural systems 
and may be designed to perform actions not observed in nature. 
Artificial transcription factors (ATFs) have diverse applications in synthetic biology, 
genomics and medicine. In synthetic biology, ATFs are useful in the construction 
of synthetic genetic circuits to introduce unnatural functions or behaviours into cells 
and organisms. Those designed to respond to ligands or physical stimuli are useful 
as biosensors for the detection of small molecules or other environmental changes 
123. 
Furthermore, ATFs have provided an alternative approach to genomic studies: 
ATFs designed to be strong repressors can achieve considerable gene knock-
down, especially when combined with gene silencing technologies such as RNAi 
124. This use of ATFs to alter transcriptional profiles has also been used in 
“phenotypic engineering" to create variants of organisms with desired 
characteristics in a temporary and reversible manner, in contrast to more 
permanent genetic manipulations 125,126. Finally, ATFs have been proposed as 
therapeutics for diseases involving aberrant or undesirable transcription such as 
cancer 127,128 and viral infections 129. 
The simplest step in transcription to target with ATFs is the formation of the closed 
promoter complex. This is because the mechanisms to promote or prevent this 
step involve simple protein-protein and protein-DNA interactions: in activation, a 




DNA-binding protein can recruit RNAP to a specific location in the DNA by 
interacting with one of its subunits (Figure 1-4a); in repression, oligomeric DNA-
binding proteins can form stable complexes on the DNA, blocking RNAP binding 
(Figure 1-4b). Therefore, by combining protein-protein interaction domains and 
DNA-binding domains, it is possible to design new, modular transcription factors. 
Previously, this has been achieved using naturally occurring domains. However, 
thanks to advances in protein engineering and rational protein design, it is now 
possible to design these domains from scratch to make fully synthetic ATFs. 
Examples of ATFs containing natural, engineered and designed domains are 
discussed below.  
1.2.2.1 DNA-binding domains (DBDs) 
Many naturally occurring DBDs have been repurposed in ATFs. For example, cI 
from bacteriophage λ has been used to make artificial transcriptional activators 
109,110. DBDs from bacterial proteins have also been used: the DBD of LexA has 
been used to make a transcriptional repressor and the CadC DBD has been used 
to make a transcriptional activator 130.  
The use of naturally occurring DBDs limits the use of ATFs to promoters that 
contain specific DNA sequences. It also increases the risk of cross talk with other 
promoters in natural hosts. While it is possible to alter the DNA-binding specificity 
of some DBDs 131,132, it is preferable to be able to design these proteins, and 
therefore the DNA sequences they bind to, from scratch. There are proteins, such 
as zinc-finger arrays and transcription activator-like effectors, that can be 





Figure 1-4 Schematics for transcription activation and repression by 
modular ATFs. (a) Transcription can be activated by recruiting a (modified) 
RNAP to a promoter. (b) Transcription can be repressed by oligomeric DNA-
binding proteins that occlude the RNAP-binding site. Green ovals, a protein-
protein interaction domain; orange ovals, a DNA-binding domain. 




Zinc fingers (ZFs) are widespread protein-folding motifs involved in DNA 
recognition (Figure 1-5a). The most widely studied and engineered type of ZFs are 
the Cys2His2 ZFs, in which a zinc ion is bound by two cysteines and two histidines 
133,134. ZF motifs can be arranged as tandem arrays in a single protein chain. 
Originally, ZF arrays with novel DNA-binding specificities were selected for using 
phage display 135-137. This led to the discovery that (1) these proteins bind DNA in 
a modular fashion where each ZF motif recognises three bases of DNA, and (2) 
different ZF modules recognise different DNA triplets 138. The DNA-binding code 
was deciphered and new ZF arrays were assembled by combining multiple triplet-
recognising modules 139-141. While it has since been found that these DNA-binding 
proteins are not as modular and designable as first believed 142, they have still 
found use in ATFs. For example, ZF arrays have been used to make transcriptional 
activators that recruit T7 polymerase to specific promoters 111. They have also been 
fused to CAP to make transcriptional activators 126. Additionally, ZF arrays have 
been used widely in designing mammalian ATFs 129,143.  
Transcription activator-like effectors (TALEs) were first identified in plant 
pathogenic bacteria from the genus Xanthomonas where they act as transcriptional 
activators that facilitate bacterial infection 144. TALEs consist of a variable number 
of 34 residue long tandem repeats. The repeats differ primarily at two key residues, 
12 and 13, which are collectively called the repeat variable diresidue (RVD) 145. 
Each repeat adopts a helix-loop-helix structure where the RVD is located within 
the loop and the helix-loop-helix repeats associate to form a superhelix that wraps 
around the DNA major groove (Figure 1-5b) 146,147. The RVDs determine the DNA-
binding specificity of the TALE but only residue 13 directly contacts the DNA. Each 
RVD is responsible for recognising one DNA base and the rules that dictate which 
amino acids bind to which nucleotides are known. This allows for the assembly of 
tandem repeats containing different RVDs to create TALEs that can bind to a 
desired DNA sequence 148,149. TALEs are particularly promising as DBDs in ATFs 
as they can be designed to bind to target DNA of any length. Furthermore, the 
strength of DNA binding can be modulated by altering the length of the TALE 150.  
Like ZF arrays, TALEs have been used extensively in the design of mammalian 
ATFs by fusing them to naturally occurring light- or ligand-inducible effector 
domains 151-153. There are also some examples of bacterial ATFs that use TALEs 
as the DBD. For example, a TALE designed to bind to the lac O1 operator can 




repress gene expression 122. A modified version of this TALE with introduced 
protease sites provides a means of controlling the repression activity 154. 
Finally, CRISPR/Cas9 ribonucleoprotein complexes can be used as DBDs 155. In 
these complexes, a guide RNA (gRNA) targets a CRISPR-associated (Cas) 
nuclease to a specific DNA location 156. A nuclease-deficient version of the Cas9 
protein, called dCas9, can also be targeted to DNA without cleaving the DNA 156. 
dCas9 has been used as the DBD in artificial transcriptional activators and 
repressors in E. coli 157.  
1.2.2.2 Protein-protein interaction domains (PIDs) 
Protein-protein interactions can be either constitutive or inducible. In constitutive 
interactions, provided the components of the interaction are present at sufficiently 
high concentrations, they will interact. In inducible interactions, the interaction 
occurs in the presence of some additional component, such as a small molecule, 





Figure 1-5 Engineerable DNA-binding domains for use in ATF design. (a) 
Zinc finger arrays (PBD ID: 1AAY 158). Zinc ions are shown in lilac. (b) TALE 
(PDB ID: 3UGM 146). Protein chains are coloured from N (blue) to C (red) 
terminus.  




While inducible interactions are more controllable, this type of interaction is 
generally more difficult to design. This is reflected by the fact that the inducible 
protein-protein interactions used in ATFs are usually natural proteins or engineered 
versions of natural proteins. For example, a maltose-binding ATF was made by 
fusing a ZF DBD to a split maltose-binding protein (MBP) 159. Maltose binding leads 
to a large conformational change in MBP, which also alters the conformation of the 
ZF such that it can no-longer bind DNA.  
Another inducible system that has been widely exploited is the monomeric FK506-
binding protein (FKBP), which binds to the small molecule drug rapamycin and 
similar synthetic ligands 160. A version of FKBP with a single amino acid substitution 
can bind a synthetic ligand that does not bind the wild type protein 161. Bivalent 
versions of this ligand, and others, can induce dimerisation of the protein 162. 
Furthermore, another point mutation can turn FKBP into a dimer that can be 
reversibly dissociated by rapamycin binding 163. Both mutants have been used to 
control the dimerisation of TALE DBDs in order to bring about DNA-looping 164.  
Single-domain antibodies have also been proposed as inducible PIDs. For 
example, a VHH fragment (a single-domain fragment of a camelid heavy-chain 
antibody) that undergoes dimerisation on binding its antigen, caffeine, has been 
used to mediate the interaction between monomers of dimeric DNA-binding 
proteins in order to facilitate DNA-binding 130,165.  
Naturally occurring proteins have also been used as constitutive PIDs in bacterial 
ATFs. For example, the Gal4 dimerisation domain-Gal11P interaction has been 
used to mediate the interaction between RNAP ω subunit and a DBD to activate 
transcription 110. Gal4 is a yeast transcriptional activator and Gal11P is a version of 
a component of yeast RNAP II 166. These components have also been used to 
mediate the interaction between RNAP α subunit and novel ZF DBDs 167 and 
between ZF domains to make dimeric ZF DNA-binding proteins 168. Novel peptide-
peptide interactions have also been identified using phage display. Although only 
15 amino acids long each, these could also mediate the dimerisation of ZF 
domains 169. 
Higher-order oligomerisation domains have also been used. For example, the λ cI 
oligomerisation domain has been used to make a highly cooperative transcriptional 
repressors when fused to various DBDs 170.  




Coiled coils and leucine zippers, which are present in many natural transcription 
factors, have also been used as constitutive interaction domains in ATFs. For 
example, the leucine-zipper region of the yeast bZIP transcription factor, GCN4, 
has been used to make dimeric ZF DNA-binding proteins 171,172. More recently, de 
novo designed coiled coils have also been used as PIDs in transcriptional 
activators 111,173. Heterodimeric coiled coils of different lengths, which have been 
shown to have different dissociation constants in vitro 174, gave different levels of 
transcriptional activation when the two components of the heterodimer were fused 
to a ZF DBD and T7 polymerase, respectively 111. Finally, a collection of 
heterodimeric coiled coils has been used to reconstitute a split-transcription factor 
to restore transcription repression in yeast 175.  
Beyond ATF design, natural and designed coiled coils have also been used 
successfully as PIDs in many other contexts, including in the assembly of 
multivalent antibodies 176,177 and to direct the assembly of photosynthetic reaction 
centres 178. There are many examples of de novo designed coiled coils in the 
literature, and there is scope yet to design many more. They therefore represent a 
valuable resource as protein-protein interactions in ATF design.  
1.3 Coiled coils: sequence, structure and function 
The coiled coil is a ubiquitous protein-folding motif consisting of two or more α 
helices wrapped around each other to form a supercoil 179,180. These protein 
domains perform a wide range of functions, including mediating protein-protein 
interactions. The sequences and structures of coiled coils have a number of 
characteristic features, which are described here.  
1.3.1 Primary structure 
The primary structure of a protein is the order of amino acids in its linear sequence 
when read from the N to the C terminus. Naturally occurring proteins usually 
consist of the 20 canonical amino acids. Every aspect of protein behaviour 
including structure, function, stability and folding is encoded within the primary 
sequence. Understanding how a protein’s sequence ultimately dictates these 
properties (the protein-folding problem) has been a field of intense study 181. While 
predicting the structure of a protein from its sequence is still difficult for the majority 
of proteins, there are some protein folds where the sequence-to-structure 
relationships are better understood. The coiled coil is one of these. As such, it is 




not only possible to predict coiled coils and their structures from the amino acid 
sequence 182,183, it is also possible to design new sequences that will fold into 
defined structures with controllable characteristics.  
The sequences of the majority of coiled coils consist of repeating seven residue 
motifs, called heptads, in which the residue positions are labelled a-g. There are 
other, less common repeat motifs but these will not be discussed here 184-186. The 
a and d positions of the heptad are generally occupied by hydrophobic residues 
while the remaining positions are usually occupied by polar residues, giving a 
characteristic HP-pattern of HPPHPPP (H, hydrophobic; P, polar, Figure 1-6). The 
exact identity of these residues controls structural features such as oligomeric 
state, partner selection, helix orientation and supercoil geometry 187-190. 
A huge variety of 3D structures can be derived from this seemingly simple heptad 
repeat. Additionally, coiled-coil properties beyond their tertiary structure can also 
be designed. For example, it is possible to modulate the strength of the interaction 
between the helices of a coiled coil to alter its stability 174,191,192. 
1.3.2 Secondary structure 
Proteins are made up of secondary structure elements that include α helices, 310 
helices and β strands. These structural elements are stabilised by regular 
backbone hydrogen bonds. For example, α helices, the secondary structure 
element that makes up α-helical coiled coils, contain hydrogen bonds between N–
H donors in the backbone amide bond of residue i and carbonyl acceptors in the 
backbone amide bond of residue i+4 (Figure 1-7a) 193.  
Secondary structure elements can also be described by a number of parameters 
including residues per turn, rise per residue, helix radius and the torsion angles, ϕ 
and ψ (Figure 1-7b-e). α-Helices have 3.6 residues per turn, a rise per residue of 
1.5 Å and a backbone radius of 2.3 Å. The ϕ and ψ angles for α helices are centred 
around -63 ° and -43 °, respectively 194-196.  
When a linear HPPHPPP heptad sequence is projected onto a helical wheel, the 
H residues at a and d align on the same side of the helix (Figure 1-6). This creates 
an amphipathic helix with both a hydrophobic and a polar face. Association of the 
hydrophobic face with other hydrophobic surfaces, resulting in burial of the 
hydrophobic residues, is a major driving force for protein folding.  




1.3.3 Tertiary structure 
Variable numbers of right-handed amphipathic α helices wrap around each other 
to form left-handed superhelical coiled coils. The supercoiling comes about due to 
the mismatch in the number of residues per turn in an α helix (3.6) and the 
periodicity of the hydrophobic residues in the heptad (3.5). The result is a 
hydrophobic seam that spirals across the face of the helix. Helices can then wrap 
around each other via these faces. Like the individual helices, the coiled-coil 
superhelix can also be described by a number of parameters (Figure 1-8a) 197-199.  
Furthermore, α helices in coiled coils take part in intimate interhelical interactions 
called knobs-into-holes (KIH) interactions where a “knob” residue on one helix 
docks into a diamond-shaped “hole” of four residues on the adjacent helix (Figure 
1-8b) 200. KIH interactions form along the length of a coiled coil such that a residue 
that forms part of a hole on one helix also acts as a knob residue, interacting with 
another hole on the adjacent helix. Thus, the helices become tightly interdigitated. 
Where residues act as both knobs and holes, these are termed complementary 
KIH interactions 201. Isolated KIH interactions can also occur.  
 
Figure 1-6 Patterning of hydrophobic and polar residues results in 
amphipathic helices. Projecting a HP-pattern (left) onto a helical wheel 
diagram (centre) demonstrates that hydrophobic residues are located on the 
same helical face. The orientation of the teardrops indicates the approximate 
direction of the Cα-Cβ bond vector the residue at each position. The result is 
an amphipathic helix (right). Polar residues are highlighted in grey; 
hydrophobic residues are highlighted in yellow.  














Figure 1-7 Structure and parameters of α helices. (a) Section of α helix 
demonstrating i to i+4 hydrogen bonds between backbone N–H and C=O 
groups. (b) An α helix viewed from the N terminus. The black dot represents 
the helical axis and the green arrow indicates the helical radius. (c) A section 
of α helix demonstrating the rise per residue and residues per turn 
parameters. The dashed black line is the helical axis. (d) A section of α helix 
demonstrating the torsion angles ϕ and ψ. Green boxes highlight planar 
amide bonds. (e) Ramachandran plot with α-helical region highlighted in 
red. Modified from reference 195. In (b) and (c), idealised values for each 
parameter are shown in green. 




One way to visualise the complementary KIH interactions that occur in coiled coils 
is using helical nets (Figure 1-8c) 200. These diagrams are a visualisation of an 
“unrolled” helix with the positions of each Cα marked. When two of these unrolled 
helices are superimposed, the locations of the complementary KIH can be 
observed along the lengths of the helices (Figure 1-8c).  
The interhelical interfaces in coiled coils fall into four categories: Type-N, Type-I, 
Type-II and Type-III (Figure 1-9). In Type-N interfaces, residues at the a and d 
positions primarily contribute to KIH packing and oligomeric state definition and 
form a single hydrophobic seam through which the amphipathic helices interact. 
Along with the e and g positions, which contribute to the hole residues, these 
residues make up a single motif called a gade motif and the heptads generally 
follow the classical HPPHPPP pattern. This type of interface is most compatible 
with dimer formation.  
However, higher-order coiled coils can also contain an additional hydrophobic 
seam such that each helix interacts with its two neighbours via separate 
hydrophobic seams 202. These “multifaceted” coiled coils are designated Type-I, -II 
or -III depending on the extent of the overlap between the two seams (Figure 1-9).  
Expanding the hydrophobic seams beyond the a and d positions means that the 
more-peripheral b, c, e and g residues become part of the coiled-coil interface. This 
results in gade-like motifs where other positions in the heptad become equivalent 
to the g, a, d and e residues in the traditional Type-N interface. For example, in 
Type-I interfaces, the two gade-like interfaces are made up of the gade and cdga 
positions, which overlap by three residues; in Type-II interfaces they are made up 
of the deab and cdga positions, which overlap by two residues; in Type-III 
interfaces they are made up of the gade and bcgf positions, which overlap by a 
single residue. These gade-like motifs are essentially two individual Type-N 
interfaces that are superimposed in a larger Type-I, -II or -III interface. The Type-N 
interfaces can be thought of as forming individual dimeric interactions within a 
larger coiled-coil assembly, but with the KIH interactions occurring between 
different groups of residues, which are characteristic for the interface type.  
The different types of multifaceted interface have different angles between the two 
hydrophobic seams 43,203,204. These inter-seam angles dictate the positions of the 
adjacent helices relative to each other; as the inter-seam angle increases, so too 
will the angle between two flanking helices interacting with the same central helix. 




This helps determine oligomeric state. For example, the idealised angle between 
the seams in Type-I interfaces should be conducive with trimer formation; in Type-II 
with pentamer formation; and in Type-III with tetradecamer formation 204. As the 
inter-seam angle increases, the oligomeric state must also increase in order to 
complete the ring of helices and “close” the coiled coil. However, while these are 
the idealised oligomeric states for these coiled-coil interfaces, they can also be 
compatible with other oligomeric states. For example, coiled coils with Type-II 
interfaces have been shown to form oligomeric states up to heptamer and are 
theoretically also compatible with tetramer formation 43.  
Tetramers have also been observed with Type-N interfaces, with hydrophobic 







Figure 1-8 Structure and parameters of coiled coils. (a) Coiled coil 
parameters: α, pitch (Å); r0, superhelix radius (Å); ω, helix phase (°) 198,199. (b) 
Knobs-into-holes packing. A Leu knob (blue side chain) packs into an Ile-Lys-
Ile-Leu hole (yellow side chains) in the adjacent helix. Figure based on a 
model of a tetrameric coiled coil. (c) Helical nets for two separate helices (left, 
crosses and circles indicate Cα positions, grey lines indicate backbones) and 
superimposed to show KIH packing in a dimeric coiled coil interface (right, 
complementary KIH interactions highlighted by yellow diamonds). Heptad d 
positions are blue, a positions are green. Magenta lines indicate trajectories 
of hydrophobic seams defined by a and d residues. 




residues at ade or adg positions 205,206. Thus, a variety of different interfaces appear 
to be compatible with tetrameric coiled coil formation. However, though the 
sequences of these coiled coils are similar to those of Type-N and Type-I coiled 
coils, they may still be forming Type-II-like structures, where the a, d, e, and g 
residues can all act as knobs in KIH interactions.  
1.3.4 Sequence to structure: oligomeric-state specification 
Seminal experiments by Harbury et al found that mutating the core a/d positions of 
the model leucine zipper GCN4-p1 to various combinations of Ile and Leu led to 
 
Figure 1-9 Types of coiled-coil interfaces. Top left: Type-N. Top right: Type-
I. Bottom left: Type-II. Bottom right: Type-III. Red dashed arrows indicate the 
approximate orientation of the hydrophobic seams. gade-like motifs are 
shown in yellow and blue, shared residues are striped. Idealised inter-seam 
angles, optimal oligomeric states and range of potential oligomeric states 
available to each type of interface are shown in red below each helical wheel 
diagram 204. Dashed grey arcs indicate that these helices make further 
interactions (not shown).  




changes in oligomeric state: a=Ile/d=Leu gave dimers; a=d=Ile or Leu, trimers; and 
a=Leu/d=Ile, tetramers 187.  
This was rationalised because Ile prefers to take part in parallel KIH packing in 
which the knob Cα-Cβ bond vector is parallel to the vector between the Cα atoms of 
the hole residues. Conversely, only Leu is compatible with perpendicular KIH 
packing in which the knob vector is oriented perpendicular to the hole vector 187,207. 
This preference is largely driven by the unfavourable packing and steric clashes 
that would occur if each amino acid took part in the other type of packing. In 
tetramers, a forms a perpendicular knob and d forms a parallel knob, hence 
a=Leu/d=Ile cores. The identification of these simple sequence-to-structure 
relationships galvanized the field of de novo coiled-coil design and the so-called 
“Harbury rules” are still used to guide the design of lower-order coiled coils 208.  
1.3.5 De novo coiled-coil design 
Coiled-coil sequences designed entirely from scratch allow us to disentangle the 
relationships between a protein’s sequence and its observed properties. They also 
provide a “blank canvas” that can be augmented with additional functions and 
improved properties either by further rational design, computational design or via 
library screening or directed evolution 209-212. In short, in order to introduce novel, 
complex behaviours into an existing protein, a simplified de novo sequence often 
provides a better starting point than a natural sequence that is already itself highly 
complex. 
Extensive investigation has been carried out into oligomeric state specification in 
coiled coils and, as a result, a “basis set” of de novo homooligomers, with 
oligomeric states ranging from dimer to heptamer has been designed (Figure 1-10) 
43,207,208,213,214. There are also examples of de novo designed heteromers, 
particularly heterodimers 174,188,215, but fewer examples for higher-order oligomers 
such as tetramers.  
Furthermore, while many de novo coiled coils have been characterised extensively 
in vitro, relatively little is known about their biological properties, that is, how they 
behave inside living organisms. Ultimately, it is not yet known whether coiled coils 
designed to have optimal properties in vitro, with high thermal stabilities and 
simple, repetitive sequences, will also be optimal for use in vivo. This area, protein 
design in the cell, remains largely unexplored.  




1.3.6 Designed tetrameric coiled coils and 4-helix bundles  
As designed constitutive PIDs, homo- and heterotetrameric coiled coils offer many 
advantages over lower-order coiled coils like dimers and trimers. Firstly, as the 
oligomeric state of a cooperatively folded protein is increased the sigmoidal 
concentration-dependent folding response becomes sharper (Figure 1-11). That 
is, tetramers are more sensitive to smaller changes in protein/peptide 
concentration than proteins with lower oligomeric states 170,216. These small 
changes in concentration lead to larger changes in folding and, therefore, 
structure-dependent functions. Such systems show a large response to a small 
range of inputs (here, the input is protein concentration and the response is 
folding/association). This gives their response (folding) curves increasingly binary 
like characteristics compared to dimers and trimers and, as such, they make useful 
biological switches with more distinct on/off states 217,218. Furthermore, such 
systems are generally more resistant to biological noise, such as fluctuations in 
gene expression 219-221. 
A further reason why tetramers are more useful as PIDs is that a tetrameric 
assembly can contain up to four separate components and could also be designed 
to form hetero systems where all four components are unique. This makes them 
useful as PIDs because they can co-localise multiple proteins of interest. For 
example, they could be used to mediate the interaction between two dimeric DBDs 
to bring about looping. Also, they could be used to recruit multiple other protein 
domains, such as enzymes, to a specific DNA location (Figure 1-12).  
Finally, tetrameric coiled coils have larger hydrophobic cores. They are therefore 
generally more stable and may be more tolerant to mutations and modifications 
 
Figure 1-10 X-ray crystal structures of the basis set de novo designed 
coiled coils. From left to right: CC-Di, CC-Tri, CC-Tet, CC-Pent, CC-Hex and 
CC-Hept. PDB IDs: 4DZM 208; 4DZL 208; 3R4A 213; 3PN8 43; 3R3K 213; 
4PNA 43.  




intended to introduce more-sophisticated properties into de novo designed coiled 
coils, such as environment-responsive behaviours. For example, PIDs could be 
designed to undergo structural rearrangements in response to small molecule 
binding or chemical modifications without adversely affecting their stability. 
Therefore, tetrameric coiled coils are in fact a good candidate for both constitutive 
and inducible PIDs in ATFs (Figure 1-12).  
Since the discovery that placing leucine at a positions and isoleucine at d positions 
in the GCN4-p1 heptad repeat leads to the formation of a parallel tetramer 187, this 
model coiled coil has been modified further in a number of ways to produce 
additional tetrameric coiled coils. For example, expanding the hydrophobic seam 
beyond the a and d residues has often been found to have a profound effect on 
the structure of the coiled coil. When valines are placed at all e positions in GCN4-
p1, the peptide forms a parallel tetrameric coiled coil with offset helices 206. This is 
in contrast to GCN4-pLI, which is blunt-ended 187. When valine is placed at all g 
positions in GCN4-p1, the peptide forms an antiparallel tetramer, again in contrast 
to GCN4-pLI, which is a parallel coiled coil 205. When alanine is placed at either all 
e or all g positions, the peptides also form antiparallel tetrameric coiled coils 205,222. 
The peptides also form antiparallel coiled coils when alanine is placed at the e 
positions and leucine and valine are placed at the a and d positions, respectively 
223. Finally, GCN4-pLI itself has also been further modified. For example, glutamate 
or lysine residues have been placed at all c and e positions to produce two 
peptides, ecE and ecK. These peptides interact to form a heterotetramer 224.  
 
Figure 1-11 Theoretical concentration-dependent folding of different 
oligomeric states. As oligomeric state is increased from dimer to trimer to 
tetramer the sigmoidal concentration-dependent folding transitions become 
steeper. Concentration is in arbitrary concentration units. Fraction folded (α) 
= [folded]/([folded]+[unfolded]). αn = Cn/(KD.C + Cn), where n is the oligomeric 
state (n = 2, 3, 4). 




Similar mutational studies have been performed with another natural coiled coil, 
the tetramerisation domain from the Lac repressor. This forms an antiparallel 
homotetramer. Modifications include increasing the length of the peptide to 
increase its stability 225 and placing oppositely charged residues at b and c 
positions to make two peptides that form a heterotetramer 192,226.   
Further examples of novel tetrameric coiled coils include: a pair of disulphide-linked 
peptides with core alanine residues that form an antiparallel heteromer 227; a 
computationally designed right-handed coiled coil (coiled coils are usually left-
handed) 228; a second computationally designed right-handed coiled coil in an 
antiparallel orientation where the helices are linked by loops to form a single-chain 
assembly 42; a variant of a de novo heterodimer with a core substitution that forms 
a heterotetramer 229; and an empirically designed parallel homotetramer 208. The 
latter, CC-Tet, was designed according to the Harbury rules as part of a set of 
novel oligomerisation domains for use in synthetic biology 187,208.  
Extensive design and characterisation of novel 4-helix bundles has also been 
carried out. These consist of four amphipathic interacting helices, often linked into 
helical hairpin or single-chain arrangements. As with coiled coils, their sequences 
follow a regular pattern of hydrophobic and polar residues, but they do not 
necessarily form the extensive knobs-into-holes interactions that are characteristic 
of coiled coils 230,231.  
Early approaches to designing 4-helix bundles involved patterning hydrophobic 
and polar residues to form amphipathic α helices. These peptides usually 
contained a reduced palette of amino acids. For example, an early example 
 
Figure 1-12 Schematics of proposed ATFs containing tetrameric 
coiled coils. Left, an A2B2 tetrameric coiled coil (light red and light blue 
helices) mediating an interaction between two dimeric DBDs (green and 
orange). Centre, an ABCD tetrameric coiled coil (light/dark red and light/dark 
blue helices) recruiting functional protein domains (light/dark green) to a 
dimeric DBD (yellow/orange). Right, a tetrameric coiled coil-based induced 
protein-protein interaction (dark red and dark blue helices) where a ligand 
(green) facilitates the interaction, resulting in formation of a dimeric DBD 
(yellow/orange). 




contained just leucine, glutamate, lysine and glycine 232,233. The peptide formed a 
tetramer. When the helices were linked up to form helical hairpins via simple loops 
these hairpins also interacted to form dimeric 4-helix bundles 234. The helices were 
also linked in a single chain to make a monomeric 4-helix bundle 235. The structures 
were later made more native-like through mutagenesis 236 and were further 
modified to impart additional behaviours on them such as metal 237 or heme 
binding 238.  
Further examples of 4-helix bundles have been identified from libraries of binary-
patterned protein sequences. In these libraries, a HP-pattern (e.g. PHPPHHP) is 
defined, then the H and P positions are populated by a subset of hydrophobic (e.g. 
FILMV) and polar (e.g. DEHKNQ) residues at random 239-241. Loop regions are also 
defined to produce single-chain proteins predicted to form monomeric helical 
bundles. The resulting libraries of proteins can then be probed for desirable 
properties. Folded 4-helix bundles with native-like structures can be readily 
extracted from such libraries 242-244. Indeed, helical proteins have also been 
extracted from libraries where no binary pattern of H/P residues was defined 245,246. 
Furthermore, the sequence diversity within the library encodes function, not just 
structure: 4-helix bundles capable of small molecule and co-factor binding and 
catalysis have been identified 211,212,247-249.  
1.3.7 Ligand-binding coiled coils and helical bundles 
Coiled coils and helical bundles that are able to bind to small molecules are a 
particularly attractive design target because, just like protein-protein interactions, 
protein-small molecule interactions are involved in a wide range of biological 
activities. These include: binding of substrates in enzymatic catalysis 250; binding 
of cofactors to expand the chemical functionality of a protein 251; sequestration and 
solubilisation of minerals 252,253; transport across membranes 254; and small 
molecule binding-induced conformational changes that allosterically alter the 
activity of a protein 255.  
The latter is often observed in inducible transcription factors, such as the Lac 
repressor, which undergoes a conformational change on binding allolactose or 
isopropyl β-D-1-thiogalactopyranoside (IPTG) 117,255, and there are some examples 
of designed, ligand-inducible transcription factors (see Section 1.2.2.2) 29,256. 
However, these attempts to design novel ligand-inducible transcription factors are 
yet to exploit the ability of some coiled coils and helical bundles to bind small 




molecules (see below for details). For example, there are several examples of α-
barrels that bind hydrophobic molecules in their axial pores. Furthermore, though 
the cores of lower order coiled coils (dimers to tetramers) are generally tightly 
packed, without pores or cavities, there are examples of natural and designed 3- 
and 4-helix bundles that not only contain channels or cavities but can also bind 
small molecules within these cavities.  
Binding of small molecules has been associated with stabilisation of helical 
bundles and conformational switching, and so ligand binding may have an effect 
on the biophysical properties of a designed coiled coil. Therefore, while this thesis 
will predominantly focus on using coiled coils as constitutive PIDs, ligand-binding 
coiled coils and helical bundles may be of use as inducible protein-protein 
interactions in the future. 
1.3.7.1 Small molecule binding to α-helical barrels  
Coiled coils with oligomeric states of pentamer and above, the α-barrels, have 
axial, solvent accessible pores where the diameter is proportional to the oligomeric 
state 43,202,203. Some naturally occurring α-barrels bind small molecules in these 
pores, most notably the coiled-coil region of the cartilage oligomeric matrix protein, 
COMPcc. This is a soluble homopentameric α-barrel that contains a pore divided 
into two chambers by a ring of glutamine residues 257,258. These chambers, which 
are lined by aliphatic residues, can bind a wide range of molecules from benzene 
to vitamins to fatty acids 259,260.  
Binding of dyes and other hydrophobic molecules has also been demonstrated for 
various de novo α-barrels with oligomeric states of pentamer to heptamer 261-264. 
Moreover, it has been shown through dye displacement assays that different de 
novo α-barrels bind different small molecules with varying affinities, indicating that 
these coiled coils can discriminate between a range of molecules 264. The 
selectivity of the barrels could also be modulated by introducing polar residues into 
the pore lumens that were proposed to make specific electrostatic interactions with 
ligands.  
1.3.7.2 Small molecule binding to naturally occurring 4-helix bundles  
The C-terminal coiled-coil region of the tetrabrachion protein from the thermophilic 
Staphylothermus marinus forms a right-handed tetrameric coiled coil. The crystal 
structure of the coiled coil (named RHCC for right-handed coiled coil) revealed it 




contains four central cavities linked by a continuous, solvent accessible axial pore 
265. In the crystal structure these cavities are occupied by ordered waters. The 
presence of the cavities has led researchers to investigate RHCC as a drug 
delivery system: the potent chemotherapy agent cisplatin can be loaded into RHCC 
in a 1:1 cisplatin:tetramer ratio to form a stable complex 266. While RHCC alone is 
neither toxic nor immunogenic, the RHCC-cisplatin complex could enter tumour 
cells and had comparable efficacy against various tumour cell lines to cisplatin 
alone. A de novo-designed right-handed coiled coil also contains solvent 
accessible cavities, although these are not linked by a central pore 228. Such de 
novo systems may also be of use in the delivery of cytotoxic drugs.  
The homotetrameric M2 protein from influenza A contains a transmembrane 
4-helix bundle 267,268. This transmembrane segment forms a proton channel and 
facilitates various functions of the protein, including endosome acidification and 
viral release 269. Antiviral drugs, including amantadine, rimantadine and other 
adamantane-derived drugs are believed to bind in the M2 channel lumen, blocking 
proton translocation 270-273.  
1.3.7.3 Small molecule binding to designed 3- and 4-helix bundles 
Various attempts have also been made to introduce ligand-binding behaviour into 
the model leucine zipper GCN4-p1 and its tetrameric derivative, GCN4-pLI 187,274. 
The first such attempt involved mutating the core asparagine in GCN4-p1 to 
alanine. The resulting variant was predominantly dimeric but was stabilised in a 
trimeric state by the addition of small hydrophobic molecules such as benzene 275. 
The variant was co-crystallised with benzene occupying a cavity with a volume of 
165 Å3. Addition of the ligand also led to an increase in the thermal stability of the 
coiled coil. This ligand-induced trimerization mechanism was dubbed an allosteric 
switch.  
The larger core volumes of tetramers compared to dimers and trimers makes them 
more amenable than smaller coiled coils to the introduction of cavities and 
channels.  Indeed, the crystal structures of some parallel tetrameric coiled coils, 
such as GCN4-pLI, already contain very small internal cavities 187. Attempts have 
been made to expand these cavities such that they may accommodate small 
molecules. Yadav et al replaced core leucine residues at various a positions in 
GCN4-pLI with various small residues 276. When Leu9 was replaced by glycine or 
alanine, the resulting tetramers co-crystallised with iodobenzene in a solvent 




accessible tunnel and a 220 Å3 cavity, respectively. Subsequently, Mizuno et al 
demonstrated that a single-chain antiparallel GCN4-pLI variant with seven core 
alanine substitutions and a single core tryptophan substitution per helix could bind 
larger hydrophobic molecules such as adamantane 277. The introduced cavity 
showed preferential binding to hydrophobic molecules and bound approximately 
350-fold more strongly to adamantane than to 1-adamantanol.   
Other attempts at introducing ligand binding into small helical proteins have 
focussed on helical bundles. One such attempt involved making cavity-creating 
leucine to alanine substitutions in a covalently templated 3-helix bundle 278. 
Peptides with one or two alanine substitutions could be mixed-and-matched to 
make heteromeric assemblies through covalent attachment to a template peptide. 
The resulting α-helical bundles bound the hydrophobic dye 8-Anilino-1-
naphthalenesulfonic acid (ANS). It is important to note that ANS is traditionally 
used to determine whether a protein adopts a unique, rather than molten globule, 
structure as it binds non-specifically to exposed hydrophobic patches in the latter. 
Therefore, the observed ANS binding could simply be an indication of a poorly 
structured core. However, based on their cooperative unfolding transitions, the 
covalently templated proteins appeared to have native-like properties. Therefore, 
here, ANS binding is an indication that the proteins contain accessible hydrophobic 
cavities that could be further modified to accommodate more-specific ligands.  
De novo 4-helix bundles have also been designed to bind to halothane, a volatile 
molecule used as a general anaesthetic 279. These bundles were initially designed 
as a model to probe halothane-protein interactions because the specific binding 
site of the molecule in vivo was unknown 280.  
Extensive work has also been done to introduce porphyrin binding activity into 
4-helix bundles through rational and computational design. These ligands, which 
include hemes and their non-natural analogues 238,281-284, act as cofactors to 
expand the chemical functionality of the proteins. Activities such as oxygen 
binding, oxidoreductase activity and light harvesting have been introduced into 
such de novo porphyrin-bound proteins 251,285,286.  
Another approach that has been taken to introduce porphyrin binding to novel 
4-helix bundles is through selection for heme binding from a library of binary 
patterned 4-helix bundles 247,248. The specific structures, and therefore the 
functions, of such proteins are not explicitly designed. However, these simple 




proteins have displayed a range of activities, which also includes small molecule 
binding 211,212. In one study, core alanine mutations were made in a well-folded 
binary patterned 4-helix bundle 211. Small hydrophobic molecules including 
benzene could bind to the resulting cavities in the proteins core. A more elaborate 
study involved screening three 4-helix bundles against a library of small molecules 
212. Strikingly, the proteins, which were not designed to be small molecule-binding 
proteins, each displayed binding to several ligands with reasonable affinity and 
selectivity.  
1.3.7.4 Metal binding to helical bundles 
The incorporation of metal binding into coiled coils is well explored 287 and will not 
be discussed here in detail. However, there are some examples of this 
phenomenon that are pertinent and interesting in the context of inducible protein-
protein interactions and transcriptional regulation. Firstly, metal binding is able to 
induce coiled-coil folding. A peptide designed to contain core histidine residues is 
able to bind various metals, including nickel 288. On metal coordination, this peptide 
forms a trimeric coiled coil. Further examples a metal binding-induced 
conformational changes include a peptide that switches from a trimeric coiled coil 
to a monomeric helix-loop-helix structure on coordinating zinc via two histidine 
residues 289 and a peptide that switches from a trimeric coiled coil to a Cys2His2 ZF 
motif on coordinating zinc 290.  
Finally, a version of the DNA-binding portion of GCN4 has been engineered to be 
metal-responsive 291. Terpyridine-linked GCN4 dimers showed some binding to 
target DNA in vitro in the absence of metal. On binding copper or zinc, the 
terpyridine linker undergoes a conformational change, which induces a 
conformational change in the peptide dimer. This leads to an increase in DNA 
binding.  
1.4 Scope of this thesis 
Coiled coils are used frequently in nature to mediate protein-protein interactions. 
The relative simplicity of coiled-coil sequences and structures makes them prime 
targets for the design of artificial PIDs in which properties such as the strength and 
specificity of the interaction can be controlled. The aim of the work described in 
this thesis was to design and characterise a set of de novo coiled coils intended 
for use as constitutive PIDs in vivo.  




Chapter 3 describes the design of a number of homotetrameric coiled coils and 
their biophysical and crystallographic characterisation. Sequence determinants 
that specify oligomeric state, including the identities of the d and g residues, are 
also explored. This is built upon in Chapter 4, where a collection of A2B2 
heterotetramers are described. These heterotetramers, which contain two copies 
each of two different peptides, have different thermal stabilities, depending on the 
identity of the core residues.  
In Chapter 5, a sub-set of these heterotetramers are examined in E. coli for their 
ability to act as artificial PIDs in a living organism. This is done using a transcription 
repression assay where the de novo coiled coils mediate an interaction between 
monomeric proteins that require oligomerisation in order to form functional DBDs. 
The work in this chapter shows that simple peptide sequences are able to locate 
their interaction partners in a complex cellular environment. Therefore, though not 
necessarily optimised for use in vivo, the coiled coils can be used successfully as 
artificial constitutive PIDs in organisms. Furthermore, a set of semi-synthetic ATFs, 
that consist of designed PIDs and a natural DBD, are produced.  
Finally, Chapter 6 describes preliminary results towards the design of an ABCD 
heterotetramer, where all four constituent peptides have a different sequence. 
Moreover, following the successful design of a number of constitutive coiled coil-
based PIDs, this chapter also discusses preliminary work relating to the design of 
ligand-binding tetrameric coiled coils with the intention that, in the future, the 
available constitutive protein-protein interactions may be made into inducible 
protein-protein interactions. Such components would be invaluable in the design 




Chapter 2: Methods and Materials 
2.1 Coiled-coil design 
All designed peptide sequences are listed in Table 8-1.  
2.1.1 Homotetramer design 
2.1.1.1 Design of CC-Tet derivatives 
The sequence of the peptide CC-Tet-KE was based on the homotetrameric coiled 
coil CC-Tet 208. CC-Tet-KE was designed by swapping the identities of the charged 
residues at the e and g positions in CC-Tet. The sequence is otherwise identical, 
including a C-terminal AG mass tag used for peptide identification.  
The CC-Tet-KE-N peptides were designed as mutants of CC-Tet-KE that 
contained Asn residues at the d and e positions of the third heptad (positions 20 
and 21). 4- and 4.5-heptad versions were designed. The 4-heptad version (CC-
Tet-KE-N-4) retained the C-terminal AG mass tag. In the 4.5-heptad version (CC-
Tet-KE-N-4.5), this mass tag was removed, and the peptide was extended 
C-terminally with an additional gabc motif (sequence: KLAA), representing 
approximately half of the full gabcdef heptad (sequence: KLAAIEf).  
2.1.1.2 Design of Glu-Lys stabilised homomers 
The peptides 1-LI-EK, 1-LI-KE, 2-LI-EK, 2-LI-KE, 3-LI-EK, 3-LI-KE, 4-LI-EK and 4-
LI-KE were designed to contain different configurations of Glu-Lys pairs at 
positions deemed to be close enough for the formation of interhelical ionic 
interactions from the crystal structure of CC-Tet (PDB ID: 3R4A) 208. Average inter-
residue distances were determined from the .pdb coordinate file for CC-Tet using 
a script implemented in Python.  
All eight peptides were designed in c-register (i.e. excepting capping Gly residues 
at the C and N termini, the peptide sequence begins at a c position) and contained 
a=Leu/d=Ile cores. Peptides 1-LI-EK and 1-LI-KE contained e/g ionic pairs where 
in 1-LI-EK g=Glu, e=Lys and in 1-LI-KE g=Lys, e=Glu. Peptides 2-LI-EK and 
2-LI-KE contained c/e ionic pairs where in 2-LI-EK c=Glu, e=Lys and in 2-LI-KE 




c=Lys, e=Glu. Peptides 3-LI-EK and 3-LI-KE contained g/b ionic pairs where in 
3-LI-EK g=Glu, b=Lys and in 3-LI-KE g=Lys, b=Glu. Peptides 4-LI-EK and 4-LI-KE 
contained b/c ionic pairs where in 4-LI-EK b=Glu, c=Lys and in 4-LI-KE b=Lys, 
c=Glu. Where e or g positions were not Glu or Lys, these positions were made Gln. 
Where b or c positions were not Glu or Lys, these positions were made Ala.  
The peptides 1-LV-EK, 1-LV-KE, 2-LV-EK, 2-LV-KE, 3-LV-EK and 3-LV-KE are 
based on 1-LI-EK, 1-LI-KE, 2-LI-EK, 2-LI-KE, 3-LI-EK and 3-LI-KE, respectively, 
except they contained a=Leu/d=Val cores. 
The f positions of all 14 homomeric peptides were populated by Gln (or Lys, where 
required to promote solubility) and a single Trp at position f19 to provide a 
chromophore. Helix-capping Gly residues were added to N and C termini. 
2.1.1.3 Design of Ala@g homomers 
The peptides 2-LIA-EK and 2-LIA-KE were designed in c-register and contained 
a=Leu/d=Ile cores. The peptides contained c/e ionic pairs where in 2-LIA-EK 
c=Glu, e=Lys and in 2-LIA-KE c=Lys, e=Glu. All g and b positions were occupied 
by Ala. Both peptides contained Gln at f positions, except at f19 where Trp was 
used to provide a chromophore. Helix-capping Gly residues were added to N and 
C termini. 
2.1.1.4 Design of ELAEIK 
ELAEIK was designed by Drew Thompson using a protocol that had previously 
been used to design water-soluble homomeric coiled-coil barrels with oligomeric 
states of pentamer to heptamer 43. The protocol was modified for the design of A2B2 
heterotetrameric coiled coils. While no successful heterotetramers were designed 
using this method, it did yield a number of homomeric coiled coils, including the 
homotetramer ELAEIK.  
Heptad positions a, d, e, and g were populated by all combinations of the residues 
Ala, Glu, Ile, Lys, Leu, Asn, Gln, Arg, Ser and Val to calculate all possible “gade” 
motifs. gade sequences that could be overlapped to give two type II gabcde 
repeats were assessed for their ability to form pairs of heterotypic interactions 
using the bZIP scores for all the possible interactions between that set of gade 
sequences 292. The best score for the undesired products (i.e. homotypic 
interactions) was subtracted from the worst score for the desired products (i.e. two 




different heterotypic interactions) to give a Δ-score for that pair of gabcde motifs. 
The following filtering was applied to the resulting pairs: core a and d positions 
must be Ile, Leu or Val; no Ile, Leu or Val at c and b positions; e and g positions 
must be polar (Glu, Lys, Gln, Asn, Ser or Thr). Sequence pairs with a Δ-score of 
>15 were considered. Full peptide sequences were designed in c-register. The f 
positions were populated by Lys and a single Trp at position f19. Helix-capping Gly 
residues were added to N and C termini. 
2.1.2 ABAB Heterotetramer design 
2.1.2.1 Design of Glu-Lys stabilised heteromers 
The peptides 1-LI-A, 1-LI-B, 2-LI-A, 2-LI-B, 3-LI-A and 3-LI-B contained 
a=Leu/d=Ile cores while the peptides 1-LV-A, 1-LV-B, 2-LV-A, 2-LV-B, 3-LV-A and 
3-LV-B contained a=Leu/d=Val cores. Oppositely charged Glu and Lys residues 
were arranged in various configurations. Peptides 1-LI-A, 1-LI-B, 1-LV-A and 
1-LV-B contained e/g ionic pairs where in 1-LI-A and 1-LV-A e=g=Glu and in 1-LI-B 
and 1-LV-B e=g=Lys. Peptides 2-LI-A, 2-LI-B, 2-LV-A and 2-LV-B contained c/e 
ionic pairs where in 2-LI-A and 2-LV-A c=e=Glu and in 2-LI-B and 2-LV-B c=e=Lys. 
Peptides 3-LI-A, 3-LI-B, 3-LV-A and 3-LV-B contained b/g ionic pairs where in 3-
LI-A and 3-LV-A b=g=Glu and in 3-LI-B and 3-LV-B b=g=Lys. Where e or g 
positions were not occupied by Glu or Lys, these positions were Gln. Where b or c 
positions were not occupied by Glu or Lys, these positions were Ala. The f positions 
were populated with Gln residues in B (basic) peptides or Lys in A (acidic) peptides 
to promote solubility and aid purification. A single Trp residue was placed at 
position f19 to provide a chromophore. Helix-capping Gly residues were added to 
N and C termini. 
The peptides 1-LI-A-g and 1-LI-B-g were identical to 1-LI-A and 1-LI-B, 
respectively, except they were designed in g-register and the Trp chromophore 
was at f22.  
2.1.2.2 Design of Ala@g heteromers 
The peptides 2-LIA-A and 2-LIA-B contained a=Leu/d=Ile cores while the peptides 
2-LVA-A and 2-LVA-B contained a=Leu/d=Val cores. All peptides contained c/e 
ionic pairs. In 2-LIA-A and 2-LVA-A c=e=Glu and in 2-LIA-B and 2-LVA-B c=e=Lys. 
All g and b positions were occupied by Ala. All peptides contained Gln at f positions 




except at f19, which was Trp to provide a chromophore. Helix-capping Gly residues 
were added to N and C termini. 
2.1.3 ABCD Heterotetramer design 
The sequences and resulting ABCD heteromer combinations of ABCD peptides 1–
8 were generated computationally using a script implemented in Python. All 
4-heptad permutations (without repetition) of the heptads ELAAxEx, KLAAxKx, 
ELAAxKx and KLAAxEx (gabcdef) were generated such that the resulting 24 
peptides contained each heptad once. Then, all possible 4-peptide permutations 
(with repetition) of the 24 peptides were generated, representing all possible 
homotetramers and ABAB, AABC and ABCD heterotetramers. All tetramers were 
scored and sorted based on whether e-g′ interactions between equivalent heptads 
in adjacent helices would result in attractive (E-K) or repulsive (E-E or K-K) ionic 
interactions. ABCD heterotetramers where all 16 possible interhelical ionic 
interactions were satisfied and ABAB and AABC heterotetramers where 13 or more 
ionic interactions were satisfied were extracted and stored. Peptides appearing in 
the “favourable” ABAB and AABC heterotetramers were cross referenced with the 
“favourable” ABCD heterotetramers. Where peptide pairs or triplets considered 
likely to interact to form ABAB or AABC heteromers appeared within ABCD 
heteromer quadruplets, these quadruplets were discarded.  
The cores of the peptides appearing in the remaining ABCD heteromers were then 
designed in order to minimise homomerisation of these peptides. Where 
favourable ionic interactions would occur in the homomer the core d positions were 
Val. Where repulsive interactions would occur, d positions were Ile. Final peptides 
sequences were generated in c register. All b and c positions were Ala, and all f 
positions were Gln. Helix-capping Gly residues were added to N and C termini. 
Models of the resulting ABCD heterotetramer sequences were generated in 
ISAMBARD then scored using Bristol University Docking Engine (BUDE) 293,294. 
Assemblies achieving better initial BUDE scores than a cut-off of -100 were kept 
and were then subject to parameter optimisation in ISAMBARD, and final BUDE 
scores for optimised models were obtained. Models were subject to 30 rounds of 
parameter optimisation for chain separation (distance between individual helical 
axes) and ΦCα (rotation of helices relative to central axis) using a genetic algorithm.  
Finally, C-terminal mass/chromophore tags were manually designed and added to 
the ABCD peptides 5–8 following the pattern GxΦ, where x is a small amino acid 




(Gly, Ala, Ser, Asn) and Φ is a chromophore (Trp, Tyr). The ABCD peptides 1–4 
did not contain mass/chromophore tags and were designed to contain Trp 
chromophores at a single f position, f19.  
2.1.4 Tetramer core mutant design 
2.1.4.1 Design of CC-Tet core mutant 
The peptide CC-Tet-IA was designed as a core mutant of the homotetrameric 
coiled coil CC-Tet 208 where two Ile residues were mutated to Ala at positions d13 
and d20. The sequence was otherwise identical to the parent, CC-Tet.  
2.1.4.2 Design of 1-LI-AB core mutant 
The peptides 1-LI-A* and 1-LI-B* were designed as core mutants of the acidic and 
basic peptides 1-LI-A, and 1-LI-B, respectively. Both peptides contained Leu to Ala 
and Ile to Ala mutations in their central heptads (positions a14 and d17). The 
sequences were otherwise identical to the parent peptides.  
2.1.4.3 Design of M2-like ELAEIK core mutants 
The peptides ELAEIK-M2-Aa, ELAEIK-M2-Ad and ELAEIK-M2-Aa-HI were based 
on the sequence for the peptide ELAEIK (Section 2.1.1.4) and the sequence of the 
4-helix bundle region of the M2 protein from Influenza B, which binds the drug 
amantadine. The amantadine-contacting residues were identified from X-ray 
crystallographic and solution phase NMR structures of the M2 4-helix bundle 
solved in the presence of amantadine 271,272. This gave the amantadine binding 
motif: VxxASxxAxxH. The peptides ELAEIK-M2-Aa and ELAEIK-M2-Ad contained 
this motif superimposed onto the parent ELAEIK sequence, with the motif designed 
to start at an a or d position, respectively (a7, d10). The peptide ELAEIK-M2-Aa-
HI was identical in sequence to ELAEIK-M2-Aa except it contained a His to Ile 
mutation at position a17.  
2.2 Peptide synthesis and purification  
2.2.1 Automated solid-phase peptide synthesis 
Peptides were synthesised on a 0.1 mmol scale by solid-phase peptide synthesis 
on ChemMatrix Rink amide resin (PCAS BioMatrix) or Novabiochem Rink amide 
resin (Merck) on a Liberty Blue automated microwave peptide synthesiser (CEM) 
using Fmoc-protected amino acids (supplied by Novabiochem or Cambridge 




Reagents) at 0.2 M in dimethylformamide (DMF, Cambridge Reagents). 
Deprotection was performed with 20 % (v/v) morpholine (Alfa Aesar) in DMF or 
with 20 % morpholine and 5 % formic acid in DMF for peptides ABCD7 and ABCD8 
to suppress aspartimide formation. Coupling was performed using 0.5 M 6-Chloro-
1-hydroxybenzotriazole (Cambridge Reagents) in DMF as the activator and 1.0 M 
N,N′-Diisopropylcarbodiimide (DIC, Acros Organics) in DMF as the activator base. 
Following synthesis, peptides were N-terminally acetylated for 20 min at room 
temperature using approximately 1 % (v/v) acetic anhydride and approximately 
1 % (v/v) pyridine in 1:1 DMF/dichloromethane (DCM, Sigma Aldrich) or 100 % 
DMF. Peptides were simultaneously cleaved from the resin and side chain 
deprotected for 2 h at room temperature using a mixture of 5 % (v/v) H2O and 5 % 
(v/v) triisopropylsaline (TIPS, Acros Organics) in trifluoroacetic acid (TFA, Acros 
Organics). Resin was removed by filtration and crude peptides were precipitated 
in cold diethyl ether (Honeywell Research Chemicals) then isolated by 
centrifugation at 4 °C. Peptides were re-suspended in 1:1 ultrapure Milli-Q 
water/acetonitrile then lyophilised prior to purification.  
2.2.2 Reversed-phase HPLC purification  
Peptides were purified by reversed-phase high-performance liquid 
chromatography (HPLC) using C18 reversed phase columns (150 x 10 mm, 100 Å 
pore size, Phenomenex). A flow rate of 3 mL.min-1 was used. Different linear 
gradients of buffer A (ultrapure Milli-Q water containing 0.1 % (v/v) TFA) and buffer 
B (acetonitrile containing 0.1 % (v/v) TFA) were used over different time periods, 
depending on the peptide. Typically, homomeric peptides and basic peptides were 
purified with a linear gradient of 20–80 % buffer B over 30 min at room temperature. 
Acidic peptides were purified with a linear gradient of 30–80 % buffer B over 50 
min at 50 °C (using a water bath or column oven). Columns were equilibrated at 
the starting buffer conditions and washed with 95 % buffer B between gradients. 
Products were collected manually as fractions of approximately 0.25–1 mL.  
Following peptide mass determination (see Section 2.2.3), fraction purity was 
confirmed by reversed-phase HPLC using analytical C18 reversed-phase columns 
(100 x 4.6 mm, 100 Å pore size, Phenomenex) with linear gradients of buffer A and 
B. A flow rate of 1 mL.min-1 was used. Representative analytical HPLC traces for 
all peptides are shown in Section 8.2. Selected fractions were pooled and 
lyophilised prior to biophysical characterisation. 




2.2.3 MALDI-TOF mass spectrometry 
Peptide masses were confirmed by MALDI-TOF (matrix-assisted laser 
desorption/ionisation time-of-flight) mass spectrometry with an ultrafleXtreme II 
mass spectrometer in positive-ion reflector mode (Bruker, UK). Samples were air-
dried onto a ground-steel target plate with α-cyano-4-hydroxycinnamic acid matrix 
(α-CHCA, Fluka Analytical). Representative mass spectra for all peptides are 
shown in Section 8.2. Theoretical masses are quoted as average masses and were 
determined using Peptide Synthetics’ online Peptide Mass Calculator (Peptide 
Protein Research Ltd., http://www.peptidesynthetics.co.uk/tools/)  
2.3 Biophysical characterisation 
2.3.1 General  
All biophysical characterisation was performed in phosphate buffered saline (PBS; 
8.2 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4) unless 
otherwise stated. Chemicals and solvents were obtained from Fisher Scientific or 
Sigma Aldrich unless otherwise stated.   
2.3.2 Peptide concentration determination  
Peptides were dissolved in ultrapure Milli-Q water and concentrations were 
measured by UV absorbance using a NanoDrop 2000 spectrophotometer (Thermo 
Scientific). For all peptides, concentration was determined using the extinction 
coefficient for the Trp chromophore at 278 nm (ε278(Trp) = 5579 M-1.cm-1) except 
peptides ABCD5 and ABCD7 where concentration was determined using the 
extinction coefficient for the Tyr chromophore at 274 nm (ε274(Tyr) = 1420 M-1.cm-1). 
2.3.3 Circular dichroism spectroscopy 
Circular dichroism (CD) spectroscopy was performed using either a JASCO J-810 
or a JASCO J-815 spectropolarimeter with a Peltier temperature controller (Jasco, 
UK). Peptide solutions were prepared at varying concentrations in buffer by dilution 
of stock solutions in ultrapure Milli-Q water followed by addition of a 10X PBS stock 
or 2X sodium phosphate (± NaCl) stock to give a 1X buffer concentration. Samples 
were analysed in quartz cuvettes with variable pathlengths depending on peptide 
concentration (10 mm: 1–8 μM total peptide concentration, 2000–4000 µL total 
sample volume; 5 mm: 5–30 μM total peptide concentration, 1000–2000 µL total 




sample volume; 1 mm: 50–200 μM total peptide concentration, 200–400 µL total 
sample volume; 0.1 mm: 750–1000 μM total peptide concentration, 50–100 µL total 
sample volume). Full spectra were measured between 190 and 260 nm with a 1 
nm step size, 100 nm.min-1 scanning speed, 1 nm bandwidth and 1 second 
response time except where very low peptide concentrations (1–2 µM) were used, 
in which case a scanning speed of 50 nm/min was used and the remaining 
parameters were kept the same. Spectra were measured at 5 °C or 20 °C unless 
otherwise stated. Variable temperature experiments were performed by heating 
and cooling samples 5–95–5 °C at a rate of 40 °C.h-1 whilst monitoring CD at 222 
nm at 0.5 °C intervals. For peptide 1-LI-B, full spectra (see above for parameters) 
were measured at 5 °C intervals while heating 5–95 °C. Data was buffer subtracted 
then CD (mdeg) was converted to mean residue ellipticity (MRE, deg.cm2.dmol-
1.res-1) by normalising for peptide concentration, number of amide bonds and 
cuvette pathlength, according to Equation 2-1. Where triplicate measurements 
were taken these were averaged and errors were calculated as one s.d. from the 
mean. Fraction helix (%) was calculated using Equation 2-2 295. Representative 
spectra and thermal denaturation measurements for all peptides are shown in 
Sections 8.3 and 8.4.  
MRE = 
CD
10 × c × l × n
 
Equation 2-1 Equation for the conversion of CD (mdeg) to MRE 
(deg.cm2.dmol-1.res-1). c, molar peptide concentration; l, sample path length 
in cm; n, number of amide bonds in sample (including C-terminal amide 
following cleavage from Rink amide resin). 
 
Fraction helix (%)  = 100 × 
MRE222 - MREcoil
-42500 × (1 - 3 n⁄ )  - MREcoil
 
Equation 2-2 Equation for calculating fraction helix (%) from MRE at 
222 nm (MRE222, deg.cm2.dmol-1.res-1). MREcoil = 640-45T; T, temperature 
(°C); n, number of amide bonds in sample (including C-terminal amide). 
2.3.4 Sedimentation velocity analytical ultracentrifugation  
Sedimentation velocity (SV) experiments were conducted at 20 °C in a Beckman-
Optima XL-I or XL-A analytical ultracentrifuge using an An-50 or An-60 Ti rotor. 
Solutions were prepared in buffer at a total peptide concentration of 140 μM except 
ABCD5678 (which contains peptides with a mix of Trp and Tyr chromophores) 




where a total peptide concentration of 220 μM was used in order to achieve A280 ≈ 
0.95, which is generally required for successful SV data fitting. Samples were 
prepared either at a volume of 305 μL and loaded into an SV cell with a 12 mm 
graphite-filled centrepiece and quartz windows, or at a volume of 410 μL and 
loaded into an SV cell with a 12 mm aluminium centrepiece and sapphire windows. 
The reference channels of the graphite and aluminium centrepieces were loaded 
with 320 μL or 420 μL of buffer, respectively. All measurements were performed in 
1X PBS (pH 7.4; density, ρ = 1.0054 g/cm2; viscosity, η = 0.01002 P), 10 mM 
sodium phosphate (pH 7.4; ρ = 0.9996 g/cm2; η = 0.01005 P) or 10 mM sodium 
phosphate with 1 M NaCl (pH 7.4; ρ = 1.0399 g/cm2; η = 0.01101 P). Following 
temperature equilibration to 20 °C for approximately 1.5 h at 3 krpm, samples were 
spun at 50 krpm. A total of 120 absorbance scans at 280 nm over a radial range 
of approximately 5.8 to 7.3 cm were measured at 5 min intervals. Data were fitted 
to a continuous c(s) distribution model using Sedfit, at 99% confidence level 296. 
The baseline, meniscus, frictional ratio (f/f0), and systematic time-invariant and 
radial-invariant noise were fitted. The partial specific volume ( v̅)  for each 
peptide/peptide combination was calculated using Sedfit 296. The buffer densities 
were calculated using SEDNTERP. Continuous c(s) distributions and residuals for 
all peptides/peptide combinations are shown in Section 8.5. For all SV 
experiments, residuals are shown below the c(s) distribution as a rectangular 
greyscale bitmap where the shade of grey indicates the magnitude of the difference 
between the data and the fit (mid-grey indicates residual value ≈ 0, i.e. agreement 
between data and fit; lighter shades indicate positive residual values and darker 
shades indicate negative residual values, i.e. deviations between data and fit). 
Each residuals bitmap displays the residuals for every scan, stacked from top to 
bottom, across the entire radial range included in the data processing, where the 
left and right edges of the bitmap represent the data boundaries at the meniscus 
and cell bottom, respectively. A homogenous grey bitmap indicates a good fit (and 
little noise).  
2.3.5 Sedimentation equilibrium analytical ultracentrifugation 
Sedimentation equilibrium (SE) experiments were performed at 20 °C in a 
Beckman-Optima XL-I or XL-A analytical ultracentrifuge using an An-50 Ti rotor 
and 12 mm six-channel epon-charcoal equilibrium cells with quartz windows. 
Solutions were prepared in buffer at a total peptide concentration of 70 μM except 
ABCD5678 where a total peptide concentration of 110 μM was used in order to 




achieve A280 ≈ 0.5, which is generally required for successful SE data fitting. All 
measurements were performed in buffers as described in Section 2.3.4. Samples 
were spun at speeds ranging from 15–42 krpm. Absorbance scans at 280 nm were 
measured at 3 or 4 krpm intervals following an initial equilibration period of 8 h and 
a second equilibration period of 1 h.  Data sets were initially fitted to a single, ideal 
species model using Ultrascan II (http://www.ultrascan.uthscsa. edu/). 99 % 
confidence limits were calculated using Monte Carlo analysis of the obtained fits. 
The v̅  for each peptide/peptide combination and the buffer densities were 
calculated using Sedfit 296. 
SE experiments were performed on individual acidic and basic peptides at 20 °C 
in a Beckman-Optima XL-I or XL-A analytical ultracentrifuge using an An-60 Ti 
rotor. Solutions at a total peptide concentration of 70 μM were prepared in 1X PBS 
at a volume of 110 μL and loaded into an SV cell with a 12 mm graphite-filled 
centrepiece and quartz windows. The reference channels were loaded with 120 μL 
of buffer and samples were spun at speeds ranging from 45 to 60 krpm. 
Absorbance scans at 280 nm were measured at 3 krpm intervals following an initial 
equilibration period of 8 h and a second equilibration period of 1 h. Data sets were 
fitted as described above. All SE data is shown in Section 8.5, where 
representative data, fitted curves and residuals at three different rotor speeds are 
plotted in different colours.  
2.3.6 Peptide crystallography 
Peptides were crystallised at 20 °C using the sitting drop method. Solutions of 
peptides 2-LI-EK, 3-LI-EK and ELAEIK were prepared at 3.0 mM in unbuffered 
deionised water. Screening was carried out using the standard commercial 
screens JCSG-plusTM, Morpheus®, Structure Screen 1 & 2 and PACT premierTM 
(Molecular Dimensions). Screens were prepared in 96-well MRC plates using an 
Oryx8000 Protein Crystallisation Robot (Douglas Instruments) with reservoir 
volumes of 50 μL. Droplets contained 0.3 μL peptide solution equilibrated with 
0.3 μL of reservoir solution. Final crystallisation conditions for all peptides can be 
found in Table 8-2.  
Single crystals were cryoprotected by soaking in 25 % (v/v) glycerol in ultrapure 
Milli-Q water and reservoir solution, prior to loop-mounting and plunge-freezing in 
N2(l). Data collection was carried out under cryogenic conditions at wavelengths of 
0.93 to 0.98 Å on beamline i03, i04 or i04-1 at Diamond Light Source (Didcot, UK). 




Data indexing and integration were carried out in MOSFLM 297 and scaling was 
carried out in AIMLESS 298. Initial phases for the peptides ELAEIK and 2-LI-EK 
were determined by molecular replacement with Phaser-MR 299 using full or partial 
poly-alanine parallel tetrameric coiled-coil models (as predicted by the Matthews 
coefficient 300) generated in ISAMBARD or CC-Builder as the search models 293,301. 
The phase for peptide 3-LI-EK was generated using ARCIMBOLDO 302. AIMLESS, 
Phaser-MR and ARCIMBOLDO were all used as implemented in CCP4 303. Final 
models were obtained through iterative rounds of model building in COOT and 
refinement in PHENIX Refine 304,305. Data collection and refinement statistics can 
be found in Table 8-3, Table 8-4 and Table 8-5. 
All protein structure images were generated in PyMol (http://www.pymol.org).  
2.3.7 DPH-binding assay 
Binding of the hydrophobic dye 1,6-Diphenyl-1,3,5-hexatriene (DPH) to the 
peptides CC-Tet-IA and CC-Tet was assayed by measuring the fluorescence of 
samples containing DPH and different concentrations of peptides. DPH fluoresces 
strongly at 452 nm when present in an apolar environment, such as a lipid bilayer 
or a protein’s hydrophobic core, where it becomes fluorescently polarized.  
A DPH stock solution was prepared in 100 % dimethyl sulfoxide (DMSO) at a 
concentration of approximately 1 mM. DPH concentration was verified using 
absorbance at 350 nm (ε350(DPH) = 88000 M-1.cm-1). Subsequently, a 10 µM stock 
of DPH in 1:1 DMSO/ultrapure water was prepared. Peptide stocks were prepared 
at 80 and 800 µM in ultrapure Milli-Q water.  
Samples containing 1 µM DPH and varying peptide concentrations were prepared 
in 1X PBS in black Nunc 96-Well Flat Bottom plates (Thermo Fisher Scientific). 
Peptide concentrations were 0, 10, 20, 50, 75, 100, 150, 200, 250 and 500 µM. 
Samples were prepared in triplicate and incubated in the dark for 2 h at RT with 
gentle rocking. DPH fluorescence was measured on a CLARIOstar microplate 
reader (BMG LABTECH) with excitation at 350 nm and emission measured 
between 380 and 600 nm. DPH fluorescence at 452 nm was normalised to maximal 
fluorescence then normalised triplicate experiments were averaged. Coiled coil 
concentration (c) was determined as peptide concentration/oligomeric state. DPH 
fluorescence at 452 nm/maximal fluorescence at 452 nm measured for that peptide 
(F452/Fmax452) was plotted against c.  




2.4 Molecular biology 
2.4.1 Buffers, solutions and cell culture medias 
Chemicals were obtained from Sigma-Aldrich, Fisher Scientific or Bio-Rad unless 
otherwise stated. All buffers, buffer components and components of cell culture 
media were prepared using distilled water (Type II, Elix, Millipore) unless otherwise 
stated. 
2.4.1.1 Buffers and solutions 
Buffer components are listed in Table 2-1. Where appropriate, solutions were pH-
adjusted using a Jenway 3150 pH meter.  
2.4.1.2 Cell culture medias 
All components were sterilised prior to use by autoclaving at 121 °C for 15 min or 
by filter-sterilisation using 0.22 µm filters (Sartorius Stedim Biotech). Following 
autoclaving/filtration, all components were handled under sterile conditions.  
Lysogeny broth (LB) media was prepared from pre-weighed sachets and LB agar 
was prepared from pre-weighed capsules (both from MP Biomedicals).  
Buffer Components 
50X TAE 2.0 M Tris, 1.0 M acetate, 0.05 M EDTA 
5X TBE 0.45 M Tris, 0.44 M borate, 0.01 M EDTA 
10X PBS 
100 mM Na2HPO4, 18.0 mM K2HPO4, 1.37 M 
NaCl, 27 mM KCl, pH 7.4 
10X Tris-Gly 250 mM Tris, 2 M glycine 
10X PAGE stacking buffer 1.25 M Tris, pH 6.8 
2X PAGE resolving buffer 0.75 Tris, pH 8.3 
2X SDS loading buffer 
100 mM Tris, 4 % (w/v) SDS, 22.5 %(v/v) 
glycerol, 2.5 mg.mL-1 bromophenol blue, 200 
mM DTT 
1X Tris-Gly-SDS PAGE 
running buffer 
25 mM Tris, 200 mM glycine, 0.05% (w/v) SDS 
1X Western blot transfer 
buffer 
25 mM Tris, 200 mM glycine, 10 % (v/v) 
methanol 
1X Western blot wash buffer 
10 mM Na2HPO4, 1.8 mM K2HPO4, 137 mM 
NaCl, 2.7 mM KCl, 0.05 % (v/v) Tween® 20 
Table 2-1 Stock buffer components. All buffers are used at 1X dilution 
unless otherwise stated. SDS, sodium dodecyl sulfate; DTT, dithiothreitol; 
EDTA, ethylenediaminetetraacetic acid. 




M9 minimal media (42.3 mM Na2HPO4, 21.6 mM KH2PO4, 18.7 mM NH4Cl, 
8.56 mM NaCl) was supplemented with 0.2 % (w/v) casamino acids, 10 mM CaCl2, 
0.25 % (v/v) glycerol, 2 mM MgSO4, 2 μg.mL-1 thiamine. Casamino acids (MP 
Biomedicals) were prepared as a 20 % (w/v) solution. CaCl2 was prepared as a 
0.1 M solution. Glycerol was prepared as a 50 % (v/v) solution. MgSO4 was 
prepared as a 1 M solution. Thiamine was prepared as a 20 mg.mL-1 solution and 
filter-sterilised.  
Where antibiotic selection was required, ampicillin, chloramphenicol and/or 
kanamycin were used at final concentrations of 100 µg.mL-1, 25 µg.mL-1 and 
50 µg.mL-1, respectively. All antibiotics were prepared as 1000X stocks and filter-
sterilised. Chloramphenicol solutions were prepared in 100 % ethanol. 
Where appropriate, media was supplemented with 0.2 % (w/v) glucose to suppress 
expression from the ParaBAD promoter or 0.0002–0.2 % (w/v) arabinose to induce 
expression from this promoter. Glucose solutions were prepared as a 20 % (w/v) 
stock and filter-sterilised. Arabinose solutions were prepared as 20 % (w/v) or 
2.0 % (w/v) stocks and filter-sterilised. 
2.4.2 Cloning and plasmid preparation  
All cloning took place in XL1-Blue Escherichia coli cells (recA1, endA1, 
gyrA96(nalR), thi-, hsdR17(rK-, mK+), supE44, relA1, lac, [F′, proA+B+, laclqZ∆M15, 
::Tn10(tetR )]). Cells were grown on LB agar in static incubators or in LB media with 
shaking at 250 rpm at 37 °C. All restriction enzymes were provided by New 
England Biolabs unless otherwise stated. All restriction digests were carried out at 
37 °C unless otherwise stated. All enzymes were used in the recommended buffers 
provided by the supplier unless otherwise stated. Where appropriate, enzymatic 
reactions were diluted with ultrapure Milli-Q water. Oligonucleotides were provided 
by Eurofins Genomics. Peptide genes and promoter DNAs were purchased as 
GeneArt Strings (Thermo Fisher Scientific). Sanger sequencing was provided by 
the Eurofins Genomics TubeSeq service. 
2.4.2.1 Preparation of chemically-competent E. coli cells 
E. coli cells were streaked onto un-supplemented LB agar plates and incubated 
overnight at 37 °C. The following day, colonies were selected for incubation 
overnight in un-supplemented LB media at 37 °C. The following day, the overnight 
cultures were diluted 100-fold into 50 mL fresh un-supplemented LB media and 




grown to OD600 = 0.3–0.8. Cells were then isolated by centrifugation (10 min, 3600 
rpm, 4 °C), resuspended in 20 mL cold (4 °C) 0.1 M CaCl2 and incubated on ice 
for 20 min. Cells were then isolated again by centrifugation, resuspended in 3 mL 
cold 0.1 M CaCl2 with 2 mL cold 50 % glycerol and incubated on ice for 1 h. 
Following this incubation, 0.5 mL aliquots were transferred to pre-chilled 1.5 mL 
tubes and flash-frozen in N2(l) prior to storage at -80 °C. Following preparation, 
competent cells were handled on ice.  
2.4.2.2 Transformation into competent E. coli cells 
Where the DNA to be transformed was a purified plasmid product, 0.5 µL DNA was 
used. Where the DNA to be transformed was a ligation product, the entire 20–
30 µL ligation reaction was used.  
The DNA was pre-chilled in 1.5 mL tubes while competent cells were thawed on 
ice. Then, DNA was mixed with 100 µL competent cells and incubated on ice for 
20–40 min. Cells were subjected to heat shock at 42 °C for 90 sec then returned 
to ice for 60 sec. Following the addition of 400 µL LB media, cells were incubated 
at 37 °C with shaking for 30-60 min. Following this recovery period, cells were 
plated on pre-dried agar plates (dried for approximately 1 h, 37 °C). Where one 
plasmid was transformed, or two plasmids were co-transformed, 150 µL of cells 
were plated. Where three or more plasmids were co-transformed, or a ligation 
product was transformed, cells were recovered by centrifugation, resuspended in 
approximately 150–200 µL media then plated. Cells were spread using 10–20 
ColiRollers™ Plating Beads (Novagen) and incubated inverted at 37 °C overnight. 
Following incubation, parafilm-wrapped agar plates were stored at 4 °C for up to 2 
weeks.  
2.4.2.3 Purification of plasmid DNA from E. coli cells 
Plasmids were purified from 5 mL overnight cultures of transformed XL1-Blue E. 
coli cells using a QIAprep® Spin Miniprep kit (QIAGEN) according to the 
manufacturer’s instructions. 
Where a larger amount of DNA was required, DNA was purified from 100 mL 
overnight cultures of transformed XL1-Blue E. coli cells using a HiSpeed® Plasmid 
Midi kit (QIAGEN) according to the manufacturer’s instructions up to and including 
the DNA precipitation step (3.5 mL isopropanol, 5 min, RT). The DNA was then 
pelleted (60 min, 5000 rpm, 4°C) and washed with 5 mL 70 % (v/v) ethanol. The 




DNA was then pelleted again (30–60 min, 5000 rpm, 4°C), air dried, and 
resuspended in 100-200 µL TE buffer (QIAGEN).  
All purified DNA was stored at -20 °C. DNA concentrations were determined by UV 
absorbance using a DeNovix microvolume DS-11 spectrophotometer (ε260(dsDNA) 
= 50 M-1.cm-1). 
2.4.2.4 Agarose gel electrophoresis 
A solution of 1–2 % (w/v) molten agarose was prepared in 1X TAE. Subsequently, 
0.005 % (v/v) ethidium bromide was added to the solution then gels were poured 
in approximately 12.5 x 17 cm gel trays and allowed to set for 1 h prior to use. Gels 
were run in 1X TAE containing 0.005 % (v/v) ethidium bromide at 120 V for 1–2 h. 
Ethidium bromide-stained DNA was visualised by UV illumination using either a 
UV transilluminator or a GelDoc XR+ gel documentation system (BioRad). DNA 
samples were prepared in 5X GelPilot® DNA Loading Dye (QIAGEN) or 6X Purple 
Gel Loading Dye (NEB).  
2.4.2.5 Non-denaturing polyacrylamide gel electrophoresis 
Non-denaturing polyacrylamide gel electrophoresis (PAGE) was used to verify 
plasmid products prior to sanger sequencing. Restriction digest products were 
analysed on 7.5 % acrylamide gels and compared to DNA standards of known size 
to confirm the presence of the correct restricted fragments.  
A solution containing 7.5 % (w/v) acrylamide, 1X TBE, 0.05 % (w/v) ammonium 
persulfate and 0.1 % (v/v) tetramethylethylenediamine was prepared in deionised 
water. Ammonium persulfate was prepared as a 10 % (w/v) stock solution. A stock 
solution of 30 % (w/v) acrylamide was used (37.5:1 bisacrylamide, Severn 
Biotech). Gels were poured between 1.5 mm glass plates and allowed to 
polymerise to 1 h prior to use. Gels were run in 1X TBE at 120 V for 45–60 min 
then stained for 10 min in a solution of 0.005 % (v/v) ethidium bromide. Stained 
gels were imaged as outlined above. DNA samples were prepared as outlined 
above. 
2.4.2.6 Polymerase chain reaction 
All polymerase chain reactions (PCRs) were performed in a Techgene thermal 
cycler (Techne) using Pfu polymerase (Promega). PCR reactions were typically 
performed in a volume of 50 µL containing 20 ng template, 1 µM PCR-grade 




deoxynucleoside triphosphates (dNTPs, Invitrogen) and 0.4 µM primer(s) in 1X Pfu 
polymerase buffer. All reactions included a single 5 min denaturation cycle at 98 °C 
(after which 1 µL Pfu was added) followed by 30 cycles of denaturation (1 min, 
94 °C), annealing (1 min, variable temperature) and extension (variable time, 
72 °C). Extension time was determined as approximately 30 sec.kbp-1. All 
reactions were completed with a final extension cycle at 72 °C.  
2.4.2.7 Plasmid construction 
The plasmids pVRb-LacUV5-SFGFP, pVRb-O1O1-LacUV5-SFGFP, pBAD-LacI-
WT, pBAD-LacI-L251A-WTtet, pBAD-LacI-L251, pBAD-LacI-L251A, pVRc-LacI-
L251A and pBAD-LacI-L251A-ccDi were provided by Abigail Smith. The plasmid 
pE-SUMOpro-Kan-LbCpf1 was provided by Kara van Aelst. All plasmids used in 
this work are listed in Table 8-6 and representative plasmid maps are shown in 
Section 8.7. All primers are listed in Table 2-2. Primers were resuspended in 
ultrapure Milli-Q water at 100 µM then prepared for use as 10 µM stocks. All stocks 
were stored at -20 °C. 
Peptide gene design. DNA sequences for A1 (1-LI-A), A2 (2-LV-A), A3 (3-LV-A), 
B1 (1-LI-B), B2 (2-LV-B) and B3 (3-LV-B) were manually designed to reduce 
repetitive sequences and optimise for E. coli codon usage (Table 2-3). DNA 
sequences also contained 5′ XbaI and 3′ Acc65I restriction sites and flanking 5′ 
and 3′ buffer sequences. Synthesised DNA was resuspended in ultrapure Milli-Q 
water at a concentration of 20 ng.µL-1 and stored at -20 °C.  
pBAD-LacI-L251A-A/B and pVRc-LacI-L251A-A/B plasmids. The plasmids 
pVRc-LacI-L251A-A1, pVRc-LacI-L251A-A2, pVRc-LacI-L251A-A3, pVRc-LacI-
L251A-B1, pBAD-LacI-L251A-B1, pBAD-LacI-L251A-B2, pBAD-LacI-L251A-B3 
and pBAD-LacI-L251A-A1 were prepared by inserting the peptide genes into pBAD 
and pVRc plasmids carrying a truncated version of the Lac repressor (residues 1–
332) lacking its C-terminal tetramerisation domain (residues 333-360) and 
containing a point mutation, L251A. These plasmids also contain XbaI and Acc65I 
restriction sites for the introduction of novel oligomerisation domains at the Lac 
repressor C terminus. Insert DNA was digested with XbaI and Acc65I in NEBuffer 
3 and products were purified from the restriction digest mixture using a QIAEX II 
gel extraction kit (QIAGEN) following instructions for desalting and concentrating 
DNA solutions. Alternately, insert DNA was extracted from existing plasmids by 
restriction digest, fragments were resolved by agarose gel electrophoresis then 




appropriate fragments were purified using a QIAquick gel extraction kit (QIAGEN) 
or using a QIAEX II gel extraction kit (QIAGEN) following instructions for agarose 
gel extraction. Plasmid DNA was digested as above then treated with 3 µL calf 
intestinal alkaline phosphatase (Promega) which was added directly to the 
restriction digest reaction and diluted with ultrapure Milli-Q water to maintain a 
glycerol concentration <5 % (v/v). Plasmid fragments were then resolved by 
agarose gel electrophoresis and the appropriate fragment was purified using a 
QIAquick gel extraction kit (QIAGEN). Fragments were ligated using 1 µL T4 DNA 
ligase (Promega) in a 20 µL reaction at 4 or 20 °C for 4–16 h. Ligation products 
were transformed into XL1-Blue E. coli. Colonies containing successful ligations 
were selected and grown overnight and resulting plasmids were purified. 
Successful insertions were confirmed by restriction digest (XbaI/Acc65I in 
NEBuffer 3) and sequencing using primers 1 and 2.  
pBAD-LacI-(L251A)-ΔHTH plasmids. The plasmids pBAD-LacI-ΔHTH and 
pBAD-LacI-L251A-ΔHTH were prepared using PCR to delete residues 14–60 
(inclusive) from the Lac repressor gene in the plasmids pBAD-LacI-L251 (does not 
contain L251A point mutation) and pBAD-LacI-L251A. Primers 3 and 4 were used 




1 AGACCGCTTCTGCGTTC 17 
2 GCATGACTGGTGGACAGC 18 
3 *GGCATACTCTGCGACATCG 19 
4 *TCGTTGCTGATTGGCGTTGCCACC 24 
5 *AGATCTCGAGCTCGGATCC 19 
6 *GCTAGCCATACCATGATGATG 21 
7 *CCCGGTCTAGAGGGTAGTG 19 
8 GATCAGAGCTAGCCTGCAGGACTCAGAAGTCAATC 35 
9 GACTACATCTAGACCCATACCTCCAATCTGTTCGCGG 37 
10 *GGGAGTTAGCGGCTATCG 18 
11 *ACTCGGCTGCGGCCGCTTCTTTTTCAATCGCTGCCAG 37 
12 *GGAAGTTAGCAGCCATCAAAC 21 
13 *ACTTGGCAGCCGCCGCCTTTTGTTTAATCGCGGCCAATTTC 41 
14 *CGGGATCGCACATGAGCTGTCTTCGG 26 
15 *CGGGATATCACATGAGCTGTCTTCG 25 
16 *CCGTTAACCACCATCAAACAG 21 
17 CTAGCTCGCCATGGTTAATTCC 22 
18 AGTCATAGACTAGTGCCACAGCTAACAC 28 
19 GTAGCCGACTAGTTGTCATAATTG 24 
20 GGGCTAACAGGAGGAATTAACC 22 
Table 2-2 List of PCR and sequencing primers used in this work. * 
indicates primer was 5′ phosphorylated. 




products were treated with DpnI (1 µL added directly to PCR reaction), resolved by 
agarose gel electrophoresis, then purified using a QIAquick gel extraction kit 
(QIAGEN). The linear, blunt-end products were then ligated using 2 µL T4 DNA 
ligase in a 20 µL reaction at 15 °C for 16 h. Ligation products were transformed 
into XL1-Blue E. coli then plasmids were verified as described above except 
restriction digests were performed with HindIII/NcoI-HF in NEBuffer 2. The gene 
for peptide B1 was then inserted into these plasmids as described for the pBAD-
LacI-L251A-A/B plasmids.  
pBAD-6H-(T7-Xpress) plasmids. The plasmids pBAD-6H-T7-Xpress and pBAD-
6H were prepared using PCR to delete the Lac repressor gene or the Lac repressor 
gene and N-terminal tags, respectively, from the plasmid pBAD-LacI-L251A. The 
plasmids pBAD-6H-T7-Xpress-B1 and pBAD-6H-B1 were prepared in the same 
way from the plasmid pBAD-LacI-L251A-B1. For pBAD-6H-T7-Xpress and pBAD-
6H-T7-Xpress-B1, primers 5 and 7 were used. For pBAD-6H and pBAD-6H-B1, 
primers 6 and 7 were used. An annealing temperature of 50 °C and an extension 
time of 10 min was used. PCR products were then processed as described for the 


























Table 2-3 DNA sequences for A1, A2, A3, B1, B2 and B3 genes with 
peptide-coding region in bold and XbaI (T:CTAGA) and Acc65I (G:GTACC) 
restriction sites underlined. Restriction enzyme cut site is indicated by :. All 
sequences are 155 bp. 




primer 1 only. The genes for peptide B2 and B3 were then inserted into pBAD-6H 
as described for the pBAD-LacI-L251A-A/B plasmids. 
pBAD-6H-SUMO plasmids. The plasmids pBAD-6H-SUMO, pBAD-6H-SUMO-B1 
and pBAD-6H-SUMO-B2 were prepared by inserting the gene for SUMO into the 
plasmids pBAD-6H, pBAD-6H-B1 and pBAD-6H-B2, respectively. The SUMO 
gene was PCR-amplified from the plasmid pE-SUMOpro-Kan-LbCpf1. Primers 8 
and 9 were used to introduce a 5′ NheI and 3′ XbaI restriction sites adjacent to the 
SUMO gene to give PCR product NheI-SUMO-XbaI. An annealing temperature of 
55 °C and an extension time of 1 min was used. The PCR products were treated 
with DpnI, resolved by gel electrophoresis then purified with a QIAquick gel 
extraction kit (QIAGEN). Inserts and plasmids were digested with NheI/XbaI in 
NEBuffer 2 then processed, purified and ligated as described for the pBAD-LacI-
L251A-A/B plasmids. Plasmids were verified as described for the pBAD-LacI-
(L251A)-ΔHTH plasmids except sequencing was performed with primer 1 only. The 
gene for peptide B3 was inserted into pBAD-6H-SUMO to generate pBAD-6H-
SUMO-B3, as described for the pBAD-LacI-L251A-A/B plasmids. 
A1/B1 L14A-I17A Point mutations. Site directed mutagenesis was used to 
introduce simultaneous L14A and I17A point mutations into A1 and B1 genes in 
the plasmids pBAD-LacI-L251A-B1, pBAD-6H-SUMO-B1 and pVRc-LacI-L251A-
A1. Primers 10 and 11 were used for the A1 gene with an annealing temperature 
of 55 °C and an extension time of 10 min. Primers 12 and 13 were used for the B1 
gene with an annealing temperature of 50 °C and an extension time of 10 min. 
Blunt-end PCR products were then processed, purified and ligated as described 
for pBAD-LacI-(L251A)-ΔHTH plasmids.  
LacI Y282A/D point mutations. Site directed mutagenesis was used to introduce 
Y282A or Y282D point mutations into the Lac repressor gene in the plasmids 
pBAD-LacI-L251A-WTtet, pBAD-LacI-L251A, pBAD-LacI-L251A-ccDi, pBAD-
LacI-L251A-B1, pVRc-LacI-L251A and pVRc-LacI-L251A-A1. PCR was performed 
with primers 14 and 16 to introduce the Y282A mutation with an annealing 
temperature of 55-56 °C and an extension time of 6-10 min. PCR was performed 
with primers 15 and 16 to introduce the Y282D mutation with an annealing 
temperature of 55 °C and an extension time of 10 min. Blunt-end PCR products 
were then processed, purified and ligated as described for pBAD-LacI-(L251A)-
ΔHTH plasmids. Alternately, the LacI-L251A-Y282A gene was extracted from 
existing plasmids by restriction digest, fragments were resolved by agarose gel 




electrophoresis then appropriate fragments were purified using a QIAquick gel 
extraction kit (QIAGEN). The insert was then ligated into the appropriate backbone.  
Constitutive promoter plasmids. Pro1 and pro5 constitutive promoter DNA was 
designed using sequences from Davis et al  with flanking buffer DNA and a 3′ NcoI 
restriction site 306. A 5′ SpeI restriction site was introduced into the promoter DNA 
using PCR mutation with primers 17 and 18 with an annealing temperature of 57 
°C and an extension time of 1 min (Table 2-4). PCR products were then purified 
using a QIAquick PCR purification kit (QIAGEN). Using primers 19 and 20 the 
ParaBAD promoter was removed from and a SpeI restriction site was introduced into 
the plasmids pBAD-LacI-L251A, pBAD-LacI-L251A-ccDi, pBAD-6H-SUMO, 
pBAD-6H-SUMO-B1, pVRc-LacI-L251A, pVRc-LacI-L251A-A1, pVRc-LacI-
L251A-Y282A and pVRc-LacI-L251A-Y282A-A1. These PCR products were 
resolved by agarose gel electrophoresis and purified using a QIAquick gel 
extraction kit (QIAGEN). Plasmids and inserts were then digested with SpeI/NcoI 
in Cut Smart buffer. Inserts were purified using a QIAquick PCR purification kit 
(QIAGEN) and plasmids were processed and purified as described for the pBAD-
LacI-L251A-A/B plasmids. Inserts and plasmids were ligated and verified as 
described for the pBAD-LacI-L251A-A/B plasmids except restriction digests were 
performed with NdeI/NheI in Cut Smart buffer and sequencing was performed with 
primers 1 and 3.  
2.4.3 GFP-repression assay 
TB28 E. coli cells (F-, λ-, ilvG-, rfb-50, rph-1, ΔlacIZYA) 307 were transformed with 
a pVRb reporter plasmid carrying superfolder green fluorescent protein (GFP) 308 












Table 2-4 DNA sequences of constitutive promoters following PCR to 
introduce SpeI site. The promoter region is in bold and SpeI (A:CTAGT) and 
NcoI (C:CATGG) restriction sites are underlined. Restriction enzyme cut site 
is indicated by :. All sequences are 190 bp. 




for their ability to repress GFP expression. Following antibiotic selection on LB agar 
plates, colonies were selected and grown overnight at 37 °C in 5 mL supplemented 
M9 media. The following morning, 10 mL fresh supplemented M9 media was 
inoculated with 50 μL of overnight culture and induced with varying arabinose 
concentrations (0.0–0.2 % (w/v)). Cultures were grown at 37 °C until OD600 = 
approximately 0.4–0.6. OD600 values were recorded to three significant figures 
using a Lambda Bio UV/Vis spectrometer (PerkinElmer). 5 mL of each culture was 
pelleted (10 min, 5000 rpm, 4 °C) then re-suspended in 250 μL 1X PBS. Two 100 
µL aliquots of each sample were loaded into consecutive wells of a black 96 well 
polypropylene microplate. GFP fluorescence of each 100 µL sample was 
measured using a FlexStation Microplate Reader (Molecular Devices) with 
excitation at 470 nm and emission at 510 nm. GFP/OD600 was calculated for each 
100 µL sample then these duplicate measurements were averaged. Next, the four 
technical replicates were averaged. Mean values were plotted on a bar chart with 
error bars as one s.d. from the mean. Fold-repression values were calculated 
relative to the GFP-only control unless otherwise stated.  
2.4.4 Western blotting 
Western blotting was performed on TB28 E. coli whole cell lysates following GFP 
assays (co-transformed with all assay plasmids) or on TB28 E. coli whole cell 
lysates of cells transformed separately with plasmids carrying each protein of 
interest. Where transformed separately, cells were grown under “assay-like” 
conditions in 10 mL supplemented M9 minimal media at 37 °C until OD600 = 0.4–
0.6. Cells were induced with 0.0–0.2 % arabinose prior to growth.  
Following growth, 1–3 mL of each culture was pelleted. Pellets were re-suspended 
in 2X SDS loading buffer according to Equation 2-3 for induced cells (0.0002–0.2 
% arabinose) and according to Equation 2-4 for non-induced cells (0.0 % 
arabinose).  
Vol. loading buffer  = 
Vol. pelleted × OD600
10
 
Equation 2-3 Equation for determining the volume of 2X SDS loading 
buffer with which to resuspend cells induced with arabinose. Vol., volume 
(µL).  
 




Vol. loading buffer = 




Equation 2-4 Equation for determining the volume of 2X SDS loading 
buffer with which to resuspend uninduced cells. Vol., volume (µL). 
Samples were denatured at 90–95 °C for 10 min then resolved on 4–15 % precast 
MiniPROTEAN TGX gels (BioRad) in 1X Tris-Gly-SDS at 175 V for 35 min. 
Resolved proteins were then transferred to 0.45 µm Immoblion®-P PVDF 
(polyvinylidene fluoride) Membrane (Millipore) at 4 °C at 230 mA in 1X Western 
blot transfer buffer for 2 h. Following transfer, membranes were fixed in methanol 
then blocked overnight at room temperature in 10–15 mL 10 % (w/v) skimmed milk 
in 1X PBS. The following day, membranes were probed with primary anti-His 
antibody (mouse, Abcam) at a final concentration of 0.2 µg.mL-1 in 10 mL 10 % 
(w/v) skimmed milk in 1X PBS, then secondary anti-mouse IgG HRP-conjugated 
antibody (goat, Abcam) at a final concentration of 0.8 µg.mL-1 in 10 mL 10 % (w/v) 
skimmed milk in 1X PBS at room temperature for 2h, with five 5 min washes with 
1X Western blot wash buffer between antibody incubations. After a final 5 min wash 
with 1X PBS, detection was carried out using either BM Chemiluminescence 
Western Blotting Substrate (POD, Roche) or Amersham ECL Western Blotting 
Detection Reagent (GE Healthcare). Membranes were imaged using an 
Amersham Imager 600 (GE Healthcare) in chemiluminescence mode using 
manually set exposure times (10–40 sec for induced samples) Alternatively, 
Amersham Hyperfilm™ MP autoradiography film (GE Healthcare) was exposed to 
membranes for approximately 10–20 sec for induced samples and approximately 
30–40 min for non-induced samples. Exposed autoradiography films were 
developed using a Curix 60 X-ray film developer (Agfa HealthCare). Digitised blot 
images were processed using ImageJ to quantify band density as a percentage of 
all quantified bands 309. Percentage densities were calculated as relative densities 
compared to a reference band then averaged. Error bars were plotted as one s.d. 
from the mean. P values were calculated from T scores using an online P value 





Chapter 3: The design and characterisation of 
homotetrameric coiled coils 
3.1 Chapter introduction  
Tetrameric coiled coils make up less than 4 % of all known coiled coil structures 
214. Conversely, more than 86 % of known coiled-coil structures form parallel or 
antiparallel dimers. As such, it is perhaps unsurprising that many de novo coiled-
coil design attempts have focussed on dimeric targets 207,214. While the study and 
design of dimers has increased our understanding of protein sequence-structure 
relationships and led to useful applications 310-313, coiled coils with larger oligomeric 
states are also important design targets. For example, tetramers offer many 
advantages over components with lower oligomeric states when the aim is to 
produce modular protein components that may be of use in synthetic biology, 
nanotechnology or materials science. As introduced in Chapter 1, tetramers are 
particularly useful in these contexts because: (1) tetramers display more binary-
like characteristics than lower oligomeric states making them more useful as 
switches; (2) they can co-localise more proteins of interest; and (3) they are more 
stable than lower order coiled coils of comparable length, making them more 
tolerant to modifications that expand their function. In this work, the de novo coiled 
coils are primarily intended for use as PIDs in artificial transcription factors. Many 
naturally occurring transcription factors rely on tetramerisation for function, 
including the Lac repressor in bacteria and p53 in humans 314,315. 
To date, most attempts at designing novel tetrameric coiled coils have centred 
around the redesign of naturally occurring coiled coils, for example through the 
redesign of their cores or through the optimisation of core-flanking ionic residues 
187,205,206,223,316. Furthermore, there has been much work in the past on designing 4-
helix bundles, which do not necessarily contain the extensive knobs-into-holes 
(KIH) interactions that characterise coiled coils 317,318. These have used both 
computational and empirical approaches 42,234,319,320. While truly de novo tetrameric 
coiled coils are generally rare, studies of this nature have allowed rules to be 
elucidated that have enabled the design of a totally de novo homotetrameric coiled 
coil, CC-Tet 208. 




CC-Tet was previously designed as part of the coiled coil basis set, a set of de 
novo coiled coils intended for use in synthetic biology applications 208. The set, 
which also includes a dimer and trimers, was designed according to established 
relationships between the identities of the a and d residues and the oligomeric state 
of coiled coils 187. For example, placing Leu at a and Ile at d leads to tetramers. As 
well as implementing these core-design rules, CC-Di, -Tri and -Tet were also 
designed under the assumption that lower-order coiled coils form Type-N 
interfaces where the residues at the a and d positions primarily contribute to KIH 
packing and oligomeric state specification (Figure 3-1a) 204,208. Furthermore, their 
heptads follow the classic HPPHPPP repeat pattern (H, hydrophobic; P, polar) 
where the a and d residues form the hydrophobic seam through which the 
amphipathic helices interact. The core-flanking e and g positions largely contribute 
to partner selection. Together, these residues form a single gade motif. However, 
as introduced in Chapter 1, higher-order coiled coils can also contain two 
hydrophobic seams where each helix interacts with its two neighbours via separate 
hydrophobic seams 202. Depending on the extent of overlap between the seams 
these coiled coils are designated Type-I, -II or -III 43,203,204. Furthermore, the inter-
seam angle helps to determine oligomeric state. While theoretically optimal for 
pentamer formation 43, the angle between the seams in Type-II interfaces should 
also be conducive with tetramer formation: the inter-seam angle in an idealised 
Type-II interface is 103 ° and the internal angle of a square (representing a 
tetramer) is 90 °, giving a discrepancy of just 13 ° (Figure 3-1c) 204. Because both 
Type-N and Type-II interfaces appear to be able to form tetrameric coiled coils, 
both approaches to describing these coiled-coil structures must be considered. 
Furthermore, in Type-N coiled coils, typically only the e and g residues take part in 
interhelical interactions, such as ionic interactions, that help to specify the coiled-
coil structure (Figure 3-1b). However, in Type-II coiled coils the e and g residues 
are increasingly involved in KIH interactions and the other core-flanking residues 
are positioned closer in space. Therefore, residues at the more-peripheral b and c 
positions may also take part in interhelical interactions and, thus, a wider range of 
interhelical interactions are potentially available to tetrameric coiled coils (Figure 
3-1d). 
This chapter describes the design and characterisation of an expanded set of de 
novo homotetramers. These coiled coils are intended for use as PIDs in vivo, 
particularly in the design of artificial transcription factors. However, they may also 
find use in the fields of nanotechnology and materials science 263,321-323. 




Furthermore, they represent a step towards heterotetrameric coiled coils, which 
will ultimately be useful for building increasingly complex components for synthetic 
biology.  
3.2 CC-Tet is not robust to mutation 
3.2.1 A CC-Tet charge-swapped variant is not tetrameric 
The coiled coils in the basis set contain different core residues that specify dimeric, 
trimeric and tetrameric oligomeric states 208. Otherwise, their sequences are very 
similar to each other. For example, all of the designs contain Glu at the g positions 









Figure 3-1 Type-N and Type-II coiled-coil interfaces and potential 
interhelical interactions. Helical wheels for a dimeric coiled coil 
demonstrating (a) a Type-N interface involving the gade (blue/yellow) 
heptad positions and (b) the potential interhelical interactions that may 
occur between core-flanking residues. Helical wheels for a tetrameric coiled 
coil demonstrating (c) a Type-II interface involving abcdeg residues as 
overlapping deab (blue) and cdga (yellow) motifs and (d) the potential 
interhelical interactions that may occur between core-flanking residues. 
Red arrows indicate approximate orientation of the hydrophobic seams. 
Potential interhelical interactions: 1, e-g′; 2, c-e′; 3, b-g′; 4, b-c′.  




ionic interactions. Altering the residues at these positions could expand the basis 
set and increase the number of available components for use in synthetic biology. 
Furthermore, it would allow for the determination of the contribution of these 
residues to oligomeric state. Therefore, a charge-swapped version of CC-Tet was 
made. That is, the residues at the g ang e positions were swapped such that g=Lys 
and e=Glu to generate the peptide CC-Tet-KE (Figure 3-2). This peptide was 
otherwise identical to CC-Tet including at the core positions, which were a=Leu 
and d=Ile; the c and b positions, which were Ala; and the f positions, which were 
Gln to promote helicity, Lys to promote solubility or Trp to provide a chromophore 
for detection and concentration determination. This peptide was made by solid-
phase peptide synthesis, purified by HPLC and confirmed by mass spectrometry 
then investigated using various biophysical techniques. 
Far UV circular dichroism (CD) spectroscopy was used to probe the folded state of 
the peptide. This technique is widely used to study protein secondary structures, 
stabilities and interactions 324-326. CD is the difference in absorption of right and left 
circularly polarised light by a chiral molecule and CD spectroscopy involves 
measuring CD as a function of wavelength. In the far UV region (190-250 nm) the 
chromophore is the amide bond, which gives signal when located in a regularly 
folded chiral environment, i.e. when the bonds adopt regular φ/ψ angles within 
secondary structure elements. The CD spectra of α helices have a characteristic 
shape with two minima at 208 and 222 nm and a maximum at 193 nm 327. A mean 
residue ellipticity at 222 nm (MRE222) value of approximately -36000 
deg.cm2.dmol-1.res-1 is indicative of a fully α-helical structure.  
When measured at 10 µM peptide concentration both CC-Tet and CC-Tet-KE had 
CD spectra with minima at 208 and 222 nm (Figure 3-3a). This showed that CC-
Tet-KE, like CC-Tet, adopted a highly α-helical structure.  
The thermal stability of CC-Tet-KE was also investigated by monitoring MRE222 
while heating the peptide from 5 to 95 °C (Figure 3-3b). As the temperature 
increased there was an increase in MRE222 with both CC-Tet and CC-Tet-KE, 
 
Figure 3-2 Peptide sequences for CC-Tet and CC-Tet-KE. Both peptides 
were in g-register and were N-terminally acetylated and C-terminally 
amidated. Ac, acetyl.  




consistent with the loss of α-helical character and partial unfolding. With 
CC-Tet-KE, part of a sigmoidal unfolding curve could also be seen and the MRE222 
at 95 °C was much higher than for CC-Tet. Therefore, CC-Tet-KE was less 
thermally stable than CC-Tet, although the thermal midpoint of unfolding (TM, the 
temperature at which the sample is 50 % unfolded) could not be determined for 
either peptide.  
Next, CC-Tet-KE was investigated using analytical ultracentrifugation (AUC) to 
determine its solution-phase molecular weight. Both sedimentation velocity (SV) 
and sedimentation equilibrium (SE) experiments were performed 328. In SV 
experiments, solutes are subject to high centrifugal force and the resulting 
sedimentation is monitored over time using absorbance. This provides information 
about the solute’s size and shape and about sample homo-/heterogeneity. In SE 
experiments, solutes are spun at lower speeds and for longer times than in SV 
experiments. This allows an equilibrium between sedimentation and back diffusion 
to establish. At equilibrium, the radial distribution of solute concentration provides 
information about solute mass and, for associating species, association constants.   
In both SV and SE experiments, the predicted molecular weights for CC-Tet-KE 
corresponded to a trimeric oligomeric state (Figure 3-3c and d, Figure 8-77). 
Therefore, although CC-Tet-KE formed an α-helical oligomer, it was not a tetramer 
like the parent, CC-Tet 208.  
The sequences differed only at the e and g positions therefore it appears that the 
identities of the residues here play some role in oligomeric state specification in 
these peptides. Although CC-Tet was designed with a traditional Type-N heptad 
repeat, its crystal structure has features of a Type-II coiled interface: some residues 
at g and e, as well as the a and d positions, act as knobs in KIH interactions, as 
determined using SOCKET 201,208. Therefore, while the g=Glu/e=Lys arrangement 
may be conducive to KIH formation in CC-Tet, the charge-swapped version may 
not be. So, without these additional stabilising KIH interactions, the weakened 
structure “defaults” to a trimer. In CC-Tri and CC-Di, only the a and d positions act 
as knobs in KIH interactions so the identities of the residues at the e and g positions 
should not affect the structure. Therefore, it is predicted that charge-swapped 
versions of CC-Tri and CC-Di would retain the oligomeric state of the parent.  
Furthermore, Glu may be accommodated at the g position in CC-Tet because it is 
relatively small. Lys, however, is a much larger residue and may be poorly 




accommodated at this position due to the direction of the Cα-Cβ bond vector that, 
in a tetramer, points towards the adjacent helix (conversely, at the e position, this 
bond vector points out into solution). Therefore, due to steric clashing, placing Lys 
at the g position may actively force the coiled coil into a lower oligomeric state 
where the g positions are more solvent-exposed and the core flanking e and g 
residues on adjacent helices are further apart in space.  
3.2.2 A buried hydrogen bonding network cannot recover tetramerisation 
Because CC-Tet-KE was trimeric, further versions of this peptide were made to 
determine whether the tetrameric state could be restored. Given that the X-ray 









Figure 3-3 Biophysical characterisation of the CC-Tet charge-swapped 
version, CC-Tet-KE. (a) CD spectra at 5 °C of CC-Tet and CC-Tet-KE. (b) 
Temperature-dependent CD measurements monitoring MRE222 between 
5 and 95 °C for CC-Tet and CC-Tet-KE, key as in (a). Peptide 
concentrations for CD spectroscopy were 10 µM. (c) Sedimentation 
velocity c(s) distributions (top) and residuals (bottom) for CC-Tet-KE 
returning a Mw of 10.5 kDa (3.1 x monomer mass). (d) Sedimentation 
equilibrium data at 30, 33, and 36 krpm (red, green and blue circles) and 
fits (black lines) (top) and residuals (same colours) (bottom) for CC-Tet-
KE returning a Mw of 9.6 kDa (2.8 x monomer mass). All measurements 
were performed in PBS (pH 7.4). Mw, molecular weight. 




core residues that acted as knobs, CC-Tet-KE was redesigned to make the 
interfaces more Type-II-like. The interfaces between adjacent helices in the 
tetramer were treated as dimeric interactions, allowing for the implementation of 
design rules known to promote dimer formation. Promoting this dimer-like 
interaction in the context of CC-Tet-KE may encourage the peptide to form a 
Type-II coiled coil and possibly a tetramer (though Type-II interfaces can also form 
larger oligomers 43,203).  
Placing Asn at a sites of coiled-coil sequences has been shown to promote dimer 
formation 208,229,329-331. It is believed that this is due to the formation of specific 
interhelical a-to-a hydrogen bonds that are only satisfied in the dimer 332-334. 
Otherwise, burying this polar residue destabilises the hydrophobic core and 
disfavours alternate oligomeric states. For example, the basis set homodimer, 
CC-Di, contains Asn at a17 (Figure 3-4b) 208. When this position is Ile, in keeping 
with the other a sites in CC-Di, this peptide forms a trimer 208.  
This dimer-specifying rule was introduced into the dimer-like interfaces of 
CC-Tet-KE (Figure 3-4c). Asn was introduced at d20 and e21, replacing Ile and 
Glu residues, respectively, to give the peptide CC-Tet-KE-N-4 (Figure 3-4a). These 
positions are equivalent to a positions when the deab and cdga interfaces are 
considered as gade-like motifs, the aim being that the Asn residues might form 
interhelical d-to-e hydrogen bonds. An additional version of this peptide was made 
with a C-terminal extension of an additional half-heptad. This peptide was 
designated CC-Tet-KE-N-4.5. For this pair of peptides, the “N” suffix denotes that 
the peptides contained Asn while the “4” or “4.5” suffixes denote the number of 
heptads in the peptides. 
CD spectroscopy showed that CC-Tet-KE-N-4 was predominantly unfolded with a 
fraction helix value of just 24 % (Figure 3-5a). The longer peptide, 
CC-Tet-KE-N-4.5, was more folded and had a characteristically α-helical spectrum 
with a fraction helix value of 83 %. It was also somewhat less folded than CC-Tet-
KE. Furthermore, temperature-dependent CD experiments revealed CC-Tet-KE-
N-4.5 was much less thermally stable than CC-Tet-KE with a TM value of 55 °C 
(Figure 3-5b). However, the thermal denaturation was not reversible and a higher 
MRE222 was observed on returning the sample to 5 °C. This was most likely due to 
loss of peptide through precipitation. The TM of CC-Tet-KE-N-4 at this peptide 
concentration was too low to measure. Thus, the introduction of two polar Asn 
residues, one at a buried d position and one at a more peripheral e position, was 




clearly very destabilising to CC-Tet-KE. Extending the length of the peptide 
increased its thermal stability and appeared to be able to overcome some, though 
not all, of this destabilisation 225.  
As CC-Tet-KE-N-4 was unfolded, AUC experiments were performed for CC-Tet-
KE-N-4.5 only. In both SV and SE experiments, CC-Tet-KE-N-4.5 returned 
molecular weights corresponding to a trimeric oligomeric state (Figure 3-5c and d, 
Figure 8-78).  
Therefore, applying the Asn@a rule to the dimer-like interfaces of a potential 
Type-II coiled coil did not encourage the assembly to form a higher oligomeric 
state. This may be because, although CC-Tet contains KIH interactions involving 
core flanking e and g positions (a characteristic of Type-II coiled coils), not all of 
the e and g positions form knobs in these interactions: most are hole residues. 
Therefore, CC-Tet, and perhaps other tetrameric coiled coils, represents an 







Figure 3-4 Buried Asn residues in dimeric and tetrameric coiled-coil 
interfaces. (a) Peptide sequences for CC-Di 208, CC-Tet-KE-N-4 and CC-
Tet-KE-N-4.5. All peptides were in g-register and were N-terminally 
acetylated and C-terminally amidated. (b) CC-Di helical wheel with helices 
numbered 1 and 2 showing Asn at a positions. (c) CC-Tet-KE-N helical 
wheel with helices numbered 1-4 showing Asn at d and e positions (which 
are equivalent to a positions within the deab and cdga gade-like motifs). 
Dashed black lines indicate possible Asn-Asn interactions.  




Furthermore, in the absence of crystallographic data for CC-Tet-KE, it is not 
possible to determine what type of interface this peptide forms. It cannot be 
assumed that it forms a Type-II coiled coil and, as a trimer, it may in fact form a 
Type-I interface where the hydrophobic seams overlap by one residue (and 
therefore the gade-like motifs are gade and cdga and overlap by three residues). 
If this is the case, it appears that introducing Type-II sequence features to an 
otherwise Type-I interface is not sufficient to cause the structure to adopt the 
former. It may be interesting to introduce Asn at d and e positions in CC-Tet as 









Figure 3-5 Biophysical characterisation of the CC-Tet-KE-N variants. (a) 
CD spectra at 5 °C of CC-Tet-KE, CC-Tet-KE-N-4 and CC-Tet-KE-N-4.5. 
(b) Temperature-dependent CD measurements monitoring MRE222 
between 5 and 95 °C (solid lines) for CC-Tet-KE, CC-Tet-KE-N-4 and CC-
Tet-KE-N-4.5 and between 95 and 5 °C (dashed line) for CC-Tet-KE-N-
4.5, key as in (a). Peptide concentrations for CD spectroscopy were 10 
µM. (c) Sedimentation velocity c(s) distributions (top) and residuals 
(bottom) for CC-Tet-KE-N-4.5 returning a Mw of 10.3 kDa (2.9 x monomer 
mass). (d) Sedimentation equilibrium data at 30, 33, and 36 krpm (red, 
green and blue circles) and fits (black lines) (top) and residuals (same 
colours) (bottom) for CC-Tet-KE-N-4.5 returning a Mw of 10.7 kDa (3.0 x 
monomer mass). All measurements were performed in PBS (pH 7.4).  




3.3 Design and characterisation of an updated homotetramer 
set 
The tetrameric coiled coil CC-Tet is not robust to an e/g charged-residue swap. 
Thus, CC-Tet may not be the optimal starting point to develop an expanded set of 
tetrameric coiled coils for applications in synthetic biology. Therefore, an updated 
set of homotetramers was designed to determine whether other heptad 
arrangements would more robustly specify tetrameric coiled coils.  
3.3.1 Leu/Ile core homotetramer design 
The design of the updated homotetramer set was based on the observation that, 
in tetrameric coiled coils, the interhelical distances between the e/g, c/e, b/g and 
b/c positions may all allow salt bridges to form between charged residues at these 
positions 187,192,224,225. The average distances between the Cα atoms of these 
positions in CC-Tet were determined from the crystal structure PDB coordinate file 
(Figure 3-6). While the e/g distance was by far the shortest, the c/e, b/g and b/c 
distances were all similar with values of 14-15 Å.  
The average Cα-Nζ and Cα-Cδ distances were also measured for Lys and Glu 
residues, respectively, at all e/g positions in CC-Tet to determine the length of 
these side chains. The average side chain length was 5.7 ± 0.5 Å for Lys and 3.3 
± 0.3 Å for Glu. While these side chains are a suitable length to form ionic 
interactions between e/g positions, they may not be able to bridge the c/e, b/g and 
b/c positions. However, the Glu and Lys side chains in the CC-Tet crystal structure 
adopt many different poses and many are not in an extended conformation. The 
maximal Cα-Nζ and Cα-Cδ distances for Lys and Glu were 6.3 and 3.9 Å, 
respectively. Therefore, it is conceivable that fully extended Lys and Glu side 
chains could bridge at least the c-e distance to form salt bridges (assuming a 
maximum distance for salt bridging of 4 Å). With the b/g and b/c charge 
configurations, salt bridges may not form due to the slightly larger inter-residue 
distances. However, the charged residues may still promote the folding of the 
coiled coils through electrostatic steering, where charged residues do not 
necessarily form salt bridges but instead take part in long-range electrostatic 
interactions that increase the rate of association without affecting the rate of 
dissociation, leading to stronger interactions 335,336. This phenomenon is likely to 
occur in all eight designs, even where salt bridges are unable to form.  




Therefore, the set of updated homotetramers was intended to test whether 
changing the heptad positions of the ionic residues would (1) still lead to the 
formation of parallel homotetrameric coiled coils; (2) allow for the formation of 
interhelical ionic interactions; and (3) lead to coiled coils with different thermal 
stabilities. For point 3, the strength of the ionic interaction should get weaker as 
the charges are moved further apart. If such ionic interactions contribute to coiled 
coil stability, they would be expected to become less significant as the charges are 
moved progressively to more-peripheral heptad positions. Therefore, coiled coils 
with charged residues at b/c positions would be predicted to be less stable than 
those with charged residues at e/g positions and those with charged residues at 
c/e or b/g would be expected to have intermediate thermal stabilities.  
Eight new homotetramer peptide sequences were designed (Figure 3-7). The 
peptides had four heptad arrangements: xLAAIxf, QLAxIxf, xLxAIQf or QLxxIQf, 
written beginning at a g position, where x is Glu or Lys and f is the heptad f position. 
The peptides were designed with oppositely charged Glu and Lys residues at all of 
the e/g, c/e b/g or b/c positions. Furthermore, all were designed with an LI-core, 
i.e. Leu at a and Ile at d. Where e or g positions were not occupied by a charged 
residue, they were made Gln. This polar residue was included at these sites to 
ensure that the hydrophobic seam was limited to the a and d positions. Placing 
additional hydrophobic residues at these positions, such as Ala or Val, can lead to 
the formation of higher-order coiled coils such as hexamers 43,213 or to the formation 
a 
 Interaction Distance (Å) 
 e/g 8.9 ± 1.6 
 c/e 14.2 ± 0.9 
 b/g 14.6 ± 0.6 




Figure 3-6 Average distances between heptad positions that could take 
part in interhelical ionic interactions in CC-Tet.  (a) Distances measured as 
the mean distances (Å) between the Cα atoms of the residues of interest 
calculated from the PDB coordinate file for CC-Tet (PDB ID: 3R4A) 208. 
Errors are one s.d. from the mean. e/g distances were calculated as gi-e′i+5 
interactions. c/e distances were calculated as ei-c′i-2 interactions. b/g 
distances were calculated as bi-g′i-2 interactions. b/c distances were 
calculated as bi-c′i+1 interactions. Residues in the adjacent helix are indicated 
with x′ where x is any heptad position. (b) Example interaction between Lys 
and Glu residues in CC-Tet with Cα atoms labelled (Cα1 and Cα2, 
respectively) and inter-Cα distance show (green dashed line).  




of antiparallel structures 205,222,337. Where b or c positions were not occupied by 
charged residues, these positions were made Ala. Finally, f positions were 
occupied by Gln, Lys or Trp and helix-capping Gly residues were added to the N 
and C termini. All peptides were designed in c-register i.e. excluding the N-terminal 
Gly, the peptides began at a c position. The peptides were named for the location 
of the charged residues (1, e/g; 2, c/e; 3, b/g; 4, b/c), the identity of the core 
residues (LI, a=Leu/d=Ile) and the orientation of the charged Glu and Lys residues 
(EK, Glu appears first in the linear heptad sequence; KE, Lys appears first in the 
linear heptad sequence).  
3.3.2 Leu/Ile core designs form homotetrameric coiled coils in solution  
3.3.2.1 CD spectroscopy shows the updated designs form α-helical homomers 
All of the peptides had characteristically α-helical CD spectra with high fraction 





Figure 3-7 Design approach for homotetrameric coiled coils. (a) 
Tetrameric helical wheel representations for peptides 1-LI-EK (far left), 2-
LI-EK (centre left) and 3-LI-EK (centre right) and 4-LI-EK (far right) 
demonstrating the different arrangements of charged residues at e/g, c/e, 
b/g or b/c positions, respectively. Dashed lines indicate potential Glu-Lys 
interactions. (b) Sequences of peptides. All peptides were in c-register and 
were N-terminally acetylated and C-terminally amidated. Core d positions 
were either all Ile or all Val (denoted as x) except in 4-LI-EK and 4-LI-KE 
where d positions were all Ile.   




highly thermally stable and most had TM values above the accessible range (Figure 
3-8b and c). The least stable peptides were 3-LI-EK and 3-LI-KE, where the 
charged residues were at the b and g positions. These were expected to be 
amongst the least stable because the b/g residues were positioned relatively far 
apart in space. Furthermore, the Cα-Cβ bond vector of the b site is oriented out into 
solution and was therefore not expected to be optimally positioned for the formation 
of ionic interactions (Figure 3-7a, centre right). For similar reasons, the peptides 
4-LI-EK and 4-LI-KE were also expected to be relatively unstable. However, they 










1-LI-EK -31603 82 > 95.0 
1-LI-KE -30056 78 > 95.0 
2-LI-EK -34375 ± 266 89 > 95.0 
2-LI-KE -35277 ± 1472 92 > 95.0 
3-LI-EK -31815 ± 817 83 67.5 ± 0.5 
3-LI-KE -35550 ± 520 92 89.8 ± 1.0 
4-LI-EK -35669 93 > 95.0 
4-LI-KE -34766 90 > 95.0 
 
Figure 3-8 CD spectroscopy data for updated homotetramer set. (a) CD 
spectra at 5 °C of 1-LI-EK, 1-LI-KE, 2-LI-EK, 2-LI-KE, 3-LI-EK, 3-LI-KE, 4-
LI-EK and 4-LI-KE. (b) Temperature-dependent CD measurements 
monitoring MRE222 between 5 and 95 °C for the above peptides, key as in 
(a). (c) MRE222, fraction helix values and TM values for the above peptides. 
a Units, deg.cm2.dmol-1.res-1. Peptides were at 10 µM. All measurements 
were performed in PBS. 




3.3.2.2 AUC shows the updated designs form homotetramers in solution 
In SV and SE experiments the majority of the peptides gave molecular weights 
corresponding to tetramers (Figure 3-9, Figure 8-80–Figure 8-87). The peptides 
also all displayed a single peak in their c(s) distributions indicating that they each 
formed a single species in solution.  
The exception was 1-LI-KE, which in both SE and SV experiments returned 
molecular weights of 3.5 x monomer mass. It was therefore not clear whether this 
peptide formed a trimer, tetramer or an interconverting mixture of the two. This is 
in contrast to CC-Tet-KE, which differs only in register but unambiguously formed 
a trimer.  
Interestingly, when the charged residues were placed at the c/e, b/g and c/b 
positions, all the designs formed tetramers in solution, regardless of the order of 
the Glu/Lys residues: charge-swapped variants of these peptides could be made 
without affecting the oligomeric state of the resulting assembly. Conversely, while 
1-LI-EK and CC-Tet did form tetramers, neither 1-LI-KE nor CC-Tet-KE could 
reliably form tetramers in solution. Therefore, the c/e, b/g and c/b heptad 
arrangements offer an improvement over the original xLAAIxf heptad for the design 
of tetramers. 
3.3.3 Crystallographic characterisation of Leu/Ile core homotetramers 
Crystal structures were solved for 2-LI-EK and 3-LI-EK at 1.7 and 1.1 Å resolution, 
respectively (Figure 3-10a). Both peptides crystallised as parallel homotetrameric 
coiled coils (Figure 3-10b). Furthermore, Glu/Lys side chains in close proximity 
could be observed in both structures, as well as in the crystal structure for CC-Tet, 
implying the formation of ionic interactions. The inter-side chain distances (Nζ(Lys)-
Cδ(Glu)) were measured for all Glu/Lys pairs. Surprisingly, the shortest average 
distances were in the 2-LI-EK structure (Figure 3-10a). This was probably due to 
the location of some of the charged residues within the unstructured termini of 
CC-Tet. Despite the larger Glu-Lys distances in CC-Tet, a higher proportion of 
these pairs appeared to form salt bridges, i.e. they had an Nζ(Lys)-Cδ(Glu) distance ≤ 
4.0 Å (Figure 3-10a). The fewest salt bridges were observed in 3-LI-EK where just 
6.25 % of Glu/Lys pairs formed a salt bridge. This corresponds to just one salt 
bridge in the whole tetramer. 3-LI-EK also had the largest average Nζ(Lys)-Cδ(Glu) 




distance. This may partially explain why 3-LI-EK and 3-LI-KE were less stable than 
the other designs. 
Therefore, only the e/g and c/e charge arrangements appear to be conducive with 

















Figure 3-9 Sedimentation velocity data for updated homotetramer designs. c(s) 
distributions (top) and residuals for: (a) 1-LI-EK returning a Mw of 12.9 kDa (4.0 
x monomer mass); (b) 1-LI-KE returning a Mw of 11.3 kDa (3.5 x monomer 
mass); (c) 2-LI-EK returning a Mw of 13.4 kDa (3.9 x monomer mass); (d) 2-LI-
KE returning a Mw of 14.4 kDa (4.2 x monomer mass); (e) 3-LI-EK returning a 
Mw of 14.5 kDa (4.2 x monomer mass); (f) 3-LI-KE returning a Mw of 13.1 kDa 
(3.8 x monomer mass); (g) 4-LI-EK returning a Mw of 15.3 kDa (4.1 x monomer 
mass); (h) 4-LI-KE returning a Mw of 15.4 kDa (4.2 x monomer mass). All 
measurements were performed in PBS (pH 7.4). 




residue distances measured in CC-Tet (Figure 3-6a). However, in both tetramers, 
not all of the Glu/Lys pairs took part in salt bridges.  Furthermore, the temperature 
factors for these side chains were relatively similar to those of the other solvent-
exposed residues that were not expected to take part in specific interactions, 
especially when Ala residues – which have short, inflexible side chains – were 














CC-Tet I222 2.07 0.209/0.270 5.6 ± 2.7 50.0 
2-LI-EK C222 1.70 0.189/0.195 4.5 ± 1.0 37.5 




Figure 3-10 Crystallographic characterisation of updated homotetramer 
designs. (a) Collection and refinement statistics and Glu-Lys interaction 
analysis for CC-Tet (structure reproduced from reference 208), 2-LI-EK and 3-
LI-EK. See Table 8-3 and Table 8-4 for full statistics. a Percentage of e/g, e/c 
or b/g Glu/Lys pairs that engage in interhelical salt bridges (i.e. Nζ(Lys)-Cδ(Glu) 
distance ≤ 4.0 Å). (b) Crystal structures for: Left, CC-Tet (PBD ID: 3R4A 208,213); 
centre, 2-LI-EK; right, 3-LI-EK. Structures shown from N termini as 
cartoons/surfaces (top) and from sides as cartoons with Glu/Lys shown as 
sticks (bottom).  




In crystallography, temperature factors (or B factors) represent uncertainty in the 
location of an atom in the crystallographic model. This increases with disorder or 
motion of that atom. The locations of more-mobile atoms are less certain, and they 
therefore have higher B factors. Generally, atoms in the main chain, in buried side 
chains and side chains involved in non-covalent interactions will have low B factors. 
The B factors of the Glu/Lys side chains in CC-Tet, 2-LI-EK and 3-LI-EK implied 
that these side chains were relatively mobile and therefore that any interactions 





Figure 3-11 B factor analysis of homotetramers. (a) Crystal structures 
of homotetramers coloured by temperature (B) factors. Left: CC-Tet (PDB 
ID: 3R4A), min. B factor (blue) = 16.7 Å2, max. B factor (red) = 70.0 Å2. 
Centre: 2-LI-EK, min. B factor (blue) = 10.8 Å2, max. B factor (red) = 84.6 Å2. 
Right: 3-LI-EK, min. B factor (blue) = 10.0 Å2, max. B factor (red) = 49.1 Å2. 
(b) Average side chain B factors for CC-Tet, 2-LI-K and 3-LI-EK for core 
residues (a, d), all peripheral residues (b, c, e, f, g), for all peripheral residues 











































The structures for 2-LI-EK and 3-LI-EK were analysed using SOCKET to determine 
which residues take part in KIH interactions 201. CC-Tet was also analysed for 
comparison (Figure 3-12) 208. There were more KIH interactions in 2-LI-EK and 
3-LI-EK than in CC-Tet. Furthermore, more of the e and g positions were knobs in 
2-LI-EK and 3-LI-KE than in CC-Tet. These additional KIH interactions might have 
been expected to increase the stability of the coiled coils. However, as shown by 
temperature-dependent CD measurements, both assemblies were less stable than 
CC-Tet (Figure 3-3a and Figure 3-8a). It is interesting to note that in all three 
structures a, d, e, and g residues act as knobs in KIH interactions, which is 
characteristic of Type-II coiled coils. However, in all of the structures only some of 
these residues are knobs. Therefore, while the tetramers have Type-II character, 
they do not have completely Type-II interfaces and may therefore represent an 
intermediate between Type-N and Type-II coiled coils.  
It remains to be seen whether additional KIH interactions and interhelical ionic 
interactions also formed in the 4-LI-EK or 4-LI-KE tetramers, where the charged 





 Helix 1 (W) --------Z--XZ--Z---Z--Z----- 
 Helix 2 (X) ----Y--YW--Y--YW--Y--Y------ 
 Helix 3 (Y) -----X--X--ZX--X---X--X----- 






 Helix 1 (W) ----XZ--X--XZ--X--XZ--XZ---- 
 Helix 2 (X) -----W--YW--W--YW--W--Y----- 
 Helix 3 (Y) ----ZX--Z--ZX--Z--ZX--ZX---- 






 Helix 1 (W) ----YZ--Y--YZ--Y--Y---Y----- 
 Helix 2 (X) ----ZY--ZY-ZY--Z--ZY--Z----- 
 Helix 3 (Y) -----W--XW-XW--XW--W--XW---- 
 Helix 4 (Z) -----X--WX--X--WX--X---X---- 
 
Figure 3-12 SOCKET output for updated homotetramers. (a) CC-
Tet. (b) 2-LI-EK. (c) 3-LI-EK. Positions of knob residues in one helix (W, 
X, Y or Z) are indicated by a letter. The identity of the letter indicates 
which helix that knob residue interacts with. Knob cut-off = 7.0 Å.  




required to determine whether the salt bridges observed in the CC-Tet and 2-LI-EK 
structures also form in solution and whether they contribute to coiled-coil stability. 
3.4 Solution-phase characterisation of Leu/Val core variants 
The design of the expanded set of homotetrameric coiled coils described above 
means that synthetic biologists wishing to use de novo designed homotetramers 
as PIDs in vivo or in vitro now have a larger number of designs to choose from. 
Furthermore, the presented designs have a range of thermal stabilities allowing 
synthetic biologists to choose the coiled coil that is most suitable for their 
application. However, relative to most natural proteins from mesophilic organisms, 
all of the designs are still hyperthermally stable. In order to be useful in applications 
where less stable coiled coils are required, the homotetramer set must be 
expanded to include coiled coils with lower thermal stabilities. This could be 
achieved in many ways such as by decreasing the length of the peptides 191,338. 
Here, however, the identities of the core residues were changed. Specifically, Ile 
at d was replaced with Val.  
Val, like Ile, is a β-branched aliphatic amino acid that should have similar core 
packing properties to Ile. The side chains of the two amino acids are very similar, 
differing only in a methylene group (-CH2). The absence of this methylene in Val 
makes the residue overall less hydrophobic than Ile so it should form less stable 
hydrophobic cores. Indeed, replacing Ile with Val at the a positions of homo- and 
heterodimeric coiled coils results in less stable assemblies 339,340.  
6 peptides based on 1-LI-EK, 1-LI-KE, 2-LI-EK, 2-LI-KE, 3-LI-EK and 3-LI-KE were 
designed that contained Val at d instead of Ile. The sequences were otherwise 
identical to the LI-core parents. This gave the LV-core (LV, a=Leu/d=Val) peptides 
1-LV-EK, 1-LV-KE, 2-LV-EK, 2-LV-KE, 3-LV-EK and 3-LV-KE, respectively.  
3.4.1 Leu/Val core variants are much less stable than Leu/Ile core 
homotetramers  
By CD spectroscopy, all six LV-core peptides were much less folded than the 
corresponding LI-core parents (Figure 3-13a and c). 3-LV-EK and 3-LV-KE were 
almost entirely unfolded. 1-LV-KE and 2-LV-EK were the most folded and α helical. 
However, the minimum at approximately 208 nm had a more negative MRE 
indicating that as well as folded material, there was also unfolded peptide present.  




Furthermore, the LV-core peptides were much less thermally stable than the 
LI-core homotetramers (Figure 3-13b and c). Indeed, where the TM values of the 
LI-core homotetramers were often too high to measure, some of the LV-core 
peptides had TMs that were too low to measure. 3-LV-EK and 3-LV-KE were 
particularly unstable and did not show any change in MRE222 with increasing 
temperature. The most stable peptides were 1-LV-KE and 2-LV-EK. 1-LV-KE had 
a TM value of 55.5 °C, which was only 12 °C lower than the TM of the least stable 
LI-core homomer, 3-LI-EK (Figure 3-8a and c). However, while 3-LI-EK had a 
typical sigmoidal unfolding transition, 1-LI-KE displayed cold denaturation where 
the peptide initially became more folded when heated to around 20 °C then 
unfolded as the temperature was increased further. This phenomenon was also 
observed with 2-LV-EK and 2-LV-KE. Cold denaturation can be an indication of 
exposed hydrophobic residues, which further shows that the peptides were poorly 
folded. This is because, at low temperatures, ordered cages of water molecules 










1-LV-EK -9605 26 < 20.0 
1-LV-KE -18272 48 55.5 
2-LV-EK -16737 ± 1219 44 41.0 ± 0.9 
2-LV-KE -10497 ± 263 28 26.8 ± 2.1 
3-LV-EK -3006 9 < 20.0 
3-LV-KE -3832 11 < 20.0 
 
Figure 3-13 CD spectroscopy data for LV-core versions of 
homotetramers. (a) CD spectra at 5 °C of 1-LV-EK, 1-LV-KE, 2-LV-EK, 2-LV-
KE, 3-LV-EK and 3-LV-KE. (b) Temperature-dependent CD measurements 
monitoring MRE222 between 5 and 95 °C for the above peptides, key as in (a). 
(c) MRE222, fraction helix values and TM values for the above peptides. a Units, 
deg.cm2.dmol-1.res-1. Peptides were at 10 µM. All measurements were 
performed in PBS (pH 7.4). 




preventing it from forming the hydrogen bonds required to stabilise its secondary 
structure 341,342. As temperature is increased and the cages are disrupted, helices 
can form. These helices then unfold again as temperature is increased further and 
the intramolecular hydrogen bonds are broken.  
3.4.2 Leu/Val core variants do not form tetramers in solution 
By AUC, the LV-core homomers had a range of oligomeric states from monomers 
potentially up to tetramers (Figure 3-14, Figure 8-88–Figure 8-91). However, for 
most of the peptides, the oligomeric state assignment was ambiguous. For 
example, in both SE and SV experiments, 1-LV-KE fitted to molecular weights 
corresponding to oligomeric states between dimer and trimer. This may reflect the 
fact that the peptides were quite unfolded: there was likely to be a mixture of 
unfolded peptide monomers and folded oligomers present. The experiments could 
also be performed at higher peptide concentrations, which should increase the 
amount of oligomer present. Furthermore, in the case of 2-LV-KE, the oligomer 
peak in the SV c(s) distribution has a broad tail (Figure 3-14c). This may be an 
indication that this peptide formed a number of different oligomeric states.  
Finally, using SV, 3-LV-KE fitted to a molecular weight corresponding to a 
monomer (Figure 3-14d). Given that the SV experiments were performed by 
centrifuging at 50 krpm and that a solute with a mass this small was not expected 
to sediment at this speed, this result needs to be verified, for example by 
performing SE experiments at increased speed.  
Placing Val residues at d does not appear to be a viable approach to expanding 
the set of homotetramers because the new peptide designs were generally poorly 
folded and did not form tetramers. Rather than producing homotetramers that were 
marginally less stable than the LI-core homotetramers, it produced peptides that 
were generally impractically unstable and unable to adopt a unique structure. They 
are therefore unlikely to be useful in synthetic biology applications. Therefore, if a 
further expanded homotetramer set is indeed required, other designs should be 
considered such as those that contain a mixture of Ile and Val residues at the d 
positions. In this way, the stability of the coiled coil might be tuned by increasing 
the Val/Ile ratio in the peptide core without complete loss of the tetramer promoting 
Ile residues. Alternatively, increasing the lengths of some of the LV-core peptides 
might make them more folded and therefore more useful. However, it is also 
possible that the a=Leu/d=Val core arrangement simply is not optimal for tetramer 




formation, despite the β-branched side chain of Val. This may be why the LV-core 
peptides failed to reliably form tetramers. Indeed, a version of GCN4-p1 that 
contains a=Leu and d=Val also fails to adopt a unique oligomeric state which 
further implies it was not a suitable choice for the d positions 187.  
The frequency at which Ile, Leu and Val occur at the core a/d positions of parallel 
tetrameric coiled coils relative to the frequency that they occur in all proteins was 
analysed using the CC+ coiled coil database 343. This revealed that Val actually 
occurs more frequently at the a positions than at the d positions (Figure 3-15). 
Therefore, peptides with a=Val/d=Ile cores might be better at specifying tetramers.  
3.5 The effect of non-polar residues at g in homotetramers 
The inclusion of Leu at a positions and Ile at d positions of coiled coils was a fairly 
reliable specifier of parallel tetrameric structures in the homotetramers described 









Figure 3-14 Sedimentation velocity data for LV-core homomer 
designs. c(s) distributions (top) and residuals for: (a) 1-LV-KE returning a Mw 
of 8.4 kDa (2.6 x monomer mass); (b) 2-LV-EK returning a Mw of 9.7 kDa (2.8 
x monomer mass); (c) 2-LV-KE returning a Mw of 11.9 kDa (3.5 x monomer 
mass); (d) 3-LV-KE returning a Mw of 3.9 kDa (1.1 x monomer mass). All 
measurements were performed in PBS (pH 7.4). 




d positions precludes the formation of dimeric structures due to steric clashes 187. 
However, while the Leu/Ile core arrangement may not be compatible with lower 
oligomeric states, it may be tolerated in higher oligomeric states such as pentamers 
and above – the so-called α-barrels 202,344. For example, expansion of the 
hydrophobic seam of CC-Tet through the inclusion of hydrophobic residues at the 
core flanking e positions yielded a hexameric coiled coil, CC-Hex, with a Leu/Ile/Ala 
core (heptad ELKAIAf) 213. Furthermore, placing Ala at all e and g positions of the 
GCN4-p1 leucine zipper dimer led to the formation of an unusual staggered 
heptameric coiled coil 345. Sequences from a library of GCN4 e/g position mutants 
that were found to form higher order oligomers also contained Ala at some e/g 
positions 346. Additionally, a blunt-ended de novo heptameric coiled coil that was 
designed computationally contained Ala at all e and g positions 43.  
However, there are also cases where placing Ala at core flanking positions does 
not lead to α-barrel formation, but instead leads to the formation of antiparallel 
tetramer structures. For example, a charge-swapped version of CC-Hex (heptad 
KLEAIAf) formed an antiparallel tetramer (C. Wood, personal communication). 
Additionally, placing Ala at just the g positions of GCN4 also led to the formation of 
an antiparallel tetramer similar to rop-like Ala-coils 205,348. The Ala-coil is a type of 
helical bundle that contains Ala (or other small, hydrophobic residues) at every 7th 
residue in addition to an a/d hydrophobic core. When these Ala residues coincide 
with e positions they are called ferritin-like Ala-coils. This group includes the Lac 
repressor tetramerisation domain 190. When the Ala residues fall at the g positions 
they are called rop-like Ala-coils 349. Both types of Ala-coil are characterised by 
antiparallel orientations that bring together the Ala residues at two of the four 
 
Figure 3-15 Normalised frequencies of Ile, Leu and Val residues at a 
and d positions in tetrameric coiled coils. Data generated from a set of 46 
parallel homo- and heterotetrameric canonical coiled coil sequences of 
length ≥14 residues that were extracted from the CC+ coiled coil database 
343. Amino acid frequencies were normalised to the frequency of that amino 



































interhelical interfaces. This results in close interhelical contacts at these Ala-
containing interfaces such that the tetramers adopt an oblate structure when 
viewed from the termini.  
In terms of sequence, the antiparallel tetrameric charge-swapped variant of 
CC-Hex, CC-Hex-KE, is similar to the ferritin-like Ala-coils. To determine whether 
peptides with sequences similar to rop-like Ala-coils would form parallel α-barrels 
(like CC-Hex), antiparallel tetramers (like CC-Hex-KE) or indeed just parallel 
tetramers, two peptides were designed that contained Ala at all of the g positions 
(Figure 3-16). These peptides, 2-LIA-EK and 2-LIA-KE, both contained Leu at a, 
Ile at d and Ala at g, forming an LIA-core. Charged Glu or Lys residues were placed 
at the c/e positions in both orientations (EK, c=Glu/e=Lys; KE, c=Lys/e=Glu). As in 
the peptides 2-LI-EK and 2-LI-KE, these Ala@g peptides may be able to form c-e′ 
interhelical ionic interactions. All b positions were also Ala and f positions were Gln, 
Lys or Trp.  
CD spectroscopy revealed that both 2-LIA-EK and 2-LIA-KE formed α-helical 
structures with fraction helix values of 86 and 79 %, respectively (Figure 3-17a). 
Both peptides were also highly thermally stable with TM values above the 
measurable range (Figure 3-17b). The peptides were also slightly more stable than 
the peptides 2-LI-EK and 2-LI-KE (Figure 3-8a). The sequences of 2-LI-EK and 
2-LI-KE are almost identical to those of 2-LIA-EK and 2-LIE-KE, except 2-LI-EK 
and 2-LI-KE contain Gln at g rather than Ala.  
When investigated using AUC, in SV and SE experiments both Ala@g peptides 
fitted to molecular weights corresponding to tetramers (Figure 3-17c and d, Figure 
8-92, Figure 8-93). In SV experiments, both peptides appeared to form a single 
species.  
Therefore, it appears that the Ala@g peptides do not form α-barrels in solution. 
Unlike the Ala@e peptides, CC-Hex and CC-Hex-KE, where the oligomeric state 
changed from hexamer to tetramer on swapping the charged residues, the Ala@g 
heptad arrangement appears to be compatible only with tetramer formation. 
However, whether these tetramers are in the parallel or antiparallel orientation 
remains to be seen. X-ray crystal structures will be needed to determine the helix 
orientation and to determine whether, if they are indeed forming antiparallel 
tetramers, the peptides adopt a true Ala-coil fold.  




Both parallel and antiparallel arrangements may be feasible with the 2-LIA-EK and 
2-LIA-KE peptides. Parallel tetramers may be possible due to the small, 
moderately hydrophobic nature of Ala. This residue is often placed at solvent-
exposed heptad positions in coiled coils (such as b or c) without affecting solubility 
or oligomeric state. However, due to the positioning of Ala at core-flanking g 
positions, it may have become part of an expanded adg hydrophobic seam. They 
may therefore have had more of an effect on core packing, and helix orientation, 
than Ala residues at more peripheral positions.  
In CC-Hex-KE, Glu/Glu and Lys/Lys pairs are brought together at the antiparallel 
interfaces. Evidently the subsequent charge repulsion is not sufficient to prevent 
the structure from forming. If 2-LIA-EK and 2-LIA-KE are forming antiparallel 
structures, these would also contain repulsive Glu/Glu and Lys/Lys interactions at 
the interhelical interfaces. Conversely, parallel structures would contain productive 
ionic interactions between the E/K pairs at the c/e positions. If the Ala@g peptides 
are found to adopt antiparallel structures, optimisation of the locations of the 
charged residues could be performed to relieve the repulsive interactions.  
 
Figure 3-16 Helical wheels and sequences for Ala@g peptides. Top: 
helical wheel diagrams for three proposed structures that could be adopted 
by 2-LIA-EK. Left: parallel tetramer; centre: antiparallel tetramer; right: α-
barrel, parallel hexamer shown as example. Bottom: sequences of peptides 
2-LIA-EK and 2-LIA-KE. All peptides were in c-register and were N-terminally 
acetylated and C-terminally amidated. 




3.6 Chapter conclusions 
To expand the available set of well-characterised, de novo tetrameric coiled coils, 
which previously contained only CC-Tet, a number of peptides have been designed 
(Figure 3-18). Of these designs, those that contain LI-cores (a=Leu/d=Ile) reliably 
form tetramers in solution and in their crystal structures. Tetramers form when 
charged residues are arranged at the e/g, c/e, b/g and b/c positions. While the 
formation of interhelical ionic interactions between charged residues at some e/g 
and c/e positions can be observed in the crystal structures, it remains to be seen 
whether these interactions form in solution and contribute to coiled-coil stability. 
Furthermore, tetrameric coiled coils are observed both when polar (Gln) and mildly 









Figure 3-17 Biophysical characterisation of the Ala@g peptides 
2-LIA-EK and 2-LIA-KE. (a) CD spectra at 5 °C of 2-LIA-EK and 2-LIA-KE. 
(b) Temperature-dependent CD measurements monitoring MRE222 
between 5 and 95 °C for 2-LIA-EK and 2-LIA-KE, key as in (a). Peptide 
concentrations for CD spectroscopy were 10 µM. (c) Sedimentation 
velocity c(s) distribution (top) and residuals (bottom) for 2-LIA-EK 
returning a Mw of 12.5 kDa (3.8 x monomer mass). (d) Sedimentation 
velocity c(s) distribution (top) and residuals (bottom) for 2-LIA-KE 
returning a Mw of 13.3 kDa (4.1 x monomer mass). All measurements 
were performed in PBS (pH 7.4).  




generally held that polar residues would be required at these positions to prevent 
the coiled coils from forming larger α-barrel assemblies, but Ala is also well 
tolerated at the g positions. It is possible that introducing increasingly hydrophobic 
residues here (e.g. Val) could lead to higher-order assemblies. One exception 
amongst the LI-core designs was when e=Glu and g=Lys. Peptides designed in 
both c- and g-register with this arrangement of charged residues do not form 
tetramers.  
Furthermore, peptides that contain LV-cores (a=Leu/d=Val) do not form stable 
tetramers. While it was deemed necessary to enhance the tetramer set with 
designs that had a greater range of stabilities, the LI-core designs have TM values 
spanning < 70 °C to > 95 °C. This range may in fact be suitable for many 
applications. Alternatively, other approaches to destabilising the coiled coils may 
be taken such as truncating the sequences of the LI-core designs or considering 
mixed LI/V-cores.   
 
 
Figure 3-18 Summary of designs discussed in Chapter 3. Successful 
designs, i.e. those that form homotetrameric coiled coils, are highlighted in 
green. Designs that formed other oligomeric states or were unfolded are 
highlighted in yellow and orange, respectively. Those designs with a=Leu 
and d=Ile were generally the most successful and were tolerant to many 
different arrangements or charged residues.  




While the structures of the novel tetramers have been characterised, it would also 
be helpful to characterise other properties that are of consideration if the coiled 
coils are to be used for in vivo synthetic biology applications. For example: what 
are their dissociation constants? Are the designs orthogonal to each other? That 
is, can the coiled coils be used together without cross interacting? Do they still fold 
in vivo? And, perhaps more importantly, are they tolerated in vivo? 
As well as being tools for synthetic biology in their own right, these homotetramers 
also represent a step towards more complex tetramer designs such as A2B2 
heterotetramers and ultimately ABCD heterotetramers. They may even be of use 
for designing coiled coils with dynamic behaviours that are capable of switching in 




Chapter 4: The design and characterisation of 
A2B2 heterotetramers  
4.1 Chapter introduction  
Following the successful design of a number of homotetrameric coiled coils, efforts 
were turned towards A2B2 heterotetramers. These contain two copies each of two 
different components, A and B, which are presumed to be arranged in an 
alternating “chequerboard” pattern. As artificial PIDs, heteromeric assemblies offer 
a more attractive target than homomeric ones as they can be used to mediate the 
interaction between different protein domains rather than simply co-localising 
multiple copies of the same protein. Therefore, multiple protein functions can be 
combined in a single assembly, allowing increasingly elaborate functions to be 
performed. For example, in the context of ATFs, multiple DBDs with different 
sequence specificities could be combined via the heterotetramer to facilitate DNA 
looping when the protein binds multiple DNA sites. Furthermore, as discussed in 
Chapters 1 and 3, tetramers and other higher order oligomers have increased 
response sensitivity.  
In the past, novel heterotetrameric coiled coils have generally been achieved by 
mutating naturally occurring homotetrameric coiled coils to convert them from 
single-peptide to dual-peptide systems. For example, a portion of the Lac 
repressor’s antiparallel coiled-coil tetramerisation domain, Lac21, and the model 
parallel tetrameric coiled coil, GCN4-pLI, have been converted into 
heterotetramers by introducing residues with charged side chains at various core-
flanking positions to produce two oppositely charged peptides 192,224-226,337. These 
peptides do not fold into homomeric coiled coils due to repulsion from the charged 
residues, but they are able to form heteromeric coiled coils where charge 
complementation relieves the repulsion. Aside from the introduced charged 
residues, the sequences of these coiled coils are generally very similar to those of 
the naturally derived homomeric parents and, therefore, few truly de novo 
heterotetrameric coiled coils have been reported. 




Here, heterotetrameric coiled coils were achieved by designing sets of overall 
acidic (-ve) and basic (+ve) peptides containing strategically placed charged 
residues and tetramer-specifying core residues. These peptides were anticipated 
to form repulsive charge interactions in the homomeric state, disfavouring these 
species, while repulsion would be relieved when acidic and basic peptides were 
paired up to form A2B2 heterotetramers.  
Through this methodical analysis of the various combinations of core residues and 
flanking charged residues, a set of de novo heterotetrameric coiled coils has been 
designed and characterised. The individual peptides vary widely in their fraction 
helix values, thermal stability and oligomeric state. Where excessive peptide 
homomerisation occurs, such species can be weakened by altering the core 
residues, without impeding heterotetramer formation. When the peptides are 
combined in acidic/basic pairs, the resulting heterotetramers have a range of 
thermal stabilities, which appear to be determined predominantly by the identity of 
the core residues.  
4.2 Design and characterisation of Leu/Ile core heterotetramers 
4.2.1 Leu/Ile core heterotetramer design 
The acidic (A) and basic (B) peptides 1-LI-A, 2-LI-A, 3-LI-A, 1-LI-B, 2-LI-B and 
3-LI-B were based on the homotetrameric coiled coil pairs 1-LI-EK/1-LI-KE, 
2-LI-EK/2-LI-KE and 3-LI-EK/3-LI-KE, respectively (see Chapter 3). However, 
rather than containing both Glu and Lys at the core-flanking positions in a single 
peptide, the acidic and basic peptides were designed to contain either all Glu give 
overall negatively charged peptides or all Lys to give overall positively charged 
peptides (Figure 4-1). As in the above homomers, the charged residues were 
placed at the e/g, c/e or b/g positions and the peptides were also designed to 
contain LI-cores (a=Leu/d=Ile) to promote tetramer formation. Where e or g 
positions were not a charged residue, these positions were populated by polar Gln 
to disfavour the formation of higher oligomeric states. Where b or c positions were 
not a charged residue, these positions were made Ala to promote helix formation. 
Thus, this set of six peptides differed in the identity and location of the charged 
residues, but their sequences were otherwise similar. All six peptides were made 
in c-register. Versions of 1-LI-A and 1-LI-B were also designed in g-register and 
are referred to as 1-LI-A-g and 1-LI-B-g. The peptides were named for the location 




of the charged residues (1, e/g; 2, c/e; 3, b/g), the identity of the core residues (LI, 
a=Leu/d=Ile) and the identity of the charged residues (A, acidic, Glu; B, basic, Lys).  
When combined in A/B pairs the peptides were anticipated to form the 
heterotetramers 1-LI-AB (and 1-LI-AB-g), 2-LI-AB and 3-LI-AB in which the 
oppositely charged residues would take part in interhelical e-g′, c-e′ or b-g′ ionic 
interactions, respectively, where the prime symbol (′) indicates that the residue is 
located in the adjacent helix (Figure 4-1).  
The individual peptides were first characterised separately and then in the various 
A/B pairings.  
4.2.2 Some LI-core peptides show off-target homomerisation 
4.2.2.1 CD spectroscopy shows the individual peptides fold to different extents 
CD spectra were measured for the individual peptides to investigate whether they 
formed any homomeric species. When investigated alone at 10 µM each, the 
peptides 1-LI-A, 1-LI-B, 1-LI-A-g and 1-LI-B-g, which contained charged residues 
 
Figure 4-1 A2B2 heterotetramer design. Top: helical wheel representations 
for the heterotetramers 1-LI-AB (left), 2-LI-AB (centre) and 3-LI-AB (right) 
where dashed lines indicate potential ionic interactions between charged 
residues. Bottom: sequences for the constituent acidic and basic peptides 1-
LI-A, 2-LI-A, 3-LI-A, 1-LI-B, 2-LI-B and 3-LI-B. All peptides were in c-register 
and were N-terminally acetylated and C-terminally amidated. A, acidic; B, 
basic; Ac, acetyl.  




at the e/g positions, were relatively unfolded (Figure 4-2a, Figure 4-4b). 
Furthermore, the fraction helix values for these peptides were all similar (Figure 
4-2d). The 1-LI-B-g peptide was slightly more folded than 1-LI-B and so the register 
of the peptides may have had some effect on how folded the homomers were. 
The peptides 2-LI-A and 2-LI-B were more folded than the e/g peptides and 
adopted highly α-helical structures with high fraction helix values (Figure 4-2d). 
Conversely, the peptides 3-LI-A and 3-LI-B had intermediate fraction helix values 
(Figure 4-2d).  
The CD signals for peptides 1-LI-A and 1-LI-B were found to be concentration-
independent, i.e. their CD spectra did not change as the peptide concentration was 
increased from 10 to 100 µM (Figure 4-2a). Conversely, the CD signals for 2-LI-A, 
2-LI-B, 3-LI-A and 3-LI-B were concentration-dependent and the peptides became 
more folded as their concentration was increased. For example, at 100 µM 3-LI-A 
and 3-LI-B reached fraction helix values of 86 and 80 %, respectively.  
The temperature-dependent behaviour of the individual peptides was also 
investigated by heating the samples from 5 to 95 °C while monitoring MRE222 
(Figure 4-2b and c). The peptides all became fully unfolded as temperature was 
increased except 1-LI-B, which appeared to become more folded above 
approximately 60 °C. There was a concern that, on heating, this peptide was 
forming some β-structure, which can be aggregation-prone. However, when CD 
spectra were taken at 5 °C intervals during the course of a variable temperature 
experiment, the peptide appeared to gain α-helical structure rather than β structure 
(Figure 8-48). While this result was certainly unusual, the peptide in question is 
unlikely to be used in applications at elevated temperatures, and so this 
temperature-dependent phenomenon was not of concern. 
Disregarding the behaviour of the basic peptide above 60 °C, the 1-LI-A and 1-LI-B 
peptides had TM values below the accessible temperature range and were almost 
fully unfolded at the physiologically relevant temperature of 37 °C (Figure 4-2b and 
c). The remaining peptides 2-LI-A, 2-LI-B, 3-LI-A and 3-LI-B had a range of TM 
values (Figure 4-2d).  
The relatively small amount of folding observed for 1-LI-A, 1-LI-B, 1-LI-A-g and 
1-LI-B-g may be explained by the location of their charged residues at the e and g 
positions. If these peptides did oligomerise, the charged residues would be close 




to the interface, providing a strong repulsive force that prevents folding of that 
species. In 2-LI-A and 2-LI-B, which have charged residues at the e and c 
positions, these residues would be slightly further apart, resulting in weaker 












 1-LI-A -13956 ± 481 37 < 20.0 
 1-LI-A-g -13367 36 < 20.0 
 2-LI-A -30678 ± 2137 80 53.3 ± 0.3 
 3-LI-A -23018 ± 990 61 28.2 ± 0.3 
 1-LI-B -13936 ± 458 37 < 20.0 
 1-LI-B-g -15486 41 < 20.0 
 2-LI-B -32634 ± 1037 85 59.7 ± 0.3 
 3-LI-B -20749 ± 1345 55 47.0 ± 2.6 
 
Figure 4-2 CD spectroscopy data for acidic and basic LI-core peptides. 
(a) CD spectra at 5 °C of 1-LI-A and 1-LI-B (left), 1-LI-A and 1-LI-B (centre) 
and 1-LI-A and 1-LI-B (right). Peptides were at 10 (solid lines) or 100 µM 
(dashed lines). Temperature-dependent CD measurements monitoring 
MRE222 between 5 and 95 °C for (b) 1-LI-A, 2-LI-A and 3-LI-A and (c) 
1-LI-B, 2-LI-B and 3-LI-B. Peptides were at 10 µM. (d) MRE222, fraction 
helix values and TM values for the above peptides at 10 µM. a Units, 
deg.cm2.dmol-1.res-1. All measurements were performed in PBS (pH 7.4). 




Finally, in 3-LI-A and 3-LI-B the charged residues at the b and g positions are not 
only further apart, but they also point away from each other due to the trajectory of 
the Cα-Cβ bond vector. These peptides were therefore expected to experience the 
weakest repulsion between the charged residues, which would potentially result in 
highly folded homomers. Unexpectedly, however, these peptides in fact had 
intermediate fraction helix and TM values. 
4.2.2.2 AUC shows some of the peptides form oligomers 
Due to the extent of folding observed with the peptides 2-LI-A, 2-LI-B, 3-LI-A and 
3-LI-B the peptides were analysed using AUC to determine the oligomeric states 
of these off-target homomers (Figure 4-3, Figure 8-95–Figure 8-100).  
The peptides were investigated using both SV and SE experiments (Figure 4-3b, 
c, e and f, Figure 8-95–Figure 8-100). With the exception of 3-LI-A, there was 
agreement between the two techniques. The peptides 2-LI-A, 2-LI-B and 3-LI-B all 
returned molecular weights corresponding to trimers. In SV experiments, 3-LI-A 
was determined to have a molecular weight of 13.0 kDa, corresponding 
approximately to a tetramer. However, in SE experiments, the molecular weight 
was determined to be 11.4 kDa, corresponding approximately to a trimer.  
1-LI-A and 1-LI-B were investigated using SE experiments at high speeds as these 
peptides were anticipated to be monomers and were therefore not expected to 
sediment at the available rotor speeds (max. 60 krpm) during SV experiments 
(Figure 4-3a and d). Both peptides returned molecular weights corresponding to 
monomers. The strong repulsion provided by placing charged residues at the core-
proximal e and g positions appeared to be sufficient to prevent these peptides from 
oligomerising.  
The peptides 2-LI-A, 2-LI-B and 3-LI-B may have formed trimers, despite having 
tetramer-promoting LI-cores, due to repulsion by the charged residues also: in a 
tetrameric coiled coil, the charged residues may have been positioned too close to 
each other leading to strong repulsion that forces the coiled coil into a lower 
oligomeric state where the repulsion was relieved. Therefore, the low thermal 
stabilities of the homomeric coiled coils relative to the heteromers may have been 
due to non-optimal core arrangements and to the repulsive forces between the 
charged residues. Conversely, 3-LI-A may have been able to adopt a tetrameric 
oligomeric state because the charged residues at the b and g positions are 




positioned further apart in space and are less optimally orientated for interaction in 
a folded coiled coil. Therefore, the repulsion may have been weaker in this coiled 
coil, allowing it to form a tetramer, albeit a marginally stable one.  
4.2.3 Leu/Ile core designs form heterotetrameric coiled coils in solution 
4.2.3.1 CD spectroscopy shows the acidic and basic peptides interact to form α-
helical assemblies 
When the LI-core peptides were mixed at equimolar concentrations in A/B pairs 













Figure 4-3 Sedimentation equilibrium data for acidic and basic LI-core 
peptides. Data (red, green and blue circles) and fits (black lines) (top) and 
residuals (same colours) (bottom) for the peptides: (a) 1-LI-A returning a 
Mw of 3.6 kDa (1.1 x monomer mass); (b) 2-LI-A returning a Mw of 10.3 
kDa (3.0 x monomer mass); (c) 3-LI-A returning a Mw of 11.4 kDa (3.3 x 
monomer mass); (d) 1-LI-B returning a Mw of 3.2 kDa (1.0 x monomer 
mass); (e) 2-LI-B returning a Mw of 11.1 kDa (3.2 x monomer mass); (f) 3-
LI-B returning a Mw of 10.4 kDa (3.0 x monomer mass). All measurements 
were performed in PBS (pH 7.4). 




2-LI-AB and 3-LI-AB pairs had low MRE222 values with fraction helix values of 87, 
88 and 90 %, respectively (Figure 4-4e). The 1-LI-AB-g pair was less folded with a 
fraction helix value of 80 %. Therefore, it appears that the c-register is more optimal 
for the 1-LI-AB heteromer.  
With the exception of the 2-LI-AB pair, in which the A and B monomers were 
themselves folded into highly α-helical structures, the A/B mixed spectra all 
showed much greater α-helical character than the constituent peptides, or the 
average of the spectra of the two peptides alone. This indicated that, on mixing, 
the peptides were interacting to form a heteromeric species rather than a mix of 
non-interacting homomeric structures. Because 2-LI-A and 2-LI-B were 
themselves highly folded, it was not obvious from the CD spectra alone whether 
these peptides were also interacting to form a heteromeric species or if the 
observed α-helicity in the mixed spectra was simply due to the individual 
homomers.  
4.2.3.2 The Leu/Ile core heterotetramers are hyperthermally stable 
The temperature-dependent behaviour of the heteromers was investigated. At a 
peptide concentration of 10 µM each, the LI-core heteromers were all 
hyperthermally stable when heated to 95 °C and did not display unfolding 
transitions (Figure 4-5). When the peptide concentration was reduced to 1 µM 
each, the heteromers still did not display unfolding transitions.  
All of the heteromers were much more stable than their constituent peptides. This 
provided further evidence that the peptides interacted to form heteromeric 
assemblies. For example, 2-LI-A and 2-LI-B, which formed homomers that were 
difficult to distinguish from the heteromer, had much lower TM values than the 
species that formed when the peptides were mixed (Figure 4-2b and c, Figure 4-5).  
While full sigmoidal unfolding transitions were not observed within the measurable 
temperature range, the MRE222 did change as the heteromers were heated. For 
example, for 1-LI-AB at 10 µM, the fraction helix value decreased from 86 % at 
5 °C to 61 % at 95 °C, representing an approximately 30 % reduction in the amount 
of folding. 2-LI-AB and 3-LI-AB showed similar decreases in the amount of folding, 
becoming 30 and 28 % less folded at 95 °C compared to 5 °C, respectively. The 
observed loss of α-helicity may have represented fraying of the α helices where 




the ends underwent local unwinding without affecting the global coiled-coil 
structure. This is observed in many coiled-coil systems. 
The temperature-dependent experiments could be performed in the presence of a 
chemical denaturant, such as guanidinium hydrochloride, in order to access the 
unfolding transitions of the heteromers. The addition of a chemical denaturant may 














 1-LI-AB -33101 ± 832 87 > 95.0 
 1-LI-AB-g -30517 80 > 95.0 
 2-LI-AB -33459 ± 112 88 > 95.0 
 3-LI-AB -34262 ± 1451 90 > 95.0 
 
Figure 4-4 CD spectra for LI-core A and B peptides alone and mixed at 
equimolar concentrations. (a) 1-LI-A and 1-LI-B. (b) 1-LI-A-g and 
1-LI-B-g. (c) 2-LI-A and 2-LI-B. (d) 3-LI-A and 3-LI-B. Peptides were at 
10 µM each and spectra were measured at 5 °C. av., average of the A 
and B spectra measured alone. (e) MRE222, fraction helix values and TM 
values for the above heteromers at 10 µM each. a Units, deg.cm2.dmol-
1.res-1. All measurements were performed in PBS (pH 7.4). 




While the absence of a sigmoidal unfolding transition can be indicative of 
hyperthermally stable coiled coils it can also be an indication that a protein does 
not adopt a unique structure. Instead these coiled coils may exist in molten globular 
states consisting of folded secondary structure elements (here, α helices) that do 
not form structured, well-packed cores 350. In this case, changes in MRE222 with 
increasing temperature may represent rearrangements of the secondary structure 
elements rather than a loss of protein structure. Hydrophobic dyes such as ANS 
and its derivatives bind to the easily-accessible and poorly-structured cores of 
molten globule states and can be used to determine whether or not a protein 
adopts a unique structure 351. Measuring whether these heteromers bind this dye 
may be necessary to determine whether they are indeed hyperthermally stable or 
are merely unable to adopt specific structures.  
4.2.3.3 AUC shows the heteromers form tetramers 
The solution-phase molecular weights of the heteromeric species were determined 
using AUC (Figure 4-6, Figure 8-113–Figure 8-116). In both SV and SE 
experiments, all the heteromers fitted to molecular weights corresponding to 
tetramers.  
The SV experiments also revealed that the 1-LI-AB, 1-LI-AB-g and 2-LI-AB 
heteromers formed discreet species in solution as indicated by the single, defined 
peaks observed in their c(s) distributions (Figure 4-6a and b). Conversely, two 
peaks were observed in the c(s) distribution of 3-LI-AB (Figure 4-6c). The larger of 
these peaks, which represented the more-prevalent species in solution, was found 
to have a molecular weight of 14.0 kDa, which was close to the predicted 3-LI-AB 
 
Figure 4-5 Temperature-dependent properties of LI-core heterotetramers. 
Temperature-dependent CD measurements monitoring MRE222 between 5 
and 95 °C for 1-LI-AB (left), 2-LI-AB (centre) and 3-LI-AB (right). Peptides 
were at 1 or 10 µM each. All measurements were performed in PBS (pH 7.4). 




heterotetramer mass of 13.9 kDa. The second, smaller peak was found to have a 
molecular weight of 28.4 kDa corresponding to an octameric oligomeric state. It is 
interesting that the larger oligomeric state is a multiple of four. This could indicate 
that the tetramers dimerise.  
The SE data for 3-LI-AB were initially analysed by fitting to a single ideal species 
model, which gave a predicted molecular weight of 14.2 kDa (Figure 4-6f). 













Figure 4-6 AUC data for the heteromers 1-LI-AB, 2-LI-AB and 3-LI-AB. 
Sedimentation velocity c(s) distributions (top) and residuals (bottom) for: (a) 
1-LI-AB returning a Mw of 12.8 kDa (3.9 x mean monomer mass); (b) 2-LI-AB 
returning a Mw of 13.7 kDa (3.9 x mean monomer mass); (c) 3-LI-AB 
returning a Mw of 14.0 and 28.4 kDa (4.0 and 8.2 x mean monomer mass). 
Sedimentation equilibrium data at 30, 33, and 36 krpm (red, green and blue 
circles) and fits (black lines) (top) and residuals (same colours) (bottom) for: 
(d) 1-LI-AB returning a Mw of 13.2 kDa (4.1 x mean monomer mass); (e) 2-
LI-AB returning a Mw of 13.6 kDa (3.9 x mean monomer mass); (f) 3-LI-AB 
returning a Mw of 14.2 kDa (4.1 x mean monomer mass). All measurements 
were performed in PBS (pH 7.4). 




octamer equilibrium model, however these gave poorer quality fits. It is possible 
that the octameric species was only present at the slightly higher concentrations 
used for SV experiments (140 µM total peptide concentration) and was therefore 
not prevalent in the SE experimental sample (70 µM total peptide concentration). 
In the future, performing SV experiments at different concentrations may help 
determine if the observed octamerisation is concentration-dependent: the ratio 
between the two peaks observed in the c(s) distribution would change if the 
proportions of the two species changed.  
4.3 Design and characterisation of Leu/Val core 
heterotetramers 
4.3.1 Leu/Val core heterotetramer design 
Ideally, the constituent peptides that make up a heteromeric coiled coil should 
themselves be unstructured. This is because homomeric interactions might lead to 
unwanted cross interactions between functional domains if the coiled coils were to 
be used as PIDs in vivo.  
Given that a number of the LI-core peptides described above formed α-helical 
homomers when investigated alone, the peptides were redesigned to limit this off-
target oligomerisation. This was achieved by changing the residues at the d 
positions in the peptides from Ile to Val to produce the peptides 1-LV-A, 1-LV-B, 
2-LV-A, 2-LV-B, 3-LV-A, and 3-LV-B (Figure 4-7). The peptide sequences were 
otherwise identical to the LI-core parent peptides and follow the same naming 
scheme (LV, a=Leu/d=Val). Like Ile, Val is a β-branched amino acid and so may 
also promote tetramer formation when included at the d positions. However, Val is 
less hydrophobic than Ile, so should produce less-stable coiled coils 340. Both the 
off-target homomers and the heteromers were anticipated to be destabilised by the 
inclusion of Val.   
4.3.2 The Leu/Val core peptides are monomeric in solution 
The LV-core acidic and basic peptides were all highly unfolded when analysed 
alone using CD spectroscopy (Figure 4-8a). With the exception of 2-LV-B, the 
peptides did not gain α-helical character on increasing the peptide concentration 
and the CD spectra at 10 and 100 µM were essentially identical. The fraction helix 
values for 2-LV-B at 10 and 100 µM were 19 and 25 %, respectively. All LV-core 




peptides were less folded than the corresponding LI-core parents. The three acidic 
peptides appeared to be slightly more folded than their basic partners. 
The temperature-dependent properties of the individual peptides were also 
investigated, and all were found to have very low thermal stabilities at 10 µM 
(Figure 4-8b and c). It was not possible to extract TM values from the data as they 
fell far below the measurable temperature range. 
SE experiments were performed on all LV-core acidic and basic peptides and all 
were found to be monomeric in solution which was likely due to a combination of 
charge repulsion and the weakened LV-cores (Figure 4-9, Figure 8-101–Figure 
8-106).  
 
Figure 4-7 LV-core A2B2 heterotetramer design. Top: helical wheels for the 
heterotetramers 1-LV-AB (left), 2-LV-AB (centre) and 3-LV-AB (right) where 
dashed lines indicate potential ionic interactions between charged residues. 
Bottom: sequences for the constituent acidic and basic peptides 1-LV-A, 
2-LV-A, 3-LV-A, 1-LV-B, 2-LV-B and 3-LV-B. All peptides were in c-register 
and were N-terminally acetylated and C-terminally amidated. A, acidic; B, 
basic; Ac, acetyl.  




4.3.3 Leu/Val core designs form heterotetrameric coiled coils in solution  
4.3.3.1 CD spectroscopy shows the acidic and basic peptides interact to form α-
helical assemblies 
When the LV-core peptides were mixed in their cognate pairs at equimolar 












 1-LV-A -5340 ± 536 15 < 20.0 
 2-LV-A -8920 ± 262 24 < 20.0 
 3-LV-A -8243 ± 222 22 < 20.0 
 1-LV-B -4574 ± 242 13 < 20.0 
 2-LV-B -6997 ± 637 19 < 20.0 
 3-LV-B -6584 ± 621 18 < 20.0 
 
Figure 4-8 CD spectroscopy data for acidic and basic LV-core peptides. 
(a) CD spectra at 5 °C of 1-LV-A and 1-LV-B (left), 2-LV-A and 2-LV-B 
(centre) and 3-LV-A and 3-LV-B (right). (b) Peptides were at 10 (solid lines) 
or 100 µM (dashed lines). Temperature-dependent CD measurements 
monitoring MRE222 between 5 and 95 °C for (b) 1-LV-A, 2-LV-A and 3-LV-A 
and (c) 1-LV-B, 2-LV-B and 3-LV-B. Peptides were at 10 µM. (d) MRE222, 
fraction helicites and TM values for the peptides at 10 µM. a Units, 
deg.cm2.dmol-1.res-1. All measurements were performed in PBS (pH 7.4). 




(Figure 4-10). The mixed spectra demonstrated significantly more folding than the 
averages of the spectra for the individual peptides, showing that these peptides 
also interacted to form heteromeric coiled coils (Figure 4-10a-c).  
These heteromers, 1-LV-AB, 2-LV-AB and 3-LV-AB, had fraction helix values of 
77, 73 and 87 %, respectively, at 10 µM (Figure 4-10e). As anticipated due to the 
lower hydrophobicity of Val, these were lower than the fraction helix values for the 
corresponding LI-core heteromers, 1-LI-AB, 2-LI-AB and 3-LI-AB, at the same 













Figure 4-9 Sedimentation equilibrium data at 54, 57 and 60 krpm (red, 
green and blue circles) and fits (black lines) (top) and residuals (same 
colours) (bottom) for the peptides: (a) 1-LV-A returning a Mw of 3.3 kDa 
(1.0 x monomer mass); (b) 2-LV-A  returning a Mw of 3.6 kDa (1.1 x 
monomer mass); (c) 3-LV-A returning a Mw of 3.4 kDa (1.0 x monomer 
mass); (d) 1-LV-B returning a Mw of 3.2 kDa (1.1 x monomer mass); (e) 2-
LV-B returning a Mw of 3.6 kDa (1.1 x monomer mass); (f) 3-LV-B returning 
a Mw of 3.7 kDa (1.1 x monomer mass). All measurements were performed 
in PBS (pH 7.4). 




fraction helix values for the LV-core heteromers increased to 81, 80 and 88 %, 
respectively.  
Temperature-dependent CD measurements revealed that the LV-core heteromers 
were also highly thermally stable, although they were all less stable than the 
corresponding LI-core heteromers (Figure 4-10d). The LV-core heteromers 














 1-LV-AB -29451 ± 1753 77 83.2 ± 1.5 
 2-LV-AB -27719 ± 284 73 86.2 ± 1.4 
 3-LV-AB -33245 ± 669 87 82.2 ± 0.8 
 
Figure 4-10 CD spectroscopy data for LV-core A and B peptides 
alone and mixed at equimolar concentrations. CD spectra at 5 °C for: (a) 
1-LV-A and 1-LV-B; (b) 2-LV-A and 2-LV-B; (c) 3-LV-A and 3-LV-B. Peptides 
were at 10 µM each. av., average of the A and B spectra measured alone. 
(d) Temperature-dependent CD measurements monitoring MRE222 between 
5 and 95 °C for LV-core heteromers 1-LI-AB, 2-LV-AB and 3-LV-AB. 
Peptides were at 10 µM each. (e) MRE222, fraction helicities and TM values 
for the heteromers at 10 µM each. a Units, deg.cm2.dmol-1.res-1. All 
measurements were performed in PBS (pH 7.4). 




reaction and TM values between 80 and 90 °C were extracted for all three (Figure 
4-10e). 
4.3.3.2 AUC shows the heteromers form tetramers 
SV and SE experiments showed that all three LV-core heteromers formed 
monodisperse tetramers demonstrating that the Ile to Val core substitutions have 
not compromised the formation of heterotetramers (Figure 4-11, Figure 8-117–
Figure 8-121).  
This is in contrast to the LV-core homomers discussed in Chapter 3, where the 
introduction of the Leu/Val core led to coiled coils with various different oligomeric 
states. That LV-core heteromers form tetramers despite this core also being 
compatible with other oligomeric states may be due to the intrinsic 2-fold symmetry 
of the A2B2 heterotetramer designs. In a heteromer, the highly charged A and B 
monomers are unlikely to be arranged adjacent to other monomers with the same 
charge, but they may be arranged in an alternating “chequerboard” pattern that 
relieves the charge repulsion. The resulting assembly must therefore contain an 
even number of components. Heterodimers are unlikely to form due to the 
presence of β-branched Val at the d positions – which would cause steric clashes 
in dimers – and higher oligomeric states such as hexamers are unlikely due to the 
polar residues at the e and g positions. Therefore, a tetramer may in fact be the 
only oligomeric state available to these assemblies.  
The LV-core heterotetramers offer many improvements over the LI-core 
heterotetramers in terms of both monomer and coiled-coil behaviour: the acidic 
and basic peptides are highly unfolded monomers in isolation that, when mixed, 
also interact to form heterotetramers. These heterotetramers demonstrate 
cooperative unfolding transitions indicating that they adopt a specific conformation 
and, while they are slightly less thermally stable than the LI-core parents, all have 
TM values above 80 °C so they are therefore more thermally stable than most 
natural proteins. 
4.4 Mixed Leu/Ile/Val core heterotetramers have intermediate 
stabilities 
Given that LI-core heterotetramers were hyperthermally stable with TM values far 
outside of the accessible temperature range, and LV-core heterotetramers had 




relatively lower TM values of 80–90 °C, coiled coils with mixed Leu/Ile/Val cores 
were anticipated to have intermediate stabilities. These mixed-core 
heterotetramers were generated by mixing A and B peptides with LI or LV cores to 
generate six additional combinations: 1-LI-A/1-LV-B, 1-LV-A/1-LI-B, 2-LI-A/2-LV-B, 
2-LV-A/2-LI-B, 3-LI-A/3-LV-B and 3-LV-A/3-LI-B. The resulting heteromers would 
have mixed cores but a single charge configuration, i.e. charged residues at only 













Figure 4-11 AUC data for the heteromers 1-LV-AB, 2-LV-AB and 
3-LV-AB. Sedimentation velocity c(s) distributions (top) and residuals 
(bottom) for: (a) 1-LV-AB returning a predicted Mw of 12.6 kDa (4.0 x mean 
monomer mass); (b) 2-LV-AB returning a predicted Mw of 13.1 kDa (4.1 x 
mean monomer mass); (c) 3-LV-AB returning a predicted Mw of 12.0 kDa 
(3.8 x mean monomer mass). Sedimentation equilibrium data (red, green 
and blue circles) and fits (black lines) (top) and residuals (same colours) 
(bottom) for: (d) 1-LV-AB returning a predicted Mw of 12.1 kDa (3.8 x mean 
monomer mass); (e) 2-LV-AB returning a predicted Mw of 12.7 kDa (4.0 x 
mean monomer mass); (f) 3-LV-AB returning a predicted Mw of 11.7 kDa 
(3.7 x mean monomer mass).  All measurements were performed in PBS 
(pH 7.4). 




The CD spectra of these mixed-core combinations showed that they all formed 
highly α-helical structures (Figure 4-12a, c and e). SE and SV experiments showed 
that all were tetrameric in solution (Figure 8-122–Figure 8-127).  
The temperature-dependent behaviours of the mixtures were also measured, and 
they were indeed found to have thermal stabilities between those of the LI- and 
LV-core heterotetramers (Figure 4-12b, d and f). All of the mixed-core 
heterotetramers had TM values above the accessible range. Nonetheless, the 
beginnings of the unfolding transitions could be observed, which was a promising 
indication that the coiled coils formed specific structures, albeit highly stable ones.  
The effect was most pronounced with the e/g set (consisting of 1-LI-AB, 
1-LI-A/1-LV-B, 1-LV-A/1-LI-B and 1-LV-AB, Figure 4-12b) where more of the 
unfolding transition could be observed. However, the effect became less obvious 
for the e/c and b/g sets where the mixed-core heterotetramers appeared to become 
more stable (Figure 4-12d and f). In the future, reducing the peptide concentration 
could make the unfolding transition accessible and potentially allow the TM values 
to be measured. 
The above mixed-core heterotetramers were made by combining peptides where 
the charged residues were at the same positions so that they only differed at the 
core residues. Hybrid heteromers, where the charged residues were located at 
different positions, were also investigated (Figure 4-13). For example, 
1-LI-A/2-LV-B, as well as containing a mixed Leu/Ile/Val core, contained e-g′ 
interactions at two of the four interhelical interfaces, and e-c′ interactions at the 
remaining two interfaces (Figure 4-13a, far left).  
The resulting hybrid heteromers were all highly α-helical and were all found to be 
tetrameric using SE and SV (Figure 4-13b, Figure 8-128–Figure 8-131). They were 
also highly thermally stable with TM values outside of the accessible range (Figure 
4-13c). However, like the initial mixed-core heterotetramers described above, they 
all displayed the beginnings of unfolding transitions. These heterotetramers would 
also benefit from investigation at lower peptide concentrations.  




While the nature of the ionic interactions may contribute to the differences in 













Figure 4-12 CD spectroscopy data for LI- LV and mixed-core 
heteromers. CD spectra at 5 °C for: (a) 1-LI-AB, 1-LV-AB, 1-LI-A/1-LV-B and 
1-LV-A/1-LI-B; (c) 2-LI-AB, 2-LV-AB, 2-LI-A/2-LV-B and 2-LV-A/2-LI-B; (e) 
3-LI-AB, 3-LV-AB, 3-LI-A/3-LV-B and 3-LV-A/3-LI-B. Temperature-dependent 
CD measurements monitoring MRE222 between 5 and 95 °C for the same 
heteromers. Keys as in (a), (c) and (e). Peptides were at 10 µM each. All 
measurements were performed in PBS (pH 7.4). 




of coiled coils and the LI- and LV-core coiled coils is probably driven largely by the 
identities of the core residues.  
4.5 Factors contributing to heterotetramer stability 
4.5.1 Glu-Lys interhelical interactions contribute to 1-LV-AB stability 
Previous analyses of de novo heterodimeric coiled coils, such the peptide Velcro 
ACID-p1/BASE-p1 system 188 and the EE/KK peptide system 352, have provided 
conflicting results regarding the contribution of interhelical ionic interactions to 
heteromeric coiled-coil stability. These systems consist of oppositely charged, 
unfolded peptides that interact to form heteromeric coiled coils when mixed. It is 
unclear whether the charged residues in such systems contribute to heteromer 







Figure 4-13 CD spectroscopy data for mixed-core heteromers 
containing mixed e-g′/c-e′ and e-g′/b-g′ ionic interactions. (a) Helical wheels 
for 1-LI-A/2-LV-B, 1-LI-A/3-LV-B, 2-LV-A/1-LI-B and 3-LV-A/1-LI-B. Dashed 
lines indicate potential interhelical ionic interactions. (b) CD spectra at 5 °C 
for the same heteromers. (c) Temperature-dependent CD measurements 
monitoring MRE222 between 5 and 95 °C for the same heteromers, key as 
in (b). Peptides were at 10 µM. All measurements were performed in PBS 
(pH 7.4).  




through charge repulsion in the individual peptides that is relieved in the 
heteromeric state. Previous analysis of designed heterotetrameric coiled coils 
suggests that specific interhelical ionic interactions do contribute to heterotetramer 
stability 226.  
Investigations into the contribution of interhelical ionic interactions to coiled-coil 
stability are often performed by measuring the coiled-coil properties under different 
pH or ionic strengths. If ionic interactions do indeed contribute to stability, the coiled 
coil would decrease in stability when the charged residues were screened, for 
example under high salt conditions, and increase in stability when charged 
residues were exposed, for example under low/no salt conditions.   
Therefore, the heterotetramer 1-LV-AB was investigated under buffered conditions 
at varying ionic strengths to assess the contribution of the interhelical Glu-Lys salt 
bridges to coiled-coil stability, and to determine whether the design was robust to 
changing conditions. Specifically, CD spectroscopy and AUC were performed in 
10 mM sodium phosphate buffer (pH 7.4) with 0.0 or 1.0 M NaCl (Figure 4-14, 
Figure 4-15).  
At concentrations of either 1 or 5 µM, 1-LV-AB was more folded in the absence of 
salt than in its presence (Figure 4-14a). At 5 µM peptide concentration, 1-LV-AB 
had fraction helix values of 77 and 68 % in the presence of 0.0 and 1.0 M NaCl, 
respectively. At 1 µm, these values were 69 and 52 %. Furthermore, the 
temperature-dependent CD measurements revealed that 1-LV-AB had 
dramatically different TM values under the different salt conditions (Figure 4-14b). 
At 5 µM peptide concentration and with no salt 1-LV-AB had a TM above the 
measurable range but with 1.0 M NaCl the TM was 77.5 °C. At 1 µM peptide 
concentration the TM obtained from the sample with no salt was also above the 
measurable range whereas in the presence of 1.0 M NaCl it was 60.0 °C. While 
the unavailability of the TM values in the absence of salt meant that ΔTM values 
could not be determined, these values must have been > 17.5 and > 35 °C at 5 
and 1 µM, respectively, indicating that coiled-coil stability was significantly 
decreased by electrostatic screening in buffer with increased ionic strength. 
Therefore, the charged residues do appear to contribute to the stability of this 
heterotetramer through the formation of interhelical salt bridges.  
When the peptides 1-LV-A and 1-LV-B were investigated alone using CD 
spectroscopy they were both highly unfolded under high and low salt conditions 




(Figure 4-14c and d). 1-LV-B became slightly more folded in the presence of 1.0 M 
NaCl.  
In SV and SE experiments, 1-LV-AB was found to be tetrameric under both salt 
conditions (Figure 4-15, Figure 8-120, Figure 8-121). However, in the presence of 
1.0 M NaCl, the peak representing the heterotetramer in the c(s) distribution was 
slightly broader than the peak observed in the absence of salt (Figure 4-15a and 
b). Furthermore, under the high salt conditions, the predicted molecular weights 
were slightly lower than the actual molecular weight with both AUC techniques. 
These observations may be related to the fact that 1-LV-AB was less well folded 
under the high salt conditions and therefore the presence of increased amounts of 









Figure 4-14 CD spectroscopy of 1-LV-A and 1-LV-B alone and mixed 
at equimolar concentrations in the presence of 0.0 or 1.0 M NaCl. (a) CD 
spectra at 5 °C for heterotetramer 1-LV-AB. (b) Temperature-dependent CD 
measurements monitoring MRE222 between 5 and 95 °C for heterotetramer 
1-LV-AB, key as in (a). Peptides were present at 1 or 5 µM each. CD spectra 
at 5 °C of (c) 1-LV-A and (d) 1-LV-B. Peptides were at 5 µM. All 
measurements were performed in 10 mM sodium phosphate buffer (pH 7.4) 
in the presence of 0.0 (solid lines) or 1.0 M NaCl (dashed lines).  




Given that the oligomeric state of 1-LV-AB did not change with increasing ionic 
strength it was likely that the presence of the interhelical ionic interactions did not 
influence coiled-coil specificity. That is, formation of the salt bridges did not have a 
role in specifying the oligomeric state of the coiled coil, which was probably dictated 
primarily by the identity of the core residues as well as by the need to position the 
charged peptides in an alternating arrangement.  
In summary, the charged residues in the 1-LV-A and 1-LV-B peptides appear to be 
able to form interhelical ionic interactions in the heterotetramer 1-LV-AB which 
contribute to coiled-coil stability but not specificity. The absolute energetic 
contribution of the salt bridges could not be quantified due to the high thermal 
stability of the coiled coil in the absence of salt, even at very low peptide 









Figure 4-15 AUC data for 1-LV-AB in the presence of 0.0 or 1.0 M 
NaCl. Sedimentation velocity c(s) distributions (top) and residuals 
(bottom) for 1-LV-AB with (a) 0.0 or (b) 1.0 M NaCl returning Mw of 13.1 
kDa (4.1 x mean monomer mass) and 12.0 kDa (3.8 x mean monomer 
mass), respectively. Sedimentation equilibrium data at 30, 33, and 36 
krpm (red, green and blue circles) and fits (black lines) (top) and residuals 
(same colours) (bottom) for 1-LV-AB with (c) 0.0 or (d) 1.0 M NaCl 
returning Mw of 12.7 kDa (4.0 x mean monomer mass) and 11.7 kDa (3.7 
x mean monomer mass), respectively.  All measurements were performed 
in 10 mM sodium phosphate buffer (pH 7.4) in the presence of 0.0 or 1.0 
M NaCl 




1-LV-B becomes slightly more folded, presumably because Lys-Lys repulsion is 
relieved. This may imply that relief from the repulsive homomeric interactions on 
formation of the heteromeric species also provides some driving force for 
heterotetramer formation.  
It would be interesting to investigate whether the other LV-core peptides are 
stabilised under high salt conditions. It would also be useful to know whether the 
charged residues in the other LV-core heterotetramers also contribute to coiled-
coil stability and, if so, which configuration of charged residues (e/g, c/e or b/g) 
provides the greatest increase in thermal stability.  
Finally, though interactions between charged residues can be observed in the 
crystal structures of homomeric coiled coils, it can be unclear whether they form in 
solution or contribute to coiled-coil stability. Therefore, it may be interesting to 
investigate the homotetrameric coiled coils described in Chapter 3, for example 
1-LV-EK and 1-LV-KE, in a manner analogous to the one described above.  
4.5.2 Heterotetramers are more stable than the equivalent homotetramers 
Intriguingly, the heterotetrameric coiled coils were consistently more highly folded 
and more thermally stable than the equivalent homomers with the same core 
residues and the same configuration of charged residues (Figure 4-16).  
The heteromers and homomers were investigated using CD spectroscopy at a total 
peptide concentration of 20 µM (Figure 4-16). For some of the coiled coil sets the 
differences were very pronounced. For example, the homomers 3-LV-EK and 
3-LV-KE had fraction helix values of just 10 and 11 %, respectively, while the 
equivalent LV-core heteromer, 3-LV-AB, had a fraction helix value of 87 % (Figure 
4-16e). In all cases the LV-core heteromers were also more thermally stable than 
the corresponding homomers (Figure 4-16b, d and f). Furthermore, although all of 
the LI-core homomers and heteromers formed highly α-helical assemblies, the 
homomers were also less thermally stable than the heteromers.  
Homomers and heteromers were expected to have similar stabilities given that 
they contained the same core residues, are the same length, and contain the same 
numbers of charged residues so have the same potential to form interhelical ionic 
interactions. Why this was not the case is unclear, but it may provide further 
indication that, on formation of a heterotetramer, relief from the repulsive 




interactions present in the individual acidic and basic components provides an 













Figure 4-16 CD spectroscopy data for homo- and heterotetramers. 
CD spectra at 5 °C for: (a) 1-LI-EK, 1-LV-EK, 1-LI-KE, 1-LV-KE, 1-LI-AB and 
1-LV-AB; (c) 2-LI-EK, 2-LV-EK, 2-LI-KE, 2-LV-KE, 2-LI-AB and 2-LV-AB; (e)  
3-LI-EK, 3-LV-EK, 3-LI-KE, 3-LV-KE, 3-LI-AB and 3-LV-AB. Temperature-
dependent CD measurements monitoring MRE222 between 5 and 95 °C for 
the same peptides/heteromers: (b), (d) and  (f). Keys as in (a), (c) and (e). 
Solid lines, LI-core designs; dashed lines, LV-core designs. The total peptide 
concentration was 20 µM. All measurements were performed in PBS (pH 
7.4). 




4.6 The effect of non-polar residues at g in heterotetramers 
As introduced in the Chapter 3, placing non-polar Ala residues at core-flanking e 
and g positions has previously been found to lead to the formation of higher 
oligomeric states such as hexamers and heptamers 213,345 or to the formation of 
antiparallel structures 222,223. When Ala was placed at the g positions of the 
homotetrameric peptides 2-LI-EK and 2-LI-KE the resulting peptides, 2-LIA-EK and 
2-LIA-KE, still formed homotetramers (Section 3.5). Whether they were forming 
parallel tetramers or antiparallel rop-like Ala-coil structures was not determined 348.   
To investigate the effect of introducing core-flanking Ala residues to 
heterotetramers, Ala was placed at the g positions of the peptides 2-LI-A, 2-LI-B, 
2-LV-A and 2-LV-B to produce the peptides 2-LIA-A, 2-LIA-B, 2-LVA-A and 
2-LVA-B, respectively. These peptides were combined to make the A/B 
heteromers 2-LIA-AB and 2-LVA-AB. As with the homomers, removing the polar 
Gln residues from the g positions could have resulted in coiled coils with higher 
oligomeric states, antiparallel tetramers or parallel tetramers.  
4.6.1 Ala@g peptides may form higher order homomers 
When the acidic and basic peptides were investigated alone at 10 µM using CD 
spectroscopy, 2-LIA-A and 2-LIA-B were highly folded into α-helical structures with 
fraction helix values of 86 and 79 %, respectively (Figure 4-17a and b). These 
values were similar to the fraction helix values for the parent peptides 2-LI-A (80 %) 
and 2-LI-B (85 %) (Figure 4-2d). The LV-core peptides 2-LVA-A and 2-LVA-B were 
less folded at the same concentration with fraction helix values of 44 and 23 %, 
respectively (Figure 4-17a, Figure 4-18b). The fraction helix value for 2-LVA-B was 
also similar to that of the parent 2-LV-B (19 %), while 2-LVA-A was more folded 
than its parent 2-LV-A which had a fraction helix value of 24 % (Figure 4-8d).  
The Ala@g peptides also demonstrated a concentration-dependent increase in 
folding (Figure 4-17a and b). At 100 µM peptide concentration, 2-LIA-A and 2-LIA-B 
were highly α-helical with fraction helix values of 92 and 87 %, respectively. At the 
higher concentration folding of 2-LVA-A and 2-LVA-B also increased to 77 and 
46 %, respectively.  
The temperature-dependent behaviour of the peptides was investigated. At 10 μM 
2-LIA-A had a TM value of 74 °C, however 2-LIA-B was much more stable than its 




acidic partner with a TM value above the accessible range. At the same 
concentration, 2-LVA-A had a much lower TM of 28 °C. Conversely, 2-LVA-B had 
a TM below the measurable range.   
When the peptides were analysed using SE and SV these experiments returned 













Figure 4-17 Biophysical characterisation of acidic and basic Ala@g 
peptides. CD spectra at 5 °C for (a) 2-LIA-A and 2-LVA-A and (b) 2-LIA-B 
and 2-LVA-B. Peptides were at 10 (solid lines) or 100 µM (dashed lines). 
Sedimentation velocity c(s) distributions (top) and residuals (bottom) for: (c) 
2-LIA-A returning a Mw of 14.2 kDa (4.4 x monomer mass); (d) 2-LVA-A 
returning a Mw of 13.6 kDa (4.3 x monomer mass); (e) 2-LIA-B returning a 
Mw of 14.5 kDa (4.5 x monomer mass); (f) 2-LVA-B returning a Mw of  12.7 
kDa (4.0 x monomer mass). All measurements were performed in PBS (pH 
7.4). 




Figure 8-112). However, the peptides generally appeared to form oligomeric states 
of tetramers and larger. This was in contrast to the parent LI- and LV-core peptides, 
which formed trimers and monomers, respectively.  
Furthermore, while single, sharp oligomer peaks were observed in the c(s) 
distributions of 2-LIA-A and 2-LIA-B, the peaks observed for 2-LVA-A and 2-LVA-B 
were much broader. This may indicate that the peptides formed a range of close 
oligomeric states that could not be resolved as separate peaks. In the c(s) 
distribution for 2-LVA-B particularly there appears to be a small, overlapping peak 
below 1 S, which may correspond to a smaller species.  
2-LIA-B had a single, clear peak in its c(s) distribution corresponding to an 
oligomeric state of 4.5. The predicted oligomeric state from SE for this peptide was 
also 4.5. This peptide may form a mix of tetramers and pentamers and, therefore, 
widening the hydrophobic seam through the addition of alanine may have allowed 
this peptide to access higher oligomeric states.  
4.6.2 Ala@g peptides interact to form heterotetramers 
When the acidic and basic peptides were mixed at equimolar concentrations the 
resulting 2-LIA-AB and 2-LVA-AB pairs were highly α-helical with fraction helix 
values of 90 and 89 %, respectively (Figure 4-18a and b). The spectra of the 
mixtures were also more highly α-helical than the averages of the individual peptide 
spectra, indicating the peptides interacted. Both A/B heteromers were highly 
thermally stable, with TM values above the accessible range (Figure 4-18c and d). 
Like the LI-core heterotetramers discussed in Section 4.2.3.2, these Ala@g 
heteromers did not display even the beginnings of an unfolding transition.  
In both SE and SV experiments the 2-LIA-AB and 2-LVA-AB heteromers returned 
molecular weighs corresponding to tetramers in solution (Figure 4-19, Figure 
8-132, Figure 8-133). The c(s) distributions indicated that each heteromer formed 
a single species in solution (Figure 4-19a and b). Therefore, like the homotetramers 
2-LIA-EK and 2-LIA-KE, these heteromers assemblies also appear to form 
tetramers in solution despite having sequences that could be compatible with the 
formation of higher oligomeric states.  




While no crystallographic data could be obtained for the heteromers to verify their 
structures, it is possible that these Ala@g heteromers may be forming antiparallel 
coiled coils, due to the similarity of their sequences to rop-like Ala-coils. In the 
absence of structural data, techniques such as disulphide exchange with Cys-
labelled peptides could provide information on helix orientation. For example, A 
and B peptides labelled with Cys at the same terminus could interact to form 
disulphide-linked A-A, B-B and A-B dimers if the peptides were oriented in the 
parallel orientation. In the antiparallel orientation, only the A-A and B-B dimers 









Figure 4-18 CD spectroscopy data for Ala@g peptides alone and 
mixed at equimolar concentrations. CD spectra at 5 °C for (a) 2-LIA-A and 
2-LIA-B and (b) 2-LVA-A and 2-LVA-B. Temperature-dependent CD 
measurements monitoring MRE222 between 5 and 95 °C for the same 
peptides/heteromers (c), (d). Keys as in (a) and (b). Peptides were at 10 µM 
each. All measurements were performed in PBS (pH 7.4). 




4.7 Chapter conclusions 
A set of acidic and basic peptides with a range of different core- and charged-
residue configurations has been designed (Figure 4-20). The in vitro properties of 
the peptides differed in various ways. For example, the peptides 2-LI-A, 2-LI-B, 
2-LIA-A and 2-LIA-B all form highly folded homomeric α-helical structures while 
other peptides, such as 1-LV-A and 1-LV-B, were almost entirely unfolded. The 
peptides also formed a number of different oligomeric states ranging from 
monomers to tetramers and perhaps higher.  
The peptides could be combined in A/B pairs to make a set of A2B2 
heterotetrameric assemblies, which also had differing properties. Primarily, the 
heterotetramers were found to differ in their thermal stabilities, which appeared to 









Figure 4-19 AUC data for the Ala@g heteromers. Sedimentation 
velocity c(s) distributions (top) and residuals (bottom) for: (a) 2-LIA-AB 
returning a Mw of 13.4 kDa (4.1 x mean monomer mass); (b) 2-LVA-AB 
returning a Mw of 12.9 kDa (4.1 x mean monomer mass). Sedimentation 
equilibrium data (red, green and blue circles) and fits (black lines) (top) and 
residuals (same colours) (bottom) for: (c) 2-LIA-AB returning a Mw of 12.8 
kDa (4.0 x mean monomer mass); (d) 2-LVA-AB returning a Mw of 12.4 kDa 
(3.9 x mean monomer mass). All measurements were performed in PBS (pH 
7.4). 




heterotetramers were the most stable; Leu/Val cores were generally the least 
stable; and mixed Leu/Ile/Val cores gave intermediate stabilities. All, or at least 
part, of a cooperative unfolding transition could be observed for the LV- and mixed-
core heterotetramers. However, the LI-core heterotetramers were much more 
stable and did not display an unfolding transition. The absence of a cooperative 
unfolding transition can be an indication of a molten globule state, however, given 
that the other heterotetramers demonstrated cooperative unfolding, it seems likely 
that the LI-core heterotetramers also form unique structures, albeit incredibly 
thermally stable ones.  
Having the ability to tune the stability of the heterotetrameric coiled coils through 
varying the core residues is useful as it allows coiled coils with specific properties 
to be designed for different applications. For example, in the context of 
transcriptional regulators, using a highly stable coiled coil as an interaction domain 
 
Figure 4-20 Summary of designs discussed in Chapter 4. 
Successful designs, i.e. those consisting of peptides that form unfolded 
monomers alone and interact to form heterotetrameric coiled coils, are 
highlighted in green. Designs where constituent peptides form folded 
homomeric species are highlighted in orange. Thermal stabilities for each 
core arrangement are indicated. LV-core designs were the least stable, 
mixed LI/V-core designs had intermediate stabilities, and LI-core designs 
and those with extended hydrophobic seams (Ala@g) were the most stable.  




to recruit RNAP to a gene of interest would drive strong expression of that gene; a 
coiled coil with a lower stability would drive a lower level of gene expression. Thus, 
the level of gene expression could be tuned by changing the coiled-coil domain. 
However, even the least stable heteromeric coiled coils discussed in this chapter 
are still hyperthermally stable when compared to most natural proteins from 
mesophilic organisms so the subtle differences in the coiled coil stabilities may be 
lost in a cellular context. Therefore, should a wider range of coiled-coil behaviours 
be required, the heterotetramers could be further destabilised by decreasing their 
length or by making further core substitutions to introduce even smaller 
hydrophobic residues such as alanine 174,191,225. However, the latter approach has 
previously been found to lead to antiparallel conformations in some coiled coils and 
should therefore be approached with caution 189.  
Heterotetramers consisting of peptides that are themselves unfolded are generally 
considered to be the most useful. This is because, should the peptides be used as 
artificial protein-protein interactions to mediate the interactions between other 
protein domains, they would not cause off target homo-oligomerisation of their 
fusion partners. In this regard, the most successful designs of the heterotetramers 
described here are 1-LI-AB, 1-LV-AB, 2-LV-AB and 3-LV-AB, as well as the hybrid 
heterotetramers that can be made by combining any of the unfolded peptides that 
comprise these coiled coils.  
While the success of these designs must still be verified through solving their 
crystal structures, the biophysical data indicates that they do adopt the anticipated 
structures in vitro. It is therefore now possible to begin investigating how these 
heterotetramers, and their constituent peptides, behave inside living organisms as 
well as to begin introducing features into the coiled coils that may allow them to 











Chapter 5: Characterisation of novel tetrameric 
coiled coils in E. coli 
5.1 Chapter introduction 
Following their design and characterisation in vitro, the in vivo behaviour of the de 
novo coiled coils was investigated to determine whether they were suitable to use 
as PIDs in ATFs. Challenges included whether the short peptides would be able to 
find their partners in the complex cellular environment; whether they would cross 
react with endogenous proteins, given the prevalence of coiled-coil sequences in 
nature; and whether the highly charged peptides would have toxic effects on the 
cell. A subset of A2B2 heterotetramers was chosen from the suite of designed 
tetramers discussed in this thesis. Heterotetramers were chosen over 
homotetramers due to their increased complexity: as they contain multiple 
components they can be used to make more-complex ATFs with more inputs 
available to increase the achievable level of control.  
The peptides 1-LI-A, 2-LV-A, 3-LV-A, 1-LI-B, 2-LV-B and 3-LV-B were selected for 
further analysis in E. coli because these peptides were unfolded monomers in 
isolation but also interacted to form α-helical heterotetramers when mixed in 
acidic/basic pairs. Furthermore, while they were all highly thermally stable, the 
heterotetramers exhibited a range of TM values. They also represented the three 
main charge configurations (e/g, c/e and b/g). For clarity and brevity these peptides 
are referred to as A1, A2, A3, B1, B2 and B3, respectively, throughout this chapter.  
To determine whether the acidic and basic peptides were able to interact in E. coli, 
a transcription repression assay based on the Lac repressor was used (Figure 5-1). 
This assay has previously been used to demonstrate the in vivo interaction of a set 
of de novo heterodimeric coiled coils 173,174. These heterodimers were designed to 
have different stabilities and their in vitro-measured KDs correlated with the level of 
transcription repression they achieved: those with the strongest interaction in vitro 
also gave the highest level of repression in vivo.  




The Lac repressor, LacI, is a bacterial transcriptional repressor that is involved in 
controlling the expression of the lac operon genes, which are involved in lactose 
metabolism in the absence of the preferred carbon source, glucose 113. Lac 
repressor monomers interact via a central dimerisation domain, bringing together 
the N-terminal helix-turn-helix DBDs to form a dimeric DNA-binding module that 
can bind to one of three operator sites, O1, O2 or O3. These are spaced at different 
distances from the lac promoter and have different sequences, therefore different 
affinities for the Lac repressor 114,353. Binding of LacI to the high-affinity O1 operator, 
which overlaps the lac promoter, is essential for repression 354. However, LacI in 
fact forms a dimer of dimers via a C-terminal tetramerisation domain 353. Tetrameric 
LacI therefore contains two DNA-binding dimers and can bind two operators 
simultaneously, looping the intervening DNA 115,315. This brings about a stronger 
level of repression by increasing the local concentration of the repressor at the 







Figure 5-1 Experimental approach for the transcription repression assay. 
(a) The LacI*-peptide fusions and GFP reporter were expressed from 
separate plasmids with different antibiotic resistance genes. (b) When 
neither peptide (LacI*) or either the acidic (A) or basic (B) peptide (LacI*-A, 
LacI*-B) were present, LacI* should not form functional DNA-binding 
modules and so the reporter gene should not be repressed. (c) When both 
the acidic and basic peptide fusions are present, a LacI*-A/LacI*-B complex 
should form via the coiled coil leading to functional DNA-binding modules 
and repression of the reporter gene.  




by inducers such as allolactose and IPTG, which cause a conformational change 
that prevents LacI from recognising operator DNA 117,118.  
In the transcription repression assay, the acidic and basic coiled-coil peptides were 
fused to the C terminus of a version of the Lac repressor, replacing the wild-type 
(WT) tetramerisation domain. This version of Lac repressor, LacI*, also contained 
a single amino acid substitution (L251A) in the dimerisation domain that interrupts 
the dimerisation interface, weakening the interaction between the monomers 357. 
As a result, the LacI* monomers were expected to form productive DNA-binding 
dimers only when brought together via some exogenous protein-protein 
interaction. If the interaction between the exogenous proteins (here, the coiled-coil 
peptides) was productive, LacI* dimers would bind to the O1 lac operator site in a 
pVRb reporter plasmid causing repression of the reporter gene, GFP 308. The 
reporter plasmid contained a single operator therefore looping was not expected 
to occur. Furthermore, the GFP reporter gene was expressed from a mutated 
version of the lac promoter, PlacUV5, which contains mutations in the -10 box that 
increase expression from this promoter 358. This promoter is also unaffected by 
CAP, which usually activates transcription from the WT lac promoter in the absence 
of glucose 106,359. To prevent cross talk between the de novo constructs and the 
endogenous WT lac operon, all transcription repression assays were performed in 
TB28 E. coli cells, which do not contain the lac operon (ΔlacIZYA) 307.  
The acidic and basic LacI*-peptide fusion proteins were expressed from different 
plasmids: either a pVRc plasmid, which contained a CmR gene, or a pBAD plasmid, 
which contained an AmpR gene. While the components could have been expressed 
from the same plasmid, placing them on separate plasmids allowed greater 
flexibility for studying different combinations of the fusion proteins.  
Both fusion proteins were expressed from the bacterial arabinose-inducible 
promoter, ParaBAD 360. This promoter is part of the araBAD operon and is involved in 
arabinose metabolism. It is regulated by the AraC protein, which both represses 
and activates transcription 361. In the absence of arabinose, an AraC dimer binds 
to two DNA sites, one proximal to the promoter (araI1) and one distal to the 
promoter (araO2), looping the intervening DNA 362,363. This causes repression by 
preventing RNAP and CAP (which also activates transcription from this promoter) 
from accessing the DNA. On binding arabinose, the AraC dimer undergoes a 
conformational change that alters the orientation of its DBDs, causing it to bind at 
two adjacent, promoter-proximal DNA sites, araI1 and araI2 363. This opens up the 




promoter allowing RNAP (and CAP, under low-glucose conditions) to bind. AraC 
may also actively recruit RNAP to the promoter when it is in the arabinose-bound 
state 364. Arabinose can therefore be used to induce the expression of a gene that 
is expressed from the ParaBAD promoter. In these experiments, increasing the 
arabinose concentration should increase the expression level of the acidic and 
basic components.  
While there are many other methods for studying the interactions of proteins in 
vivo, this approach has the benefit of demonstrating that the peptides interact while 
also generating ready to use semi-artificial transcription factors consisting of a 
designed protein-protein interaction and a natural DNA-binding module. 
When studied in E. coli using this transcription repression-based interaction assay, 
all the peptides interacted in the anticipated heterotetramer pairs. Additionally, 
western blotting was used to investigate the effect of fusing de novo peptides to 
naturally occurring proteins. This revealed that the designed coiled-coil sequences 
generally led to a reduction in expression level. Therefore, while the de novo 
peptides still interacted as designed, they were not necessarily optimal for use in 
living organisms. 
5.2 De novo coiled coils assemble in vivo 
5.2.1 Acidic and basic peptides interact in E. coli 
Initially, to determine whether they were able to interact in E. coli, both the A1 and 
B1 peptides were fused to LacI* (Lac repressor that contained the L251A 
substitution and was C-terminally truncated to remove the WT tetramerisation 
domain) via a Gly-Ser-Gly linker, generating the proteins LacI*-A1 and LacI*-B1 
(Figure 5-2a, Figure 8-156). The peptide gene sequences were manually optimised 
for E. coli codon usage 365 and to reduce repetition to minimise the risk of 
recombination. The proteins were also fused to an N-terminal 6 His tag, a T7 
epitope tag and an Xpress™ epitope tag. The acidic and basic proteins were 
placed on separate pVRc or pBAD plasmids, respectively, and were expressed 
from the arabinose-inducible promoter, ParaBAD. However, it is important to note that 
these experiments were performed without arabinose induction. While arabinose 
binding to AraC is required to achieve maximal gene expression from ParaBAD, a 
small amount of basal gene expression from this promoter is observed even in the 
absence of arabinose 360,366.  




When LacI*-A1 and LacI*-B1 were co-expressed, a decrease in the level of GFP 
was observed relative to the controls where just LacI* or just one of the LacI*-
peptide fusions was expressed (Figure 5-2b). A 4.5-fold increase in repression 
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Figure 5-2 Transcription repression with the A1/B1 de novo coiled coil 
with induction by 0.0 % arabinose. (a) Peptides were fused C-terminally 
to LacI*, which was fused N-terminally to 6 His, T7 and Xpress tags. The 
construct was expressed from the arabinose-inducible ParaBAD promoter. 
The * indicates the approximate location of L251A substitution. DNA 
architectures were identical in both the pVRc and pBAD plasmids. (b) 
Transcription repression assay and (c) fold repression values relative to 
the GFP-only control where LacI*-A1 was expressed from pVRc and 
LacI*-B1 was expressed from pBAD. (d) Transcription repression assay 
and (e) fold repression values relative to the GFP-only control where 
LacI*-A1 was expressed from pBAD and LacI*-B1 was expressed from 
pVRc. LacI (WT), wild-type Lac repressor; LacI*-WTtet, Lac repressor 
with L251A substitution and wild-type tetramerisation domain; LacI*, Lac 
repressor with L251A substitution and no coiled-coil domain. Error bars 





















































































the acidic and basic peptides and the formation of a complex that repressed GFP 
expression (Figure 5-2c). The fact that the coiled-coil interaction could still be 
observed when the fusion proteins were expressed at basal levels, which were 
expected to be very low, demonstrates the strength of the interaction between the 
peptides. Furthermore, though the strength of repression achieved by the complex 
containing the de novo A1/B1 coiled coil was lower than that achieved by the 
completely WT Lac repressor, LacI (WT), it was greater than that achieved by LacI* 
that still contained the WT tetramerisation domain (LacI*-WTtet). 
To investigate whether swapping the plasmids influenced the strength of 
repression, the transcription repression assay was also performed with the 
LacI*-A1 and LacI*-B1 proteins placed on the pBAD and pVRc plasmids, 
respectively (Figure 5-2d).  The plasmids had different origins of replication 
resulting in a slightly higher copy number of pBAD (origin of replication: pBR322) 
relative to pVRc (origin of replication: p15A).  This may have resulted in slightly 
higher expression of the protein encoded on the pBAD plasmid, which may have 
affected the results. However, the results were similar to those with the opposite 
plasmid arrangement with the complex giving 4.1-fold repression relative to the 
GFP-only control (Figure 5-2d and e). As the identity of the plasmid appeared to 
have little effect on the strength of repression, all of the remaining experiments 
were performed with the acidic peptide fusions expressed from the pVRc plasmid 
and basic peptide fusions expressed from the pBAD plasmid.  
Furthermore, to determine whether other de novo coiled coils with lower in vitro 
thermal stabilities were also able to interact in E. coli, the transcription repression 
assay was performed with the A2/B2 and A3/B3 heterotetramers (Figure 5-3a and 
c). These coiled coils gave fold repression values of 4.6 and 2.6 relative to the 
GFP-only control indicating that these peptides also interacted in E. coli (Figure 
5-3b and d). Additionally, when acidic/basic cross reactions were investigated 
using the A2/B1 and A1/B2 pairs, these heteromers also formed and gave fold 
repression values of 3.5 and 4.7, respectively (Figure 5-3e). A low level of 
repression was observed with the A3/B3 coiled coil, which had a relatively low 
thermal stability in vitro, and an intermediate level of repression was observed with 
A2/B1, which had an intermediate stability in vitro. However, there did not appear 
to be a robust correlation between the in vitro stability and the in vivo level of 
repression for the other pairs. This may have been due to other confounding factors 




that would have altered the observed amount of repression, such as variable 
cellular levels of the fusion proteins. 
Both LacI*-A1/LacI*-B1 and LacI*-A2/LacI*-B2 appeared to repress GFP 
expression more strongly than LacI*-WTtet while LacI*-A3/LacI*-B3 showed similar 
levels of repression to LacI*-WTtet. The Lac repressor tetramerisation domain is 
itself a tetrameric coiled coil, albeit an antiparallel one 367. The difference in the 











Figure 5-3 Transcription repression with the A2/B2, A3/B3 A2/B1 and 
A1/B2 de novo coiled coils with induction by 0.0 % arabinose. (a) 
Transcription repression assay and (b) fold repression values relative to the 
GFP-only control for LacI*-A2/LacI*-B2. (c) Transcription repression assay 
and (d) fold repression values relative to the GFP-only control for LacI*-
A3/LacI*-B3. (e) Transcription repression assay with LacI*-A2/LacI*-B1 and 






































































































longer length of the designed sequences – 30 amino acids versus 22 amino acids 
– which can contribute to the stability of coiled coils 225. Additionally, de novo 
proteins are often hyperthermally stable relative to natural proteins 3,31,42,43,368.  In 
the context of coiled coils, this may reflect the fact that designed sequences are 
often idealised, primarily containing amino acids that favour α helix formation. 
Conversely, natural sequences have been subject to a multitude of selective 
pressures and their sequences are generally more varied in composition.  
5.2.2 A second operator site enhances repression 
In the above assays a single O1 lac operator was present in the GFP reporter 
plasmids. However, as introduced above, the WT lac operon contains three 
separate operator sites, O1, O2 and O3 114. While binding of Lac repressor to the O1 
operator, which is located near the promoter, is always necessary for repression, 
binding of a Lac repressor tetramer simultaneously to two operators has the effect 
of tethering Lac repressor at the DNA, preventing it from diffusing away and 
increasing its local concentration. This enhances the level of repression that can 
be achieved. A reporter plasmid containing a second O1 operator site 92 bp 
upstream of the first O1 site (the same distance between O1 and O3 in the lac 
operon) was used to measure whether the presence of a second operator led to 
an enhancement in the level of repression by the LacI*-A1/LacI*-B1 complex 
(Figure 5-4a). Because the A1/B1 coiled coil should form a tetramer, the resulting 
LacI*-A1/LacI*-B1 complex should also be tetrameric with two DNA-binding 
dimers, like the WT Lac repressor.  
When investigated with induction by 0.0 % arabinose, with a single O1 operator the 
LacI*-A1/LacI*-B1 complex gave 5.0-fold repression relative to the GFP-only 
control (Figure 5-4b). With two operator sites this value was 7.1, therefore the 
complex showed a 1.4-fold enhancement in repression on adding the second 
operator (Figure 5-4c). Conversely, the wild-type Lac repressor gave a much 
greater 6.5-fold enhancement. However, it is more meaningful to compare the 
LacI*-A1/LacI*-B1 complex to the LacI*-WTtet sample, given that both contain the 
L251A substitution so rely primarily on the tetramerisation domain for both 
dimerisation and tetramerisation. The LacI*-WTtet complex gave a 2.0-fold 
enhancement.  




The LacI*-A1/LacI*-B1 complex achieved a higher overall level of repression than 
LacI*-WTtet. It also gave a small enhancement in the strength of repression in the 
presence of two lac operator sites, which was similar to that observed with LacI*-
WTtet. However, the enhancement in repression observed for LacI*-A1/LacI*-B1 
on adding the second O1 site did not necessarily show that the complex was able 
to loop DNA: the parallel tetramer may not have held the dimeric DNA-binding 
modules in the correct conformation to bind two DNA sites simultaneously and the 
second operator may simply have maintained the complexes in the vicinity of the 
DNA for longer, leading to the observed increase in repression. Further 
investigation of the complex is needed to determine whether it can in fact loop 
DNA, for example by comparing it to a complex with just one DNA-binding dimer, 
such as a dimer of LacI* monomers. Alternately, in vitro techniques such as gel 
shift assays with DNA substrates of different lengths or electron microscopy could 







Figure 5-4 Transcription repression with the A1/B1 de novo coiled coil 
with one or two O1 operator site with induction by 0.0 % arabinose. (a) 
Transcription repression assay (one O1 operator, green; two O1 
operators, blue) and fold repression values relative to the GFP-only 
control with (b) one or (c) two O1 operator sites. Error bars are one s.d. 





























































5.2.3 Weakening the Lac repressor dimerisation interface improves 
repressor properties 
In the above experiments, all of the acidic/basic pairings demonstrated GFP 
repression showing that they were able to interact in E. coli when fused to LacI*. 
However, while the LacI* system was sufficient to demonstrate the interaction 
between these peptides, it is not necessarily optimal for more extensive analysis 
or for use in ATFs. This is because the LacI*/LacI*, LacI*-A/LacI* and LacI*/LacI*-B 
controls all gave fold repression values of around 1.4, showing that residual 
dimerisation between the LacI* monomers was occurring (Figure 5-2c, Figure 5-3b 
and d). Therefore, while the L251A substitution did somewhat weaken the 
dimerisation interface in the Lac repressor, the interaction was not entirely 
abolished and the LacI* monomers were still able to dimerise, forming DNA-binding 
dimers that could repress GFP expression regardless of whether they were fused 
to the de novo peptides.  
Furthermore, when the LacI*-A1/LacI*-B1 transcription repression assay was 
performed with induction by 0.2 % arabinose high levels of repression were 
observed both in the controls where neither or just one peptide was present, and 
when the acidic and basic peptide were present (Figure 5-5a). With induction, the 
LacI*-A1/LacI*-B1 complex repressed only around 1.3-fold more strongly than any 
of the controls (Figure 5-5b). However, without induction, this complex repressed 
at least 3-fold more strongly than the controls (Figure 5-2). Thus, at increasing 
protein concentrations the LacI* residual dimerisation increases and begins to 
overwhelm the contribution of the de novo coiled coil to oligomerisation.  
To improve the properties of the repressors, further substitutions were made to the 
Lac repressor dimerisation interface. A tyrosine in this interface, Y282, was 
selected for mutagenesis as substitutions at this position often produce a 
monomeric phenotype 370-372. Y282A and Y282D substitutions were introduced into 
LacI* resulting in the double L251A/Y282A and L251A/Y282D variants LacIAA and 
LacIAD (Figure 5-6). The Y282A substitution was proposed to weaken the interface 
by interrupting the shape complementarity due to the small size of alanine relative 
to tyrosine. The Y282D substitution was proposed to weaken the interface by 
introducing repulsive charges into the interface that would actively prevent the 
monomers from dimerising unless they were brought together by an interaction 
domain that was strong enough to overcome the repulsion. 




The LacIAA and LacIAD variants were tested with a simple model coiled-coil system 
before implementation with the heterotetramers. The variants were fused to the de 
novo homodimeric coiled coil, CC-Di to make the proteins LacIAA-ccDi and 
LacIAD-ccDi 208. The Y282A and Y282D substitutions were also made in LacI*-
WTtet to make the proteins LacIAA-WTtet and LacIAD-WTtet.   
The new proteins were initially examined in the transcription repression assay with 
induction by 0.0 and 0.2 % arabinose (Figure 5-7a). Unlike LacI*, the LacIAA and 
LacIAD proteins did not display any residual dimerisation at 0.0 % arabinose and 
showed similar levels of GFP to the GFP-only control. Furthermore, the LacIAA-
WTtet and LacIAD-WTtet proteins showed no repression at 0.0 % arabinose; at this 
arabinose concentration, LacI*-WTtet showed some repression activity. Finally, 
LacIAA-ccDi repressed around 1.6-fold more strongly than LacAA alone and LacIAD-
ccDi did not show any repression at this arabinose concentration. 
With induction by 0.2 % arabinose, LacI* displayed extensive residual dimerisation 
and had a fold repression value of 11.3. With LacIAA, the residual dimerisation was 
roughly halved with a fold repression value of 6.2 at the same arabinose 
concentration. Therefore, though the additional Y282A substitution further 
weakened the dimerisation interface, it also did not entirely eliminate the residual 
dimerisation.  
LacIAD showed little residual dimerisation at 0.2 % arabinose. However, at the same 





Figure 5-5 Transcription repression with the A1/B1 de novo coiled coil 
with induction by 0.0 and 0.2 % arabinose. (a) Transcription repression 
assay and (b) fold repression values relative to the GFP-only control with 













































than LacIAD alone. The poor repression activity displayed by LacIAD-ccDi may be 
due to the aspartates causing excessive disruption to the local conformation of the 
dimerisation interface, such that the parallel homodimeric coiled coil CC-Di could 
no-longer mediate the interaction between the monomers. Conversely, the WT 
tetramerisation domain, an antiparallel tetramer, may still have been able to 
mediate this interaction in LacIAD-WTtet, which did demonstrate relatively strong 
repression at 0.2 % arabinose.  
Western blotting was performed on a sample of E. coli cells taken during the assay 
using an antibody specific for the 6 His tag that is present on all of the Lac repressor 
derivatives. All of the proteins were expressed at relatively similar levels (Figure 
5-7b). Therefore, the differences in repression were not due to different levels of 
expression or degradation of the proteins.  
Due to poor repression by LacIAD-ccDi, the LacIAA proteins were selected for further 
analysis at 0.02, 0.002 and 0.0002 % arabinose (Figure 5-7c). With increasing 





Figure 5-6 Crystal structure of a C-terminally truncated Lac repressor dimer 
(PDB ID: 1EFA 373) showing the domain structure and the locations of L251 
and Y282. The structure is presented from (a) the side, with DNA-binding and 
regulatory domains labelled, and (b) the top. The tetramerisation domain (not 
present in this structure) is located at the top of the structure in (a). LacI 
monomers, green and yellow; DNA, orange/purple; L251, magenta; Y282, 
blue. Image generated using PyMol.  




transcription factors, the level of repression caused by LacI*-ccDi and LacIAA-ccDi 
was also increased.  
Above 0.002 % arabinose LacI*-ccDi consistently gave fold repression values of 
13–14, potentially indicating that the maximal achievable level of repression for this 
protein had been reached (Table 5-1). The fold repression values for LacIAA-ccDi, 
however, continued to increase up to 0.2 %. Furthermore, LacI*-ccDi induced with 
0.2 % arabinose repressed GFP expression only 2.2-fold more strongly than un-
induced LacI*-ccDi, whereas LacAA-ccDi induced with 0.2 % arabinose repressed 







Figure 5-7 Transcription repression by the CC-Di de novo coiled coil fused 
to LacI* containing additional Y282 substitutions with induction by different 
arabinose concentrations. (a) Transcription repression assay with LacI*-
ccDi, LacIAA-ccDi and LacIAD-ccDi with induction by 0.0 and 0.2 % arabinose, 
n=4. (b) Expression levels of LacIAA and LacIAD variants relative to LacI*, 
n=3, representative gel image in Figure 5-20a. (c) Transcription repression 
assay with LacI*-ccDi and LacIAA-ccDi with induction by 0.0, 0.0002, 0.002, 
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unlike the LacI* system, could essentially be “turned off” because in the absence 
of arabinose the level of repression was much lower than in the LacI* system. 
Furthermore, by altering the arabinose concentration the repression level of LacIAA-
ccDi could be tuned over a wider range than LacI*-ccDi.  
To ensure that the LacIAA system behaved similarly with other coiled coils, it was 
tested with the A1/B1 heterotetramer. Both the acidic and basic peptides were 
fused to LacIAA and investigated with induction by 0.0 and 0.2 % arabinose (Figure 
5-8). With 0.0 % arabinose the controls with neither or just one of the coiled-coil 
peptides showed no repression (Figure 5-8b, top). When both LacIAA-A1 and 
LacIAA-B1 were present there was a small decrease in GFP, showing that the 
LacIAA-A1/LacIAA-B1 complex was able to cause some repression even in the 
absence of arabinose. 
When induced with 0.2 % arabinose, some residual dimerisation was observed in 
the controls however this was less extensive than that observed with LacI* (Figure 
5-8b, bottom). Around half the amount of residual dimerisation was observed with 
the LacIAA system compared with the LacI* system (Figure 5-5b). Also, there is a 
larger difference between the levels of repression observed with 0.0 and 0.2 % 
arabinose with LacIAA-A1/LacIAA-B1 compared to LacI*-A1/LacI*-B1. Therefore, 
LacIAA-A1/LacIAA-B1, like LacIAA-ccDi can be switched off and the repression level 
can also be tuned more finely.  
Overall, the LacIAA system provides another tool for studying the interactions 
between exogenous proteins in E. coli and also makes LacIAA-ccDi and LacIAA-













GFP 1.0 1.0 1.0 1.0 1.0 
LacI* 1.3 2.5 6.3 10.1 11.3 
LacI*-WTtet 2.8 6.7 14.3 14.7 17.4 
LacI*-ccDi 6.1 10.0 13.6 13.8 13.1 
LacIᴬᴬ 1.0 1.2 1.9 4.0 6.2 
LacIᴬᴬ-WTtet 1.0 1.2 2.7 7.0 8.2 
LacIᴬᴬ-ccDi 1.6 2.7 6.2 8.9 12.0 
Table 5-1 Fold repression values for LacI* proteins and LacIAA 
proteins relative to the GFP-only control at different arabinose 
concentrations.  




5.3 Demonstrating tetramerisation 
The systems introduced above were able to demonstrate that the de novo 
designed peptides interact in the anticipated pairings in E. coli. However, these 
versions of the assay do not distinguish between dimers and tetramers: either 
oligomeric state would have formed complexes that contained at least one dimeric 
DNA-binding module and so could have brought about GFP repression. Therefore, 
to obtain more information from the assay, the assay was modified such that 
functional DNA-binding dimers could only form when tetramerisation (or higher-
order oligomerisation) occurred. To achieve this, the proteins fused to the basic 
peptides were changed to non-DNA-binding proteins. Initially a DNA-binding-
deficient variant of Lac repressor was used, followed by a small solubility tag, 
SUMO. Finally, the effect of expressing the basic peptides alone, without folded 
protein domains fused to them, was investigated. In the resulting complexes, the 
DNA-binding dimers should only have formed between the LacI* monomers that 
were still fused to the acidic peptides. Because LacIAA was generated after these 
experiments were performed, the LacI* variant is used throughout this section.  
5.3.1 Lac repressor helix-turn-helix deletions 
A variant of the Lac repressor that could not bind DNA was generated by removing 






Figure 5-8 Transcription repression with the A1/B1 de novo coiled coil with 
LacIAA with induction by 0.0 and 0.2 % arabinose. (a) Transcription repression 
assay and (b) fold repression values relative to the GFP-only control with 
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Figure 5-6). This HTH deletion was made in the Lac repressor both with and 
without the L251A substitution to generate the proteins LacI*-ΔHTH and LacI-
ΔHTH, respectively. Then, the basic peptide B1 was fused to the C termini in place 
of the WT tetramerisation domain to generate the proteins Lac*-ΔHTH-B1 and 
LacI-ΔHTH-B1 (Figure 5-9a). When co-expressed with LacI*-A1 these proteins 
were anticipated to form a complex that contained one Lac repressor dimer that 
could bind DNA and one that could not (Figure 5-9b).  
The LacI-ΔHTH and LacI*-ΔHTH proteins were first investigated alone to ensure 
that DNA-binding had been eliminated (Figure 5-9c). Neither of the ΔHTH variants 
displayed any ability to repress GFP, even with induction by 0.2 % arabinose. LacI* 
showed strong repression with induction by 0.2 % arabinose due to the residual 
dimerisation discussed in Section 5.2.3. The LacI-Trunc protein (WT dimerisation 
domain, C-terminally truncated to remove the tetramerisation domain) showed 
strong repression at both 0.0 and 0.2 % arabinose. The dimerisation interface in 
this protein was intact and so DNA-binding dimers could form in the absence of an 
exogenous PID.  
The LacI-ΔHTH-B1 and LacI*-ΔHTH-B1 proteins were then investigated in 
combination with LacI*-A1 (Figure 5-9d and e). With both complexes, repression 
was observed at 0.2 % arabinose, presumably due to residual dimerisation of the 
LacI*-A1 proteins. Neither the LacI*-A1/ LacI-ΔHTH-B1 or the LacI*-A1/ LacI*-
ΔHTH-B1 complex demonstrated GFP repression at 0.0 % arabinose. This may 
have been an indication that the A1/B1 heterotetramer was in fact not forming a 
tetramer in E. coli. However, given the extensive in vitro data showing that this 
coiled coil is a heterotetramer in solution, this result may have been due to a 
limitation of the assay.  
Specifically, it was initially assumed that two Lac repressor dimers would form, one 
between the monomers attached to the acidic peptides and one between the 
monomers attached to the basic peptides. However, it is also possible, and 
perhaps more likely, that the dimers could have formed between one monomer 
attached to an acidic peptide and one monomer attached to a basic peptide. In this 
assay, this would have resulted in hybrid Lac repressor dimers that contained one 
monomer that could bind DNA and one that could not, producing a dimer that 
overall could not bind DNA and could not repress GFP expression (Figure 5-9f). In 
other words, rather than the monomers that were opposite each other in the coiled 
coil interacting, the monomers that are adjacent to each other interacted. This 




model for complex formation would prevent linker concatenation and is therefore 













Figure 5-9 Transcription repression with ΔHTH variants of the Lac repressor 
with induction by 0.0 and 0.2 % arabinose. (a) B1 peptides were fused 
C-terminally to LacI-ΔHTH or LacI*-ΔHTH, which were fused N-terminally to 
6 His, T7 and Xpress tags and the constructs were expressed from the ParaBAD 
promoter. The * indicates the approximate position of the L251A substitution. 
(b) Initially proposed model for DNA-binding of LacI*-A1/LacI-ΔHTH-B1 and 
LacI*-A1/LacI*-ΔHTH-B1 where light grey proteins represent Lac repressor 
with intact HTH domains and dark grey proteins represent ΔHTH variants. (c) 
Repression assay with LacI-ΔHTH and LacI*-ΔHTH proteins. (d) Repression 
assay with LacI*-A1/LacI-ΔHTH-B. (e) Repression assay with LacI*-A1/LacI*-
ΔHTH-B. Keys as in (c). (f) Updated model for complex formation containing 






















































5.3.2 SUMO fusions 
Next, in order to produce a complex that should have contained only a single, 
dimeric DNA-binding module, the Lac repressor proteins were removed from the 
basic peptides entirely. Initially, the basic peptides B1, B2 and B3 were fused via 
a Gly-Ser-Gly linker to the C terminus of yeast SUMO (Smt3, small ubiquitin-related 
modifier), which is a small, monomeric protein often used as a solubility tag for 
protein expression 374. SUMO was also fused to an N-terminal 6 His tag. This gave 
the proteins SUMO-B1, SUMO-B2 and SUMO-B3 (Figure 5-10a). When co-
expressed with the corresponding LacI*-A proteins, the resulting complexes were 
anticipated to contain a single dimeric Lac repressor DNA-binding module, two 
separate, non-interacting SUMO domains and a linking heterotetrameric coiled coil 
(Figure 5-10b).   
The LacI*-A1/SUMO-B1 complex was examined with induction by 0.0, 0.0002 and 
0.002 % arabinose (Figure 5-10c). Low arabinose concentrations were used to limit 
residual dimerisation of the LacI*-A1 protein. With 0.0 % arabinose, the complex 
gave 2.0-fold repression relative to the GFP-only control (Figure 5-10d). This value 
increased as the arabinose was increased. The level of repression in the controls 
with neither or just one peptide also increased as the arabinose concentration was 
increased, presumably due to residual dimerisation of LacI* and LacI*-A1. 
However, at every inducer concentration there was a stronger level of repression 
with LacI*-A1/SUMO-B1 compared to the controls. The fold repression values of 
LacI*-A1/SUMO-B1 relative to the LacI*/SUMO (no-coiled coil) controls at each 
arabinose concentration were similar (Figure 5-10e). Therefore, even when there 
was residual dimerisation of the LacI* proteins, this did not overwhelm the signal 
and the A1/B1 interaction could still clearly be observed. This is in contrast to the 
LacI*-A1/LacI*-B1 system where the signal from the coiled coil was overwhelmed 
when expression of the proteins was induced with high arabinose concentrations 
(Figure 5-5). This may be because the arabinose concentrations used here are 
much lower.  
The LacI*-A2/SUMO-B2 and LacI*-A3/SUMO-B3 complexes were also 
investigated with induction by 0.0 % arabinose (Figure 5-11a and b). These 
complexes gave fold repression values of 1.4 and 1.3, respectively, relative to the 
GFP-only control. 




The strengths of repression achieved by the LacI*-A/SUMO-B complexes were 
much lower than those achieved by the LacI*-A/LacI*-B complexes. There may 
have been many reasons for this. For example, the SUMO domains may have 
sterically hindered the formation of the coiled coil: the LacI* and SUMO proteins 
were both fused to the N termini of the peptides, so all these protein domains would 
have projected from the same end of the coiled coil, potentially forming a crowded 
environment that hinders the coiled-coil interaction. Introducing longer linkers 











Figure 5-10 Transcription repression with the LacI*-A1/SUMO-B1 
complex with induction by various arabinose concentrations. (a) Basic 
peptides were fused C-terminally to SUMO, which was fused N-terminally to 
6 His, constructs were expressed from ParaBAD. (b) Proposed model for DNA-
binding of LacI*-A/SUMO-B complexes where light grey squares represent 
SUMO. (c) Transcription repression assay with LacI*-A1/SUMO-B1 with 
induction by 0.0, 0.0002 and 0.002 % arabinose, (d) fold repression values 
relative to the GFP-only control with induction by 0.0 % arabinose and (e) 
fold repression values relative to LacI*/SUMO (no-coiled coil) control with 
induction by 0.0, 0.0002 and 0.002 % arabinose, key as in (c). Error bars are 



































































crowding could also have forced the coiled coils into a less-optimal antiparallel 
conformation where the strength of the interaction was weaker. 
Alternatively, the SUMO-B proteins may have been present at a lower 
concentration than the LacI*-B proteins, either because they were expressed less 
strongly or degraded more rapidly, resulting in fewer LacI*-A/SUMO-B complexes 
available to repress GFP expression.  
Finally, because only the acidic peptides were fused to the DNA-binding protein, 
the concentration of active DBDs would have been lower in the cell overall. 
Furthermore, because the LacI*-A/SUMO-B complexes contained only a single 
dimeric DNA-binding module, the local concentration of these dimers at the DNA 
would also have been lower. Therefore, on dissociation from the DNA, rebinding 
may have been less likely with the LacI*-A/SUMO-B complexes. Removing LacI* 
from the basic peptides would have roughly halved the total number of DBDs, 
which would be expected to also halve the observed amount of repression. 
However, less than half the amount of GFP repression was observed with the 
LacI*-A/SUMO-B complexes compared to the LacI*-A/LacI*-B complexes 
containing the same coiled coil. Therefore, it may have been a combination of 





Figure 5-11 Transcription repression with the LacI*-A2/SUMO-B2 
and LacI*-A3/SUMO-B3 complexes with induction by 0.0 % arabinose. 
Transcription repression assays with (a) LacI*-A2/SUMO-B2 and (b) LacI*-
A3/SUMO-B3 with induction by 0.0 % arabinose. Error bars are one s.d. from 









































5.3.3 Defining the minimal basic peptide 
As well as fusing the de novo peptides to other protein domains in order to co-
localise those proteins, at times it would also be useful to be able to express a 
single, un-tagged coiled-coil peptide. For example, a single peptide designed to 
interact with a second peptide could be used to disrupt a complex between the 
second peptide and a third peptide. This would trigger disassembly of the complex 
so that proteins attached to the second and third peptides are no-longer co-
localised. Therefore, though SUMO appears to be a suitable fusion partner and is 
itself a very small protein that should not interfere with coiled-coil assembly, it 
would be useful to determine whether single de novo coiled-coil peptides can be 
expressed and are functional in vivo.  
To investigate the effect of expressing minimal coiled-coil peptides, the basic 
peptides B1, B2 and B3 were fused to N-terminal 6 His, T7 and Xpress tags, to 
make the 6H-Tags-B proteins, or to only an N-terminal 6 His tag, to make the 6H-B 
proteins (Figure 5-12a and b). The T7 and Xpress tags were included initially for 
consistency with the previously described fusion proteins while the 6 His tag was 
included to enable future detection of the proteins by western blotting. When co-
expressed with the LacI*-A proteins, these basic components were anticipated to 
take part in the formation of complexes containing a single dimeric DNA-binding 
module that is held together, or “pinned”, by the tetrameric coiled coil (Figure 
5-12c).  
When 6H-B1 and 6H-Tags-B1 were investigated with LacI*-A1 with induction by 
0.0 % arabinose, the resulting complexes gave fold repression values of 1.6 and 
1.5, respectively (Figure 5-12d). Because these values are similar and the T7 and 
Xpress tags appeared to do little to improve the strength of repression, the 
remaining experiments in this section used only the LacI*-A/6H-B system.  
The LacI*-A1/6H-B1 complex was also examined with induction by 0.0002 and 
0.002 % arabinose (Figure 5-13a). As with the LacI*-A1/SUMO-B1 complex, the 
strength of repression by LacI*-A1/6H-B1 also increased as the arabinose 
concentration was increased (Figure 5-13b). Furthermore, while the level of 
repression with the controls also increased as the arabinose concentration was 
increased, the level of repression with LacI*-A1/6H-B1 was higher than in the 
controls at every inducer concentration. Also, the fold repression values of LacI*-
A1/6H-B1 relative to the LacI*/6H (no-coiled coil) controls at each arabinose 




concentration were similar, again showing that the residual dimerisation of LacI* 
was not overwhelming the signal from the A1/B1 coiled-coil interaction at these 
arabinose concentrations (Figure 5-13c). Therefore, as with the LacI*-
A1/SUMO-B1 complex, though the residual dimerisation of LacI*-A1 was at least 
partially responsible for the observed increase in repression as the inducer 
concentration was increased, some of the repression must also have been due to 
the formation of the heterotetrameric coiled coil.  
When the LacI*-A2/6H-B2 and LacI*-A3/6H-B3 complexes were investigated with 
induction by 0.0 % arabinose, the fold repression values relative to the GFP-only 
controls were 1.2 and 1.1, respectively, which were similar to the values in the 
controls (Figure 5-13d and e). Therefore, the A2/B2 and A3/B3 heterotetramers did 









Figure 5-12 Transcription repression with LacI*-A1/6H-Tags-
B1 and LacI*-A1/6H-B1 complexes with induction by 0.0 % arabinose. 
Basic peptides were fused C-terminally to (a) 6 His, T7 and Xpress 
tags or (b) to just a 6 His tag and the constructs were expressed from 
the ParaBAD promoter. (c) Proposed model for DNA-binding of LacI*-
A/6H-Tags-B or LacI*-A/6H-B complexes. (d) Transcription repression 
assay with LacI*-A1/6H-Tags-B1 and LacI*-A1/6H-B1 with induction 























Like the LacI*-A/SUMO-B complexes, these LacI*-A/6H complexes showed lower 
GFP-repression activity than the LacI*-A/LacI*-B complexes, which again could 
have been due to a combination of factors.  In the LacI*-A/6H-B complexes, steric 
hinderance from the fusion partners of the basic peptides should not have been a 











Figure 5-13 Transcription repression with A1/B1, A2/B2 and A3/B3 de 
novo coiled coils in LacI*-A/6H-Tags-B and LacI*-A/6H-B complexes with 
induction by different arabinose concentrations. (a) Transcription repression 
assay with LacI*-A1/6H-B1 with induction by 0.0, 0.0002 and 0.002 % 
arabinose, (b) fold repression values relative to GFP-only control with 
induction by 0.0 % arabinose and (c) fold repression values relative to 
LacI*/6H (no-coiled coil) control with induction by 0.0, 0.0002 and 0.002 % 
arabinose, key as in (a). Repression assays with (d) LacI*-A2/6H-B2 and (e) 
LacI*-A3/6H-B3 with induction by 0.0 % arabinose. Error bars are one s.d. 
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may have reduced the level of repression by reducing both the local and global 
DNA-binding module concentration. Furthermore, protein degradation may have 
been a more significant issue for the 6H-B proteins than for the SUMO-B proteins. 
The 6H-B components are highly basic and, when not part of a heterotetrameric 
complex, highly unfolded. These proteins may have therefore been targets for 
rapid degradation in E. coli. Therefore, increasing the expression levels of these 
components may have increased the achievable level of repression. 
5.4 Tuning the level of repression 
In the experiments described above, the LacI*-A/SUMO-B and LacI*-A/6H-B 
complexes repressed GFP expression less strongly than the LacI*-A/LacI*-B 
complexes. One reason for this may have been decreased cellular concentrations 
of the basic component. Therefore, increasing the level of the 6H-B and SUMO-B 
components should lead to stronger repression. It would be useful for these 
complexes to be able to repress more strongly as it would provide a clearer 
indication that the acidic and basic peptides interact as designed in these 
complexes. A simple way to increase the protein concentration would be to 
increase the concentration of arabinose used to induce the cells. However, 
because both the acidic and basic components are expressed from the same 
ParaBAD promoter this would also increase the concentration of the LacI*-A 
components, complicating the matter with the residual dimerisation of LacI*. 
Therefore, if the control of the acidic and basic components was decoupled by 
expressing them from different promoters the concentrations of the SUMO-B or 
6H-B components could be increased independently while the LacI*-A components 
are kept at a constant, low level where they should not exhibit residual dimerisation. 
To this end, a library of constitutive bacterial promoters designed by Davis et al for 
synthetic biology applications was utilised 306. This library of variable-strength 
promoters was generated by mutagenesis of the -10 and -35 boxes within an 
insulated promoter cassette that spans the region -105 to +55 from the 
transcription start site. The introduced insulator sequences make the promoters 
largely insensitive to changes in upstream and downstream sequences. A number 
of these promoters were selected for investigation.  




5.4.1 Expressing LacI* proteins from constitutive promoters 
A subset of promoters with low relative strengths was selected from the library and 
was initially tested with LacI*-ccDi to determine whether any of the promoters 
expressed this protein at a similar level to the un-induced ParaBAD promoter, or at 
least at a low level where residual dimerisation was minimal (Figure 5-14).  
The promoters pro1 and pro5, which Davis et al report to have relative strengths 
of 0.009 and 0.05, respectively, were introduced into pBAD plasmids containing 
the genes for the LacI* proteins, replacing the ParaBAD promoter and the gene for 
the AraC transcription factor. While these were the promoters with the weakest 
relative strengths available, they still appeared to be much stronger than un-
induced ParaBAD and strong repression was observed when LacI*-ccDi was 
expressed from both promoters (Figure 5-14b). Fold repression values relative to 
the GFP-only control of 14.4 and 25.9 where observed when LacI*-ccDi was 
expressed from pro1 and pro5, respectively, which were higher than the fold 
repression value achieved by LacI (WT) (Figure 5-14c). However, the LacI* 
controls also strongly repressed GFP expression when expressed from pro1 and 
pro5 indicating that residual dimerisation was occurring. The fold repression values 
relative to LacI* expressed from the same promoter for pro1-LacI*-ccDi and pro5-
LacI*-ccDi were just 1.4 and 1.1 (Figure 5-14d). Therefore, as the level of 
expression was increased by changing the promoter, the residual dimerisation of 
LacI* began to overwhelm the signal such that the presence of the de novo coiled 
coil became redundant. The observation that the level of expression of LacI*-ccDi 
from pro1 and pro5, measured as high levels of GFP repression, was much higher 
than from un-induced ParaBAD was perhaps not surprising given that the level of 
expression from ParaBAD in the absence of arabinose (i.e. when AraC is in the 
repressive state) was expected to be very low.  
While the level of residual dimerisation was high when LacI*-ccDi was expressed 
from pro1 or pro5, it was possible that a complex that was more highly degraded 
would be more suitable for use with the constitutive promoters as the high 
expression might be balanced by the high degradation (see Section 5.5.2). 
Therefore, the LacI*-A1/SUMO-B1 complex was selected because the LacI*-A1 
protein was found to be present at lower cellular levels than LacI* and the other 
acidic components (Figure 5-19). The pro1 promoter (the promoter with the 
weakest relative strength) was introduced to the pVRc plasmid containing the gene 
for LacI*-A1, replacing ParaBAD and araC. When LacI*-A1 and SUMO-B1 were 




co-expressed with induction by 0.0 and 0.2 % arabinose, high repression was 
observed (Figure 5-15a). However, residual dimerisation was also observed in the 
controls with pro1-LacI*/SUMO, pro1-LacI*-A1/SUMO and pro1-LacI*/SUMO-B1 
and high fold repression values were observed, even with induction by 0.0 % 
arabinose (Figure 5-15b). Furthermore, the fold repression value of 
pro1-LacI*-A1/SUMO-B1 relative to LacI*/SUMO was only 1.4 (Figure 5-15c). This 
was similar to the value observed for LacI*-ccDi expressed from pro1.  
Therefore, it seemed that residual dimerisation was unavoidable when the LacI* 









Figure 5-14 Transcription repression with LacI*-ccDi when expressed 
from different promoters with induction by 0.0 % arabinose. (a) CC-Di was 
fused C-terminally to LacI* (and LacIAA), which was fused N-terminally to 6 
His, T7 and Xpress tags and the construct was expressed from ParaBAD, pro1 
or pro5. The * indicate the approximate locations of L251A and Y282A 
substitutions. (b) Transcription repression assay with LacI*-ccDi. Fold 
repression values relative to (c) the GFP-only control and (d) LacI* (no-coiled 







































































weaker constitutive promoters would be available. Rather than attempting to alter 
the expression level further with other promoters or, for example, by introducing 
degradation tags to the proteins, the approach that was taken was to limit the 
residual dimerisation by using the LacIAA variant introduced in Section 5.2.3. 
5.4.2 Expressing LacIAA proteins from constitutive promoters 
To determine whether LacIAA-A/SUMO-B and LacIAA-A/6H-B complexes could 
form, the LacIAA-A1 protein was initially tested with SUMO-B1 and 6H-B1 where all 
proteins were expressed from ParaBAD (Figure 5-16a and c). With induction by 0.0 % 
arabinose, both the LacIAA-A1/SUMO-B1 and LacIAA-A1/6H-B1 complexes showed 
little repression with fold repression values relative to the GFP-only control of 1.1 
and 1.2, respectively (Figure 5-16b and d). As observed previously, with induction 







Figure 5-15 Transcription repression with LacI*-A1/SUMO-B1 
when LacI* was expressed from pro1 and SUMO was expressed from 
ParaBAD with induction by 0.0 and 0.2 % arabinose. (a) Transcription 
repression assay with LacI*-A1/SUMO-B1. Fold repression values 
relative to (b) the GFP-only control and (c) the LacI*/SUMO (no-coiled 
coil control) with induction by 0.0 % arabinose. Error bars are one s.d. 



































































less than the LacI* proteins under the same conditions. The level of repression 
increased 5.6-fold for LacIAA-A1/SUMO-B1 and 6.6-fold for LacIAA-A1/6H-B1 on 
inducing with 0.2 % arabinose compared to the non-induced state. 
Consequently, the LacIAA-A1/SUMO-B1 and LacIAA-A1/6H-B1 complexes were 
investigated where LacIAA-A1 was expressed from pro1 and SUMO-B1 or 6H-B1 
were expressed from ParaBAD. The desired outcome was for the LacIAA proteins to 
undergo no, or at least limited, residual dimerisation when expressed from pro1 
and for the level of repression to increase as the arabinose concentration, and 
therefore the SUMO-B1 or 6H-B1 concentration, was increased.  
When the pro1-LacIAA-A1/SUMO-B1 complex was investigated, at all arabinose 









Figure 5-16 Transcription repression with LacIAA-A1/SUMO-B1 and 
LacIAA-A1/6H-B1 when all proteins were expressed from ParaBAD with 
induction by 0.0 and 0.2 % arabinose. (a) Transcription repression assay 
and (b) fold repression values relative to the GFP-only control with 
induction by 0.0 % arabinose with LacIAA-A1/SUMO-B1. (c) Transcription 
repression assay and (d) fold repression values relative to the GFP-only 
control with induction by 0.0 % arabinose with LacIAA-A1/6H-B1. Error bars 
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just one coiled-coil peptide was present, indicating that residual dimerisation was 
not occurring when the double L251A/Y272A dimerisation variants were expressed 
from pro1 (Figure 5-17a). The levels of the LacIAA proteins in these samples was 
presumably constant. This could be confirmed in the future with western blotting. 
Furthermore, when both components of pro1-LacIAA-A1/SUMO-B1 were present, 
the strength of repression increased as the arabinose concentration was increased 
up to 0.2 % (Figure 5-17b and c).  
The fold repression relative to the LacIAA/SUMO (no-coiled coil) also increased as 
the arabinose concentration was increased, and the values were similar to the fold 
repression values relative to the GFP-only control (Figure 5-17d). This further 
highlighted that little, if any, residual dimerisation of LacIAA was occurring. 
Furthermore, because the level of repression increased as the arabinose 
concentration was increased, the complex is also a useful tool for controlling the 
expression of a gene of interest because the level of repression can be finely and 
reliably tuned via the inducer concentration. 
The level of repression achieved by the pro1-LacIAA-A1/SUMO-B1 complex with 
induction by 0.2 % arabinose in this experiment was comparable to the level of 
repression achieved by LacI*-A1/LacI*-B1 with induction by 0.0 % arabinose 
(Figure 5-2b and c). Therefore, relatively strong levels of repression can also be 
achieved by the LacIAA-A1/SUMO-B1 complex, demonstrating unambiguously that 
this complex is capable of forming and repressing GFP expression in E. coli and 
that the A1/B1 coiled coil must therefore form a tetramer. 
Furthermore, the fold increase in repression by pro1-LacIAA-A1/SUMO-B1 on 
inducing with 0.2 % arabinose relative to the level of repression with 0.0 % 
arabinose was 2.8. While the corresponding values for LacI*-A1/LacI*-B1 and 
LacIAA-A1/SUMO-B1 when all components were expressed from the ParaBAD 
promoter were 4.3 and 5.6, respectively, the 2.8-fold increase when LacIAA-A1 was 
expressed from pro1 could be attributed solely to the formation of the A1/B1 
heterotetrameric coiled coil rather than to the aberrant dimerisation of LacIAA.  
The pro1-LacIAA-A1/6H-B1 complex was also investigated with induction by 0.0 
and 0.2 % arabinose (Figure 5-18a). Again, at both arabinose concentrations a 
high level of GFP was measured when neither or just one coiled-coil peptide was 
present showing that residual dimerisation was not occurring and that repression 
required the presence of both coiled-coil peptides. Also, the level of repression with 




the pro1-LacIAA-A1/6H-B1 complex increased as the arabinose concentration was 









Figure 5-17 Transcription repression with LacIAA-A1/SUMO-
B1 where LacIAA-A1 was expressed from pro1 and SUMO-B1 was 
expressed from ParaBAD with induction by 0.0, 0.002, 0.02 and 0.2 % 
arabinose. (a) Transcription repression assay and fold repression 
values relative to the GFP-only control with induction by (b) 0.0 and 
(c) 0.2 % arabinose. (d) Fold repression values relative to the 
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Furthermore, the LacIAA-A1/6H-B1 complex was capable of strong repression, 
providing a clear indication that the A1/B1 pair form a tetramer in E. coli and that 
minimal coiled-coil peptides can be expressed at useful levels and can be used as 
“pinning” parts to direct co-localisation of protein domains.  
The levels of repression with induction by 0.2 % arabinose achieved by the LacIAA-
A1/SUMO-B1 and LacIAA-A1/6H-B1 complexes were similar to each other (4.6 and 
5.0 relative to the GFP-only control, respectively). Furthermore, as the arabinose 
concentration was increased, the strength of repression achieved by the LacIAA-
A1/SUMO-B1 complex appeared to plateau and the level of repression may have 
been approaching a maximum achievable value. This value may have been 









Figure 5-18 Transcription repression with LacIAA-A1/6H-B1 where 
LacIAA-A1 was expressed from pro1 and 6H-B1 was expressed from ParaBAD 
with induction by 0.0 and 0.2 % arabinose. (a) Transcription repression 
assay. (b) Fold repression values relative to the LacIAA/6H control with 
induction by 0.0 and 0.2 % arabinose, key as in (a). Fold repression values 
relative to the GFP-only control with induction by (c) 0.0 and (d) 0.2 % 
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repression by both complexes at some point becomes limited by the availability of 
LacIAA-A1 and therefore by the availability of DNA-binding modules.  
It would be interesting to now test A2/B2 and A3/B3 with the updated assays as 
these pairs showed only weak repression with the LacI*-A/SUMO-B assay where 
all components were expressed from the ParaBAD promoter (Figure 5-11) and no 
repression with the original LacI*-A/6H-B assay (Figure 5-13d and e).  
Finally, an alternative approach to decoupling the expression of the two 
components of the heteromeric complex was to change the promoter from which 
the basic component was expressed 375. When SUMO-B1 was expressed from 
pro1, it appeared to be expressed at a slightly higher (though still useful) level 
compared to when it was expressed from un-induced ParaBAD, measured as an 
increase in the level of repression relative to the GFP-only control (data not shown). 
Therefore, the pro1 promoter may be a useful tool in the construction of 
rudimentary genetic circuits using these semi-artificial transcription factors. 
5.5 Expression levels of de novo coiled coils 
The de novo coiled coil-based transcription factors developed in this chapter are 
able to repress transcription and therefore they must themselves be expressed in 
vivo. However, it remains to be seen how well they are expressed and how rapidly 
they are degraded. For example, the de novo peptides discussed here are 
generally highly charged and highly unfolded and may therefore be targets for 
degradation in vivo. Alternatively, they may be poorly expressed. Both would lead 
to a decrease in the level of repression brought about by the components because 
they would be unable to reach high cellular concentrations.  
Western blotting was performed to determine whether appending de novo peptide 
sequences to Lac repressor and SUMO had an effect on their concentration in 
cells. Blotting was performed using an antibody specific for the 6 His tag that was 
present at the N terminus of all of the proteins. The cells used for blotting were 
either harvested following growth for a transcription repression assay (and were 
therefore co-transformed with multiple plasmids) or were harvested after growth 
under the same conditions used in transcription repression assays (which were 
transformed with a single plasmid). The latter was performed, for example, where 
proteins of interest had the same mass and therefore would not have been 
resolved by gel electrophoresis. While assays were often performed without 




induction by arabinose, blotting was generally performed on cells that had been 
induced with arabinose as this aided protein detection.  
While the experiments that follow offer some initial information about the cellular 
levels of the proteins, it is important to note that they were performed without a 
loading control and therefore further investigation is needed. However, the 
preliminary results suggest that such further investigation would indeed be fruitful.  
5.5.1 De novo coiled-coil sequences change the expression level of 
proteins fused to them  
The LacI*-peptide fusions were investigated with induction by 0.02 % arabinose to 
determine the effect of appending the de novo heterotetramer peptides to this 
protein. All de novo heterotetramer peptides appeared to lead to a decrease in the 
level of LacI* (Figure 5-19). The proteins were expressed from the same plasmids 
as in the transcription repression assays, i.e. acidic components were expressed 
from the pVRc plasmid and basic components, LacI (WT) and LacI*-WTtet were 
expressed from the pBAD plasmid. When LacI* was expressed from the pVRc 
plasmid, it was present at a lower level than when it was expressed from the pBAD 
plasmid, possibly reflecting the different copy numbers of the plasmids (Figure 
5-19a).  
The acidic peptides A1, A2 and A3 all led to a decrease in the level of LacI* when 
fused to the C terminus, with A1 producing the largest decrease (Figure 5-19b). 
The basic peptides B1, B2 and B3 also all led to a small decrease in the level of 
LacI* when fused to the C terminus and all had similar mean relative densities 
(Figure 5-19c). 
While the proteins were quantified at 0.02 % arabinose (Figure 5-19d), the proteins 
were also detectable at 0.0 % arabinose when very long exposures were used 
(Figure 5-19e). With increasing exposure times, non-specific bands, which were 
consistent across all samples, could also be observed in the blots between the 35 
and 40 kDa markers.  
The LacI*-ccDi, LacIAA-ccDi and LacIAD-ccDi samples were blotted following cell 
growth for a repression assay with induction by 0.2 % arabinose (Figure 5-20a). 
Here, all proteins were expressed from the pBAD plasmid. LacI* was at a higher 
level than LacI (WT) but its level decreased progressively as it was fused to the 
WT lac tetramerisation domain or CC-Di (Figure 5-20b and c).  




The LacIAA and LacIAD variants were present at lower levels than both LacI (WT) 
and LacI* (Figure 5-20b) and the levels of these proteins also decreased when the 
coiled-coil sequences were fused to their C termini. When compared to their 
respective no-coiled coil control (LacI*, LacIAA or LacIAD), both the Lac repressor 












Figure 5-19 Western blotting analysis of LacI*-peptide fusion proteins. 
(a) Mean relative densities of detected bands relative to LacI (WT), measured 
following induction by 0.02 % arabinose, n=3. (b) Mean relative densities of 
LacI* fused to acidic peptides A1, A2 and A3, relative to LacI* where all 
proteins were expressed from pVRc, n=3. (c) Mean relative densities of LacI* 
fused to basic peptides B1, B2 and B3, relative to LacI* where all proteins 
were expressed from pBAD, n=3. Representative membranes for samples 
induced with (d) 0.02 and (e) 0.0 % arabinose. Non-specific bands are 


















































































variants (Figure 5-20c). The samples were also blotted following induction with 
0.02 % arabinose (Figure 5-20d).  
LacIAA fused to the heterotetrameric peptides A1 and B1 was investigated following 
induction with 0.02 % arabinose (Figure 5-21a). Like LacI, LacIAA was also present 
at a lower level when expressed from the pVRc plasmid compared to when it was 
expressed from pBAD (Figure 5-21b). The acidic peptide A1 led to much lower 
levels of both LacI* and LacIAA (Figure 5-21c) while the basic peptide B1 led to 









Figure 5-20 Western blotting analysis of LacI*-ccDi, LacIAA-ccDi and 
LacIAD-ccDi proteins. (a) Representative membrane for samples induced 
with 0.2 % arabinose. (b) Mean relative densities of detected bands relative 
to LacI (WT), measured following induction by 0.2 % arabinose, n=3. (c) 
Mean relative densities of LacI*, LacIAA or LacIAD fused to WT 
tetramerisation domain or CC-Di, relative to LacI*, LacIAA or LacIAD, 
respectively, n=3. (d) Representative membrane for samples induced with 






































































When investigated with induction with 0.2 % arabinose, the ΔHTH variants LacI-
ΔHTH and LacI*-ΔHTH were both present at much lower levels than the versions 
with intact HTH domains, LacI and LacI* (Figure 5-22a and e). The addition of the 
basic peptide B1 to the C terminus of these proteins decreased their cellular level 
further to a level 10-fold lower than the level of LacI (WT). When the mean density 
of the bands was calculated relative to LacI-ΔHTH and LacI*-ΔHTH, B1 appeared 









Figure 5-21 Western blotting analysis of LacIAA-peptide fusion 
proteins. (a) Representative membrane for samples induced with 0.02 
% arabinose. (b) Mean relative densities of detected bands relative to 
LacI (WT), measured following induction by 0.02 % arabinose, n=3.  (c) 
Mean relative densities of LacI*-A1 and LacIAA-A1 relative to LacI* and 
LacIAA, respectively, n=3. (d) Mean relative densities of LacI* and LacIAA 
fused to basic peptide B1 relative to LacI* and LacIAA, respectively, n=3. 




































































































The SUMO-B fusion proteins were investigated with induction by 0.02 % arabinose 
(Figure 5-22d and f). The B2 peptide decreased the level of SUMO relative to the 
SUMO only (no-coiled coil control) following the pattern observed for LacI*. 
However, unlike with LacI*, the peptides B1 and B3 appeared to increase the level 













Figure 5-22 Western blotting analysis of LacI-ΔHTH-peptide and 
SUMO-peptide fusion proteins. (a) Mean relative densities of detected bands 
for LacI-ΔHTH proteins relative to LacI (WT), measured following induction 
by 0.2 % arabinose, n=3. (b) Mean relative density of LacI-ΔHTH-B1 relative 
to LacI-ΔHTH, n=3. (c) Mean relative density of LacI*-ΔHTH-B1 relative to 
LacI*-ΔHTH, n=3. (d) Mean relative densities of detected bands for SUMO 
proteins relative to SUMO (no-coiled coil control), measured following 
induction by 0.02 % arabinose, n=3. Representative membranes for (e) LacI-
ΔHTH samples induced with 0.2 % arabinose and (f) SUMO samples induced 











































































































In summary, appending coiled-coil sequences to the C termini of the investigated 
proteins generally led to a decrease in the level of those proteins in the cell, as 
detected by western blotting. This may have been due to increased degradation or 
to lower levels of protein synthesis for these proteins. For example, when the acidic 
and basic peptides are not interacting with their partners to form a heterotetrameric 
coiled coil, they are fully unfolded. This may make them a target for cellular 
unfolded protein stress responses, leading to the degradation of whatever protein 
they are fused to 376-379.  
The heterotetramers can be compared to intrinsically disordered proteins: the 
acidic and basic peptides are highly disordered alone, but they undergo a disorder-
to-order transition and gain structure on interacting with their partner. Intrinsically 
disordered proteins are believed to be very widespread in nature and more than 
20 % of essential proteins in E. coli are predicted to contain an intrinsically 
disordered region 380,381. Furthermore, though often involved in important cellular 
functions, these proteins tend to be tightly regulated and maintained at low levels. 
This mitigates the problems associated with accumulating unfolded proteins in the 
cell such as aggregation and other non-specific, off-target interactions 382,383. The 
components of the novel transcription factors described here may be treated in the 
same way as these endogenous intrinsically disordered proteins.  
However, though the components of the heterotetramers were expected to be 
disordered when alone, both the WT Lac repressor tetramerisation domain and 
CC-Di, were expected to be folded as homomers. Yet these coiled coils also led to 
lower levels of the fusion partner. As homomers, these coiled coils do not rely on 
a partner for folding so, provided they are present at a high enough concentration, 
there should be little unfolded peptide present. Therefore, there may be some other 
feature of the de novo coiled coils, not just their structure, that influences their 
stability in the cell.  
For example, the peptide A1 led to much lower protein levels than the other acidic 
peptides A2 and A3, which may imply the decrease in protein levels was influenced 
by the peptide sequence. For example, the A1 peptide sequence may have 
contained a protease recognition sequence, which would have led to a decrease 
in the protein level through increased degradation. The degradation could also 
have occurred at the mRNA level rather than the protein level.  




Alternatively, rather than degradation being the source of the low protein levels, 
the LacI*-A1 protein may instead have been synthesised less efficiently than the 
other proteins. The LacI*-A1 protein runs at a slightly lower molecular weight than 
expected and, though this could be due to the high localised charge on the acidic 
peptide causing the protein to run aberrantly, it may have also been an indication 
of a specific truncated product. Mass spectrometry could be used to determine 
whether the protein is indeed synthesised correctly and further investigation using 
techniques such as qPCR might help determine whether this truncation, if present, 
occurs at the transcription, translation or post-translation level. 
The changes in protein level may be context-dependent. For example, the B1 and 
B3 peptides were found to destabilise the Lac repressor derivatives but stabilise 
SUMO. The peptides may induce misfolding of some of the proteins but not others, 
leading to increased degradation. However, the function of the Lac repressor 
derivatives did not appear to be excessively perturbed – they were still able to 
cause gene repression – so their structures may have only been partially disrupted.  
Finally, while CC-Di has an overall charge of +1 with a pI of approximately 8.4, the 
acidic and basic components of the heterotetramers are highly charged. For 
example, A1 has an overall charge of -5 and a pI of approximately 4.3 and B1 has 
an overall charge of +8 and a pI of approximately 10.9. Given that these pI values 
are far from the cytoplasmic pH of E. coli (approximately 7.2-7.8 384,385) the peptides 
are likely to retain their extreme charge inside the cell, making them prime targets 
for non-specific interactions with other, charged cellular components including 
proteins. For the basic peptides this could also include DNA, RNA and ribosomes 
386. While non-specific interactions would surely interfere with their in vivo 
functions, it remains to be seen what effect high localised charge has on protein 
stability, if indeed there is one given that localised charge can be an important 
aspect of some protein functions, such as specific and non-specific interactions 
between DNA-binding proteins and DNA. 
5.5.2 Heteromeric peptides have a chaperoning effect over their partners 
An observation that indicated the unfolded nature of the acidic and basic 
components of the heterotetramers may have contributed to the decreased stability 
of the fusion proteins was that the co-expression of acidic and basic partner-tagged 
proteins appeared to somewhat protect both proteins from degradation. That is, 
when LacI*-A1 and SUMO-B1 were co-expressed, each protein was present at a 




higher level compared to when either LacI*-A1 or SUMO-B1 were expressed with 
the corresponding SUMO or LacI* no-coiled coil control.  This phenomenon was 
measured by blotting cells harvested post-repression assay with induction by 
0.002 % arabinose (Figure 5-23a and c). 
When LacI*-A1 was co-expressed with SUMO-B1 the mean relative density 
relative to LacI* increased to 0.8 from 0.2 when LacI*-A1 was co-expressed with 
SUMO alone (Figure 5-23a). Similarly, when SUMO-B1 was co-expressed with 
LacI*-A1 the mean relative density relative to SUMO increased to 0.8 from 0.5 







Figure 5-23 Western blotting analysis of LacI*-A1 and SUMO-B1 
proteins following cell growth for a repression assay with induction by 0.002 
% arabinose. Cells were co-transformed with pVRc plasmids encoding LacI* 
or LacI*-A1 and pBAD plasmids encoding LacI* or LacI*-B1 (and a pVRb 
plasmid encoding the reporter gene). (a) Mean relative densities of detected 
bands for proteins relative to LacI (WT), measured following induction by 
0.002 % arabinose where co-expressed proteins are indicated by different 
shades of blue, n=4. (b) Mean relative densities of LacI*-A1 in the presence 
of SUMO-B1 relative to the level of LacI*-A1 on the presence of SUMO, and 
SUMO-B1 in the presence of LacI*-A1 relative to the level of SUMO-B1 in 
the presence of LacI*, n=4. (c) Representative membrane for LacI*-A1 and 
SUMO-B1 samples induced with 0.002 % arabinose, positions of LacI 
derivatives and SUMO proteins indicated. Non-specific bands are indicated. 
































































This effect was more obvious when the level of LacI*-A1 in the presence of SUMO-
B1 was normalised relative to the level of LacI*-A1 in the presence of SUMO (i.e. 
in the absence of B1) and when the level of SUMO-B1 in the presence of LacI*-A1 
was normalised relative to the level of SUMO-B1 in the presence of LacI* (i.e. in 
the absence of A1) (Figure 5-23b). When analysed in this way, the level of LacI*-A1 
increased 2.4-fold in the presence of B1 and the level of SUMO-B1 increased 
1.5-fold in the presence of A1. Hence, it appears that the A1 and B1 peptides have 
a chaperoning effect over each other where, on folding into the obligate A1/B1 
heterotetramer, they protect each other from degradation. This implies that the 
decreased levels of the proteins fused to the de novo sequences may be due to 
increased degradation of these proteins rather than decreased synthesis. 
However, there are certainly more questions to answer here and the 
destabilising/stabilising effects of de novo protein sequences, as well as their 
influences over the proteome at large, remain ripe for investigation. 
5.6 Chapter conclusions 
When fused to various other proteins the de novo designed heterotetrameric coiled 
coils A1/B1, A2/B2 and A3/B3 have been found to interact in E. coli to form 
complexes that bring about repression of a reporter gene, GFP (Figure 5-24). The 
strongest levels of repression are achieved when both the acidic and the basic 
components are attached to the DNA-binding protein, LacI*, where the resulting 
complexes are presumably tetrameric and contain two dimeric DNA-binding 
modules. However, this variant of the Lac repressor was also found to display 
residual dimerisation at elevated concentrations so alternative variants were 
considered. When fused to the Lac repressor variant LacIAA the heterotetramer 
A1/B1 is still able to repress GFP expression and the LacIAA proteins exhibit 
reduced residual dimerisation.  
The heterotetramers are also able to repress GFP expression when the basic 
peptides are fused to the non-DNA-binding protein SUMO or to just a 6 His tag, 
albeit with lower strength than when both peptides are fused to a DBD. The level 
of repression can be improved by increasing the arabinose concentration, but this 
also leads to increased residual dimerisation of the LacI*-A and LacIAA-A proteins. 
Therefore, alternative means of controlling the expression of the components were 
investigated. When LacIAA-A1 is expressed from a low-level constitutive promoter, 
pro1, and SUMO-B1 or 6H-B1 are expressed from ParaBAD, the level of the basic 




components can be increased independently by increasing the arabinose 
concentration. This also leads to an increase in repression but avoids the residual 
dimerisation. As well as demonstrating that the de novo coiled coils fold as 
expected in E. coli, this work has generated a number of well characterised, semi-
artificial transcription factors that are ready to be used to control the expression of 
more-useful genes of interest.  
Furthermore, regulatory components that are compatible with the transcription 
factors have been identified. These could now be used to design genetic circuits 
based on coiled coils with increasingly complex behaviours, such as switching or 
strand displacement. For example, in a triggered-disassembly system (like the one 
introduced in Section 5.3.3), where a single peptide disrupts a complex between a 
second and third peptide by interacting strongly with one of those peptides, the 
disrupting component could be expressed from an inducible promoter such as 
ParaBAD while the other two components could be expressed from constitutive 
promoters like pro1. Thus, the interaction between the second and third peptides, 
 
Figure 5-24 Summary of constructs discussed in Chapter 5. The 
constructs that were able to achieve relatively strong levels of repression are 
highlighted in green, while those that achieved a small amount of repression, 
or no repression are highlighted in yellow and orange, respectively.  




and co-localisation of any proteins they are fused to, could be disrupted in an 
inducible manner.  
Western blotting revealed that appending de novo coiled-coil sequences to 
naturally occurring proteins impacts the level of those proteins in E. coli. Generally, 
the de novo peptides lead to decreased protein levels. Though the reasons for this 
remain unclear, the unfolded nature of the acidic and basic peptides is likely to be 
a key contributing factor 377. Therefore, though the peptides do interact as 
anticipated, their sequences are not necessarily optimised yet for in vivo 
applications.  
While an initial analysis of the in vivo behaviour of de novo coiled coils has been 
performed, many questions remain. For example, do the de novo peptides have 
off-target interactions with other cellular components? Is the behaviour of the de 
novo complexes homogenous across the population, or is there cell-cell variability 
in the level of repression achieved by the complexes? How do the characteristics 
of the tetramers differ from those of, for example, dimers or coiled coils with higher 
oligomeric states? And what are the effects of expressing these, and other, semi- 
or fully-artificial proteins on the endogenous E. coli proteome? 
The work presented in this chapter represents a first step into the arena of protein 
design in the cell, that is, designing completely novel proteins that will behave 
predictably and effectively inside living organisms, not just in the test tube. Just as 
a toolkit of routine techniques has been refined for the characterisation of de novo 
coiled coils in vitro, so too should an equivalent toolkit be developed for 
characterising new designs in vivo. Such a toolkit might include pull-down assays 
or co-immunoprecipitation to analyse protein-protein interactions; quantitative 
western blotting to determine how effectively proteins are expressed; 
bioinformatics to detect the presence of unwanted sequence features such as 
protease sites; and proteomics techniques such as Stable Isotope Labelling with 
Amino acids in Cell culture (SILAC) for measuring the effect of de novo proteins 
on endogenous protein levels. In time, this will allow for the determination of rules 
to guide the design of proteins that are more and more suited for use in living 








Chapter 6: Towards increasingly complex 
tetrameric coiled coils 
6.1 Chapter introduction 
Thus far, a set of homo- and heterotetrameric coiled coils has been designed and 
characterised in vitro. Select A2B2 heterotetramers have also been demonstrated 
to interact as designed in E. coli. These designs can therefore be used as artificial 
PIDs in vivo. However, there are still targets within tetrameric coiled coil and 4-
helix bundle design space that have not been explored here, including ABCD 
tetramers and dimeric helix-loop-helix or helix-turn-helix structures.  
Furthermore, the A2B2 protein-protein interactions are currently constitutive: 
provided the two components are co-expressed at sufficient concentrations they 
will interact. Therefore, the only means of controlling the interaction is at the 
transcription/translation level by selectively activating or repressing the expression 
of the heteromer components. However, control at this level is generally slow. 
Methods for promoting or blocking protein-protein interactions at the post-
translational level, for example through ligand binding or post-translational 
chemical modifications, would be very useful in the context of ATFs. Ligand binding 
is a particularly alluring, albeit highly challenging, prospect.  
6.2 Towards ABCD heterotetramers 
Discussed here are preliminary results towards designing ABCD heterotetramers, 
where all four constituent peptides have different sequences. As well as being an 
unexplored target in de novo coiled-coil design, these coiled coils would represent 
a highly useful addition to the set of artificial PIDs.  
6.2.1 ABCD heterotetramer design 
Using a design strategy modified from that of a previously characterised 
heterotrimeric coiled coil 387,388, the sequences and ABCD heterotetramer 
combinations of the peptides 1–8 were generated computationally (Figure 6-1). In 




all peptides, e and g positions were Glu or Lys with charge patterning designed to 
achieve the maximum number of productive ionic interactions in the ABCD 
species. Attractive interactions in the alternative unwanted A2B2 and A2BC states 
were minimised. All a positions were Leu to promote tetramer formation while all d 
positions were β-branched Ile or Val. The identity of the d residues depended on 
the nature of the ionic interactions in the heptad in question: where interactions 
were predicted to be attractive in the homomer (Glu/Lys), d positions were Val to 
destabilise that heptad; where homomer interactions were predicted to be 
repulsive (Glu/Glu or Lys/Lys), d positions were Ile to promote a tetrameric 
oligomeric state. Therefore, the homomers would contain both all-Ile and all-Val 
(which are more destabilising) d-layers in their cores. The ABCD heterotetramers 
would contain mixed Ile/Val d-layers. 
ABCD heterotetramers where all possible ionic interactions were made (16 Glu-
Lys interactions in total) were filtered to remove those that contained peptide 
combinations judged likely to also engage in A2B2 or A2BC interactions (based on 
predicted ei-gi+2′ ionic interactions). Parametric models of the 120 ABCD 
heterotetramers remaining after this initial filtering were generated using 
ISAMBARD and scored using BUDE 293,294. Heterotetramers were further filtered 
by their initial BUDE scores and to remove redundant sequences. The remaining 
three ABCD heterotetramers were then subject to parametric optimisation in 
ISAMBARD and scored again. The final generated ABCD heterotetramers 
contained 8 different peptides (peptides 1–8) in the combinations 1/2/3/4, 3/4/7/8 
and 5/6/7/8 (Figure 6-2). The 1/2/3/4 and 5/6/7/8 combinations were selected for 
study and are referred to as 1234 and 5678, respectively. The 3/4/7/8 combination 
was not pursued due to time constraints.  
Peptides 5–8 were given C-terminal mass tags to aid peptide identification. These 
mass tags follow the pattern GGxψ, where x is a small polar residue (Ser or Asp) 
and ψ is a chromophore (Trp or Tyr). 
6.2.2 ABCD designs form heteromers in solution 
6.2.2.1 CD spectroscopy shows ABCD designs form α-helical homomers and 
heteromers 
Peptides 1–8 were investigated using CD spectroscopy alone and in pair, triplet 
and quadruplet (ABCD) combinations (Figure 6-3). Individually, the peptides 
showed a range of behaviours: some were relatively highly folded, such as 




peptides 1 and 6, while others were very unfolded, such as peptides 3 and 8 
(Figure 6-3a and b). When investigated in the ABCD combinations, both 1234 and 
5678 adopted α-helical structures with fraction helix values of 68 and 69 %, 
respectively. In both cases, the measured spectra for the ABCD combinations had 
greater α-helical character than the average of the spectra for the four individual 
peptides. This indicated that the peptides were interacting to form heteromeric 
species rather than existing as non-interacting homomeric species. However, it 
was not possible to determine whether all four constituent peptides were 
represented in the heteromers or if they were made up of a subset of the peptides. 
Given that peptides 3, 4, 7 and 8 were each relatively unfolded, the 3478 heteromer 
should also be investigated in the future. 
Temperature-dependent CD measurements for the 1234 and 5678 combinations 
showed that both underwent reversible, cooperative unfolding transitions with 
similar TM values of 72 and 71 °C, respectively (Figure 6-3c).  
The off-target AB and ABC interactions were also investigated, i.e. the unwanted 
interactions between peptide pairs and triplets (Figure 6-3d, Figure 8-73–Figure 
8-76). In most cases there appeared to be some unwanted interaction between 
these peptide combinations. For example, peptides 2 and 4 interacted to form a 
heteromer with a fraction helix value of 75 % – more folded than either ABCD 
heteromer (Figure 6-3d). For all other off-target combinations of peptides 1–4 the 
measured CD spectra had more negative MRE222 values than the averages of the 
spectra for the individual peptides (Figure 6-3e).  
 
Figure 6-1 Schematic of the design strategy for ABCD heterotetramers. 




Given that the peptides cross-interact extensively, it is not clear whether the ABCD 
combinations form a single heteromeric species (the ABCD heteromer) or a mix of 
several off-target heteromers and homomers. Only one unfolding transition was 
observed for each ABCD combination implying that only one species was present. 
However, if all of the species had similar TM values it would not be possible to 







Figure 6-2 De novo designed ABCD heterotetramers. (a) Sequences of 
peptides 1–8. All peptides were N-terminally acetylated and C-terminally 
amidated. (b) Molecular models of heterotetramers 1234, 3478 and 5678 
generated and optimised in ISAMBARD 293. (c) Potential Glu-Lys ionic 
interactions in heterotetramer 1234 (left) and helical wheel showing one 
representative heptad (right). Interhelical ionic interactions are represented 
as grey lines. Peptide 1 interacts with 4, indicated by dashed grey lines. The 
heptad represented on the helical wheel is highlighted by the box.   




The appearance of the off-target heteromers, despite the inclusion of potentially  
destabilising repulsive interactions in these heteromers may be explained in that 
the method used to generate the ABCD heterotetramers only considered ei-gi+2′ 
ionic interactions, i.e. those where an e residue interacts with a g residue in the 











Figure 6-3 CD spectroscopy data for ABCD heteromers. (a) CD spectra at 
20 °C of peptides 1–4. (b) CD spectra at 20 °C of peptides 5–8. (c) 
Temperature-dependent CD measurements monitoring MRE222 between 5 
and 95 °C for heteromers 1234 and 5678. (d) CD spectra at 20 °C of peptides 
1 and 2. (e) Bar graph showing MRE222 values of all combinations of peptides 
1–4 (yellow) overlaid with the average MRE222 values of the individual 
peptides in those combinations (grey). Peptides were at 2 µM. All 
measurements were performed in PBS (pH 7.4).  




Lys means ei-gi-5′ interactions are also possible, were an e residue interacts with 
the g residue in the previous heptad of the adjacent helix.  
Revisiting the design procedure may be necessary to eliminate the unwanted 
“failure modes” more robustly, for example by introducing scoring penalties for 
these possible ei-gi-5′ interactions. Furthermore, while the optimal ionic interactions 
were selected with the assumption that the heterotetramers would adopt parallel 
orientations, the peptides may in fact have adopted antiparallel conformations that 
relieve repulsive ionic interactions.  
6.2.2.2 AUC shows the ABCD designs do not form tetramers in solution 
When the 1234 and 5678 heteromers were investigated by AUC, in both SE and 
SV experiments the heteromers fitted to molecular weights corresponding to 
trimers (Figure 6-4, Figure 8-135, Figure 8-136). In SV, both heteromers showed 
a single peak in their c(s) distributions (Figure 6-4b and d). However, it was not 
clear whether the ABCD combinations formed a single trimeric species or a mix of 
several trimers with very similar (or identical) molecular weights. 
The trimeric oligomeric states may have been due to the presence of Val at d. 
While the LV-core A2B2 designs reliably formed heterotetramers, the LV-core 
homomers formed a range of oligomeric states and placing Val at d did not appear 
to promote tetramer formation (Chapters 3 and 4). Placing Ile at all d positions of 
peptides 1–8 may better promote tetramerisation but is also likely to increase the 
off-target homomerisation of these peptides.   
While the strategy described here was not suitable for the design of ABCD 
heterotetramers, one side effect of the protocol was the generation of 576 novel 
A2B2 heteromer pairs. While filtering would be required to select the designs where 
the Glu-Lys interactions are optimised, all of the resulting pairs should be charge 
neutral, unlike the previously described A2B2 heterotetramers, which consist of 
overall highly acidic and basic peptides. As discussed in Chapter 5, such designs 
might be more suitable for use in vivo. Furthermore, given that LV-cores are 
compatible with A2B2 heterotetramer formation, it should be simpler to destabilise 
the homomers without affecting the heteromer oligomeric state.  




6.3 Towards ligand-binding coiled coils 
Although coiled coils are usually involved in simple protein-protein interactions, 
some coiled coils also demonstrate more-complex behaviours, notably ligand 
binding. There are many varied examples of small molecule binding to natural and 
designed coiled coils and helical bundles. This includes dye binding to α-barrels 
261-264, drug and heme binding to 4-helix bundles 238,266,279,284 and metal binding 
288,289. Furthermore, binding can modify the structural properties of coiled coils by 
changing the oligomeric state or by inducing folding 275,282. Therefore, attempts 
were made to introduce ligand binding into various coiled coils discussed in this 









Figure 6-4 AUC data for ABCD heteromers. (a) Sedimentation equilibrium 
data at 30, 34, and 38 krpm (red, green and blue circles) and fits (black lines) 
(top) and residuals (same colours) (bottom) for 1234 returning a Mw of 9.1 
kDa (2.8 x mean monomer mass). (b) Sedimentation velocity c(s) distribution 
(top) and residuals (bottom) for 1234 returning a Mw of 9.7 kDa (2.9 x mean 
monomer mass). (c) Sedimentation equilibrium data at 30, 33, and 36 krpm 
(red, green and blue circles) and fits (black lines) (top) and residuals (same 
colours) (bottom) for 5678 returning a Mw of 10.2 kDa (2.9 x mean monomer 
mass). (d) Sedimentation velocity c(s) distribution (top) and residuals 
(bottom) for 5678 a predicted Mw of 10.9 kDa (3.1 x mean monomer mass). 
All measurements were performed in PBS (pH 7.4). 




In nature, ligand binding occurs in many transcription factors with binding of 
specific ligands causing allosteric changes to the protein’s structure that ultimately 
alter its mode of activity. There are many examples of these inducible transcription 
factors, including LacI, AraC and TetR 118,363,389. These systems allow cells to sense 
small molecules in their environments and alter their behaviour accordingly. They 
have also been exploited widely by molecular and synthetic biologists as they allow 
gene expression to be switched on or off simply by adding small molecules to 
growth media.  
Novel ligand-inducible transcription factors present a very appealing design target: 
transcription factors that can be readily engineered to respond to non-natural small 
molecules of interest would be invaluable in the design of biosensors 390. Attempts 
have been made to alter the ligand specificity of naturally-occurring transcription 
factors and to convert existing binding proteins into transcription factors through 
protein fusions 29,159,391,392. However, using rational protein design to approach this 
challenge remains largely unexplored.  
Discussed here are initial attempts at introducing ligand binding into de novo 
designed coiled coils. The approaches taken are: (1) grafting of specific ligand 
binding motifs from other helical proteins into de novo tetramers; (2) introducing 
internal cavities that may be occupied by non-specific hydrophobic ligands to 
stabilise the otherwise destabilised structures; and (3) introducing destabilising 
core mutations to provide a starting point for high throughput selection for peptide 
sequences that undergo ligand-induced folding. The focus has been on promoting 
coiled-coil interactions using small molecules, although disruption of interactions 
using ligands also presents a powerful and rapid method for controlling the 
assembly state of coiled coil-based PIDs.  
6.3.1 Binding motifs from natural proteins 
An amantadine binding motif identified from the influenza A virus M2 proton 
channel was grafted into a de novo tetrameric coiled coil in an attempt to confer 
amantadine binding on this coiled coil.  
The M2 proton channel is a transmembrane homotetrameric helical bundle 
involved in endosome acidification and viral release into the cytoplasm 267-269. 
Amantadine is an antiviral drug previously used in the treatment of influenza that 
binds to the M2 transmembrane channel as well as at other secondary locations 




270-272,393-395. Channel-lining residues proposed to contact amantadine were 
identified from X-ray crystal and NMR structures and introduced into a de novo 
homotetrameric coiled coil. The resulting peptides were intended to be water-
soluble versions of the transmembrane M2 protein. 
6.3.1.1 Design of M2-like homotetrameric coiled coils 
The core and amantadine-contacting residues were identified from crystal and 
NMR structures of M2TM (a 25 residue transmembrane portion of M2 396,397) solved 
in the presence of amantadine 271,272. Residues Val27, Ala30, Ser31 and Gly34 
surround the drug and the 4-helix bundle core also contains a His residue involved 
in proton sensing, His37 (Figure 6-5a). As Gly is destabilising to α helices, Gly34 
was replaced with Ala. The crystal structure of M2TM was solved for a variant with 
Ala at this position 271. The resulting motif, VxxASxxGxxH (where x is any residue), 
was superimposed onto the sequence of ELAEIK, a homotetrameric coiled coil that 
was previously designed using a computational method. Two versions were 
designed, ELAEIK-M2-a and ELAEIK-M2-d where the motif started at a core a or 
d position, respectively (Figure 6-5b). In ELAEIK-M2-a, the His residue fell at a 
core d position. As placing charged residues in hydrophobic cores can be 
destabilising, a version of this peptide was also made without the His residue, 
ELAEIK-M2-a-HI (Figure 6-5b). In this peptide the d position is Ile, as in the parent 
sequence.  
Peptide models based on the ELAEIK crystal structure were generated using the 
mutagenesis tool in PyMol (Figure 6-5a). Cavity volumes were determined using 
the CASTp server using a probe radius of 1.4 Å 398. The cavity volumes of ELAEIK-
M2-a, ELAEIK-M2-a-HI and ELAEIK-M2-d were calculated as approximately 236, 
195 and 96 Å3, respectively. The volume of one molecule of amantadine (Figure 
6-6d) was determined to be approximately 228 Å3, using Equation 6-1. While this 
volume is slightly smaller than the cavity volume of ELAEIK-M2-a, it is unlikely that 
amantadine would bind to any of the peptides without significant structural 
rearrangements to enlarge the cavity.  




Equation 6-1 Equation for determining the volume of one molecule. 
Vol, volume of one molecule, cm3; Molar volume, cm3.mol-1; N, Avogadro’s 
number, mol-1.  




6.3.1.2 The M2-like peptides are highly unfolded 
The M2-like peptides and the parent, ELAEIK, were investigated using CD 
spectroscopy (Figure 6-6a). ELAEIK formed a well folded α-helical structure with a 
TM of 84 °C (Figure 8-22). ELAEIK also formed a tetramer both in solution and in 
the crystal structure (Figure 8-94, Table 8-5). Conversely, all three M2-like peptides 
were entirely unfolded at 10 µM. When the peptide concentrations were increased 
to 750-1000 µM, the peptides still showed no folding (Figure 6-6b). In the presence 
of 1 mM amantadine, neither ELAEIK-M-a nor ELAEIK-M2-a-HI showed an 
increase in folding.  
The peptides showed no folding at all in the presence and absence of ligand and 
were deemed too unstable to pursue further. In contrast, the M2 channel folds into 
a transmembrane 4-helix bundle even in the absence of amantadine 271. Increasing 
the stabilities by increasing the lengths of the M2-like peptides may improve the 





Figure 6-5 Design of M2-like peptides. (a) NMR structure of M2TM bound to 
amantadine (left, PDB ID: 2KQT) and models of ELAEIK-M2-d (centre) and 
ELAEIK-M2-a-HI (right). Models were generated from the ELAEIK crystal 
structure using the mutagenesis tool in PyMol. Amantadine-binding motifs 
are shown below each structure. (b) Sequences of M2TM 397 and M2-like 
peptides. All peptides were N-terminally acetylated and C-terminally 
amidated. Amantadine-binding motifs are highlighted in green.  




isn’t compatible with coiled coil formation: while the M2 protein forms a 4-helix 
bundle, it does not form a coiled coil. Even a visual inspection of the structures 
shows that M2 and the ELAEIK-based models have quite different structures and 
that the residues identified as forming contacts with amantadine are not positioned 
in the same locations (Figure 6-5a). Therefore, more care is needed to design 
tetrameric coiled coils with amantadine binding sites. Additionally, less complex 
analogues could be pursued such as adamantane, which does not contain any 
polar substituents 277.  
6.3.2 Non-specific hydrophobic ligands and chemical rescue of structure 
Attempts were also made to introduce hydrophobic cavities into a coiled coil. These 









Figure 6-6 CD spectroscopy of M2-like peptides. (a) CD spectra at 5 °C of 
M2-like peptides at a peptide concentration of 100 µM. (b) CD spectra at 5 °C 
of M2-like peptides at variable peptide concentrations. Key colours as in (a). 
(c) CD spectra at 5 °C of peptides ELAEIK-M2-a and ELAEIK-M2-a-HI at a 
peptide concentration of 100 µM in the presence (+A) and absence of 1 mM 
amantadine. (d) Structural formula of amantadine. All measurements were 
performed in PBS (pH 7.4). 




been achieved in the past in trimers 275, tetramers 276,277 and covalently templated 
3-helix bundles 278 by replacing larger core hydrophobic residues such as Ile and 
Leu with smaller residues such as Gly and Ala.  The resulting hydrophobic cavities 
can be occupied by small hydrophobic molecules such as benzene 275,276, 
adamantane 277 and hydrophobic dyes 278. The bound hydrophobic molecules 
essentially replace the lost hydrophobic moieties and stabilise the otherwise 
destabilised, cavity-containing structures. This is akin to the phenomena of 
“chemical rescue of structure” and “chemical rescue of function” by small molecule 
complementation that have been demonstrated with various enzymes 399-403, 
receptors 404,405 and in an ATF 256. Chemical rescue of structure generally involves 
substituting a bulky residue for a smaller one such that the protein structure is 
perturbed. The structure is then restored by adding some small molecule that binds 
to the protein, replacing the lost side chain. These mutations are often made in 
interaction interfaces such that the interaction can only occur in the presence of 
that small molecule. Inducible interactions of this nature would be invaluable in the 
design of ATFs because protein-protein interactions (and subsequent transcription 
repression or activation) could be induced rapidly on the addition of a small 
molecule. Similarly, chemical rescue of function can be achieved by mutating key 
catalytic residues in enzymes then replacing the functionality of the lost side chain 
by adding an analogous small molecule.  
To investigate whether the structure of a coiled coil could be perturbed by mutation 
then restored by small molecule binding, substitutions were made in the core of 
the homotetrameric coiled coil CC-Tet 208. The substitutions were proposed to 
create a cavity that could accommodate the environmentally-sensitive dye, DPH 
(Figure 6-7b). DPH fluoresces strongly at 452 nm when present in a hydrophobic 
environment and as such it has previously been used to probe lipid bilayers 406-408. 
This property also makes it useful for probing cavities and channels in the 
hydrophobic cores of proteins and so, more recently, it has also been used to 
investigate the binding properties of hydrophobic pores in α-helical barrels 264. 
While DPH was found to bind to the pores of the de novo barrels CC-Pent, CC-
Hex2 and CC-Hept, it did not bind to CC-Tet, presumably because its tightly 
packed core does not contain any channels or cavities 208,264. Therefore, core 
substitutions were made in CC-Tet that were proposed to enable DPH binding.  
Two d Ile residues in CC-Tet were changed to Ala to produce the peptide 
CC-Tet-IA (Figure 6-7a). This was anticipated to result in a roughly dumbbell-




shaped cavity in the tetramer core that may have accommodated DPH, where the 
aromatic rings of DPH would occupy one lobe each.  
A molecular model of CC-Tet-IA was generated from the crystallographic model of 
CC-Tet (PDB ID: 3R4A 208,213) using the mutagenesis tool in PyMol. The resulting 
model contains two separate cavities that form channels to the protein surface at 
two of the four interhelical interfaces in the coiled coil (Figure 6-7c). Given that 
these cavities were not linked in the model it is unlikely that DPH could occupy 
them without structural rearrangements that allow the aliphatic portion of the 
molecule to be accommodated. It may be necessary to make further substitutions 
to make a continuous channel. For example, the Leu at a17 could be changed to 
a smaller hydrophobic residue such as Val. However, all additional changes that 
introduce more small residues to the core are likely to further destabilise the coiled 







Figure 6-7 Design of DPH-binding homotetramer. (a) Peptide sequences of 
CC-Tet 208 and CC-Tet-IA. Both peptides were N-terminally acetylated and C-
terminally amidated. Ile-Ala substitutions at d13 and d20 are highlighted in 
green. (b) Structural formula of DPH, an environmentally sensitive dye. (c) 
Molecular models of CC-Tet-IA showing the N-terminal (left, upper) and 
C-terminal (left, lower) cavities and the whole structure from the side (right). 
Structures are shown from the N-terminus or with the N-terminus at the top. 
Models were generated using the mutagenesis tool in PyMol using the 
crystallographic model of CC-Tet (PDB ID: 3R4A 208,213).  




would need to be very thermodynamically favourable in order to rescue the 
structure of the coiled coil.  
When investigated with CD spectroscopy CC-Tet-IA formed an α-helical structure, 
like the parent peptide, CC-Tet (Figure 6-8a). Despite containing core Ala residues, 
which were expected to destabilise the structure, CC-Tet-IA was in fact almost as 
highly folded as CC-Tet. However, it was much less thermally stable than CC-Tet, 
with a TM value of just 39 °C (Figure 6-8b). CC-Tet has a TM above the measurable 
range at 10 µM. Furthermore, AUC revealed that CC-Tet-IA had a molecular weight 
corresponding to a dimer in both SV and SE experiments (Figure 6-8c, Figure 
8-79).  
Therefore, rather than resulting in a destabilised tetramer, the Ile-Ala substitutions 
have resulted in a completely different structure – a folded, though marginally 
thermally stable, dimer. The collapse to a dimer may minimise the volume of the 
internal cavities, which are expected to be destabilising. This has previously been 
observed in a model antiparallel coiled coil system where the relative positions of 
Ala residues in the cores controlled the oligomeric state: where the Alas were 
present in the same core layer in the coiled-coil structure the peptides formed a 
dimer with a relatively small cavity 227.  
Furthermore, it remains to be seen whether this is a parallel or an antiparallel 
dimer. Previously, coiled coils with core Alas have resulted in antiparallel structures 
because, again, they minimise the volume of the destabilising internal cavities 189.  
It was possible that the addition of DPH could induce CC-Tet-IA to re-adopt the 
parallel tetrameric structure. Such “allosteric” switches have been observed in 
coiled coils before, for example in a system based in GCN4-p1 with a core Ala 
substitution 275. The resulting cavity somewhat destabilised the dimeric state but 
could accommodate benzene when the coiled coil adopted a trimeric state. 
Benzene binding stabilised the trimeric coiled coil and so it underwent a 
conformational change from dimer to trimer on ligand binding. Therefore, DPH 
binding by CC-Tet-IA was investigated using a fluorescence-based DPH-binding 
assay. Increasing peptide concentrations were incubated with 1 µM DPH and 
investigated using fluorescence spectroscopy. As previously demonstrated, 
CC-Tet did not demonstrate DPH binding 264, and there was no significant increase 
in DHP fluorescence on increasing the peptide concentration. CC-Tet-IA also did 
not show a significant increase in DPH fluorescence, indicating that DPH did not 




bind to this peptide either. Therefore, the presence of the cavity-forming core 
substitutions at d13 and d20 was not sufficient to introduce hydrophobic dye 
binding activity into this peptide. Instead, the peptide formed a folded dimer that 
could not be encouraged to re-adopt a tetrameric structure by DPH binding.  
6.3.3 In vivo selection strategies for generating ligand-binding coiled coils 
A final approach to introducing cavities into the cores of coiled coils involved 
placing Ala at the a and d residues in the central heptad of a heterotetrameric coiled 









Figure 6-8 Biophysical characterisation of the CC-Tet core variant, 
CC-Tet-IA. (a) CD spectra at 5 °C of CC-Tet and CC-Tet-IA. (b) 
Temperature-dependent CD measurements monitoring MRE222 between 5 
and 95 °C for CC-Tet and CC-Tet-IA. The peptide concentration for CD 
spectroscopy was 10 µM. (c) Sedimentation velocity c(s) distribution (top) 
and residuals (bottom) for CC-Tet-IA returning a predicted Mw of 6.5 kDa 
(2.0 x monomer mass). All biophysical measurements were performed in 
PBS (pH 7.4). (d) DPH-binding assay with CC-Tet and CC-Tet-IA. Varying 
concentrations of CC-Tet and CC-Tet-IA were incubated with 1 µM DPH then 
DPH fluorescence at 452 nm was measured. The assay was performed in 




























cavity directly in the centre of the coiled coil. As such, adopting an alternative 
conformation, such as an antiparallel structure, would not have led to a decrease 
in cavity volume and so the coiled coil should be globally destabilised (i.e. all 
possible structures are destabilised) and exist in a partially unfolded state. This is 
in contrast to CC-Tet-IA discussed above in which core Ala substitutions 
destabilised the tetrameric conformation but did not globally destabilise the 
peptide. Therefore, the peptide simply adopted a different structure rather than a 
partially unfolded structure, as intended.  
Positions a14 and d17 in the peptides 1-LI-A and 1-LI-B (described in Chapter 4) 
were both changed to Ala to make the peptides 1-LI-A* and 1-LI-B*, respectively 
(Figure 6-9a). A molecular model of the heterotetramer was generated using CC 
Builder 2.0 because a crystal structure was unavailable for the 1-LI-AB parent 301. 
The model revealed a cavity in the centre of the coiled coil (Figure 6-9b). The cavity 
was determined to have a volume of 51.8 Å3 using the CASTp server with a probe 
radius of 1.4 Å. A cavity of this size would not be able to accommodate very large 
molecules. Even small hydrophobic molecules like benzene, which has a 
molecular volume of approximately 150 Å3 according to Equation 6-1, would be too 
large. However, the peptides provide a proof of principle that coiled coils can be 
globally destabilised in this way, and the cavity volume could be enlarged in the 
future if necessary.  
When 1-LI-A* and 1-LI-B* were investigated alone, both had similar CD spectra to 
the parent peptides 1-LI-A and 1-LI-B, indicating little folding (Figure 6-10a). When 
the peptides were mixed at 10 µM each, the CD spectrum looked similar to the 
spectra of the individual peptides and to the average of the individual spectra, 
showing the peptides did not interact at this concentration. When the peptide 
concentrations were increased to 100 µM there was a small increase in MRE222 
and the fraction helix value increased from 39 % at the lower concentration to 53 % 
at the higher concentration (Figure 6-10a). Therefore, the peptides were still able 
to interact to some extent, but the interaction was greatly weakened. This is in 
contrast to the parent heterotetramer 1-LI-AB, which was essentially fully folded at 
10 µM (Figure 6-10a).  
The 1-LI-A* and 1-LI-B* peptides were also investigated using AUC, both alone 
and together. SE experiments of the individual peptides showed that they were 
monomeric in solution, like the parent peptides (Figure 8-107, Figure 8-108). SV 
experiments of the peptides together gave a predicted molecular weight of 4.3 kDa 




(Figure 6-10c, Figure 8-134). This corresponded to an oligomeric state of 1.4, 
showing that there was lots of unfolded monomer present.  
Unlike CC-Tet-IA, where only the tetrameric state was destabilised, this heteromer 
appears to be globally destabilised; the core substitutions have not caused the 
coiled coil to adopt an alternate structure and the peptides are instead mostly 
unfolded. This is likely due to the central location of the Ala substitutions that would 
create a similar cavity in both parallel and antiparallel structures. However, it is 
interesting that the peptides did not form, for example, a dimer in which the cavity 
volume would have been smaller, as was the case in CC-Tet-IA. Therefore, it 
remains to be seen whether the peptides will still form a tetramer when the 
concentration is greatly increased to the point where the peptides form a well folded 





Figure 6-9 Design of a heterotetramer core mutant. (a) Peptide sequences 
for 1-LIA, 1-LI-B, 1-LI-A* and 1-LI-B*. All peptides were N-terminally 
acetylated and C-terminally amidated. Alanine substitutions are highlighted 
in green. (b) Molecular model for the 1-LI-AB* heterotetramer shown from the 
N-terminus (left), from the side with the N-terminus at the top (centre) and 
from the side with the N-terminus at the top with the cavity highlighted (right). 
The cavity volume is shown above the model. Models were generated in CC 
Builder 2.0 301 using the default parameters for CC-Tet (radius, 6.8 Å; pitch, 
213 Å; interface angle, 22.1 °). The cavity volume was calculated using the 
CASTp server using a probe radius of 1.4 Å 398.  




Globally destabilised coiled coils, like the heteromer described above, may present 
a starting point for developing coiled coils that can undergo chemical rescue of 
structure. A coiled coil that is truly destabilised may be better than those that adopt 
alternative, metastable conformations as these other conformations represent 
competing states that may themselves be stabilised by ligand binding instead of 
the desired oligomeric state.  
One possible approach to achieving chemical rescue of structure in this 
destabilised coiled coil is through high throughput screening and selection for 
ligand binding that induces the interaction between the peptides. Here, the de novo 
coiled coils could potentially undergo coupled folding and binding, as is observed 
with many intrinsically disordered proteins 409,410. Alternatively, a partially 
destabilised protein could undergo ligand-induced stabilisation 411. Destabilised or 
unfolded protein are generally degraded more rapidly in vivo 377, while stabilised 
proteins should have greater longevity. Ligand-stabilised mutants have been 
identified for many natural proteins including E. coli dihydrofolate reductase 412, 
human FKBP12 413 and estrogen receptor 414, and a fluorescent protein from a 
freshwater eel, Anguilla japonica 415.  
There are two main ways that coiled coils displaying ligand-induced folding or 
stabilisation could be generated: (1) libraries of small molecules could be screened 
for binding to a cavity containing coiled coil target; or (2) libraries of peptide 
sequences could be screened for binding to a ligand of interest.  
Protein complementation assays use interacting exogenous components to bring 
together fragments of a reporter protein to restore its activity 416. Such assays could 
be used to screen for peptide-small molecule combinations that rescue coiled-coil 
folding or stability and thus facilitate the interaction between the components of the 
split system (Figure 6-11a). These assays include bacterial two-hybrid assays like 
the Lac repressor-based transcription repression assay described in Chapter 5. 
Other two-hybrid assays based on transcription activation have also been 
described 109,167. A transcription activation assay using a chemiluminescent 
reporter has previously been used to identify small molecules that can mediate the 
interaction between DNA and a mutant zinc finger deficient in DNA binding 256. 
Alternatively, systems that involve the reconstitution of split fluorescent proteins 
417,418 or enzymes could be used 419-422. For example, a split dihydrofolate reductase 
system has previously been used to select optimal heterodimer sequences from 
an in vivo library of coiled-coil sequences 209,210. A split T7 RNA polymerase has 




also been proposed as a tool for selecting protein-protein and protein-ligand-
protein interactions 423. Other approaches to screening protein-protein interactions 
and protein folding that do not involve protein complementation include FRET-
based assays and proteolysis assays 424,425. Variants of the latter have been used 
to select stably folded variants of ubiquitin 426, de novo designed mini proteins 427 
and ligand-stabilised variants of human FKBP12 (FK506 binding protein) 413. 
Ligand-stabilised variants of computationally designed steroid-binding proteins 









Figure 6-10 In vitro and in vivo characterisation of the heterotetramer 
core mutant. (a) CD spectra at 5 °C of peptides 1-LI-A* and 1-LI-B* and 
heteromers 1-LI-AB and 1-LI-AB*. (c) Temperature-dependent CD 
measurements monitoring MRE222 between 5 and 95 °C for heteromers 
1-LI-AB and 1-LI-AB*. Peptides were at 10 µM, except where indicated. (c) 
Sedimentation velocity c(s) distribution (top) and residuals (bottom) for 
1-LI-AB* returning a predicted Mw of 4.3 kDa (1.4 x mean monomer mass). 
All biophysical measurements were performed in PBS (pH 7.4). (d) 
Transcription repression assay for LacI*-1-LI-A/LacI*-1-LI-B and LacI*-1-LI-
A*/LacI*-1-LI-B* with induction by 0.0% arabinose. Error bars are one s.d. 























To demonstrate that the coiled coils described here may also be amenable to in 
vivo screening or selection, the 1-LI-A* and 1-LI-B* peptides were examined in the 
transcription repression assay introduced in Chapter 5 (Figure 6-10d). When 
neither or just one peptide was present, no repression of the GFP reporter was 
observed. The same was observed with the parent peptides, 1-LI-A and 1-LI-B. 
When the acidic and basic LacI*-peptide fusions were co-expressed, the 1-LI-A 
and 1-LI-B peptides interacted, with a fold repression value of 4.6. Conversely, the 
1-LI-A* and 1-LI-B* peptides did not interact, and the fold repression value was the 
same as in the no coiled coil-control. Therefore, the core mutant peptides did not 
interact in E. coli.  
This LacI*-1-LI-A*/LacI*-1-LI-B* system could potentially now be used to screen a 
library of small molecules for those that can rescue the heterotetramer interaction. 
However, as discussed above, the cavity in this heteromer was predicted to be 
very small and therefore the availability of small molecules that could occupy the 
cavity is likely to be quite limited.  
The alternative approach is to screen a library of peptide sequences for binding to 
a small molecule of interest. A DNA library encoding peptides with a subset of 
amino acids at select core positions could be generated, transformed into E. coli 
and screened for ligand-dependent folding using a high throughput method such 
as fluorescence-activated cell sorting (FACS) (Figure 6-11b and c). This approach 
would not only allow greater freedom for the user to define the ligand properties 
(e.g. pharmacological activity), but it also expands the range of ligands that could 
be bound by the peptides. This is because, rather than simply containing 
hydrophobic cavities that can bind hydrophobic molecules, the coiled coils could 
contain cavities with more diverse chemical properties due to the introduction of 
residues with other chemical functionalities. For example, polar or charged amino 
acids could make specific interactions with complementary ligands.  
Such in vivo selection strategies may, in principle, provide a means for generating 
coiled coils that undergo chemical rescue of structure. However, it is likely that the 
A2B2 heterotetramers described above are not the optimal starting point for such 
endeavours because the coiled coil-ligand interaction would involve five different 
components. The likelihood of all components colliding at the same time is very 
low. Therefore, other coiled coil or 4-helix bundle arrangements may need to be 
considered. For example, dimeric 4-helix bundles consisting of two helix-loop-helix 
(HLH) monomers, or single chain 4-helix bundles may be better options (Figure 




6-12). These systems would reduce the number of components that need to come 
together to give a productive interaction. They would also allow cavities with 
greater chemical diversity to be generated because the sequences of the individual 
helices, particularly the residues lining the cavity, can be changed independently. 
Furthermore, parallel and antiparallel conformations can be explored relatively 
simply and reliably because the peptides are constrained in one conformation by 
the linkers. Finally, the HLH dimers may allow for the design of components with 
prearranged binding sites where the monomers are folded prior to ligand binding, 
and ligand binding merely bridges the two components, facilitating the interaction.  
These alternative 4-helix bundle folds represent novel design targets that must first 
be achieved before more-complex properties can be considered. However, once 







Figure 6-11 Design strategy for heterotetrameric core mutants that 
bind small molecules. (a) Schematic of ligand-binding heterotetrameric coiled 
coil in a reporter system. The ligand (yellow) promotes the interaction 
between the coiled-coil components (red and blue) leading to 
complementation of the components of the reporter system (green). Reporter 
outputs could include fluorescence, enzymatic activity, transcriptional 
regulation. (b) Helical wheel (left) and sequences of potential peptide core 
mutant library. Amino acids that may be placed at the selected core positions 
would be chosen for chemical diversity. (c) Schematic outlining in vivo 
selection steps and possible outcomes. 




they should also be amenable to high throughput in vivo screening for small 
molecule-induced folding. 
6.4 Chapter conclusions 
Here, very preliminary steps have been made towards the design of novel ABCD 
heterotetrameric coiled coils and 4-helix bundles that undergo ligand-induced 
folding.  
Firstly, attempts have been made to design ABCD heterotetramers using a 
computational method that optimised charge interactions. While the peptides that 
were generated did appear to show some interaction, they did not form the desired 
assemblies. The method could be improved by better considering the off-target 
charge interactions that could occur. The search space could also be increased by 
screening peptides that can contain any combination of all four heptads, rather 
than containing all four heptads in a different order. This would generate 256 initial 
peptides, rather than 24, and would result in over 4 billion possible tetramer 
combinations. While this would significantly increase the computational power 
required to perform the screening, it may increase the likelihood of finding a 
successful design.  
Attempts were also made to design coiled coils that bind small-molecule ligands 





Figure 6-12 Ligand induced 4-helix bundles. (a) A dimer of helix-loop-
helix monomers. The interaction between the helical monomers (blue and 
yellow) is mediated by a small molecule (pink). (b) A single-chain 4-helix 
bundle (yellow) that exists as an intrinsically disordered protein in the absence 
of the ligand and is induced to fold by small molecule binding. In both (a) and 
(b), small molecule binding could be selected for in vivo using various protein 
complementation assays.  




homotetrameric coiled-coil sequence. However, the structures of the chosen 
amantadine-binding 4-helix bundle and the de novo coiled coil were not 
compatible, and the resulting peptides were excessively destabilised by the 
introduced binding motif. 
Subsequently, steps were made towards the design of coiled coils that could 
potentially undergo ligand-induced folding in a manner analogous to intrinsically 
disordered proteins or proteins that undergo chemical rescue of structure. These 
steps included demonstrating that coiled coils can be globally destabilised through 
core mutations and that these destabilised coiled coils may be amenable to high 
throughput in vivo screening experiments. However, for future experiments it is 
expected that other 4-helix bundle structures will need to be explored such as 
dimers of HLH motifs or single-chain designs.  
Rationally designing ligand binding sites in proteins is by no means a simple task. 
Various computational methods have previously been used to introduce small 
molecule binding sites into proteins 428-431. However, in vivo selection and directed 
evolution has also provided a powerful means of introducing novel ligand binding 
properties into proteins. Indeed, work by Hecht and co-workers has shown that 
small molecules bind readily to binary patterned 4-helix bundles, both with and 
without cavities 211,212. While these experiments demonstrate the suitability and 
versatility of 4-helix bundles as ligand-binding proteins, they do not consider the 
effects of ligand binding on protein stability nor whether small molecule binding can 
elicit 4-helix bundle folding.  
If achieved, ligand-inducible 4-helix bundles would be highly useful in the design 
of novel transcription factors that respond to a small molecule of interest. This type 
of protein-protein interaction would also be particularly useful in the design of 
biosensors, where binding of an environmental small molecule leads to a 
conformational change in the coiled coil, which in turn leads to a readily detectable 
output 432. Implementation of a high-throughput method for screening a large library 
of 4-helix bundles for ligand-induced folding would provide a means of rapidly and 
flexibly identifying proteins that respond to novel ligands. 
Finally, there are other approaches for post-translationally modulating protein 
structure and activity that are not explored here, including light-mediated 
conformational changes and chemical modifications. Light-induced conformational 
changes have been introduced into individual peptides and coiled coils through the 




inclusion of residues and modifications that undergo photoinduced isomerisation 
433-437. However, such designs cannot be readily expressed in vivo and must 
instead be introduced into cells, for example, via transfection 438. This limits their 
use as in vivo switchable protein-protein interaction systems.  
Post-translational chemical modifications include reduction and oxidation of 
cysteines and methionines. For example, a peptide has been designed that 
undergoes a conformational change from monomeric helical hairpin to 
homodimeric coiled coil on reduction of an inter helical disulphide bond 439. 
Additionally, homodimers that undergo dissociation 440 and a peptide that 
undergoes an α-β conformational switch on methionine oxidation 441 have also 
been described. A key post-translational chemical modification, however, is 
phosphorylation of serine and threonine residues. Coiled coils that respond to 
enzymatic phosphorylation and dephosphorylation have been designed and 
demonstrated in vitro. Depending on the location of the phosphorylatable residue 
442, phosphorylation can be both stabilising 443 and destabilising 444-446 to coiled-coil 
structures, making it a useful means of controlling peptide association. Such 





Chapter 7: Conclusions and future work 
7.1 Overall conclusions 
Through the work described in this thesis, a set of homo- and heterotetrameric 
coiled coils has been designed and characterised both in vitro and in vivo. The 
results of the characterisation demonstrate that the de novo coiled coils are useful 
as artificial protein-protein interaction domains for synthetic biology applications 
inside cells. 
Firstly, a number of homotetramers have been designed by varying the 
arrangement of charged glutamate and lysine residues in peptides with Leu/Ile 
cores (i.e. a=leucine and d=isoleucine). The resulting seven homotetramers have 
different thermal stabilities, however this is not dictated by the locations of the 
charged residues as initially proposed. Furthermore, changing the identity of the d 
positions to valines, which was predicted to give less-stable homotetramers, in fact 
leads to a loss of structural specificity and the Leu/Val core peptides do not form 
tetramers within the investigated concentration range. Therefore, this approach 
cannot be used to create additional homotetramers with a wider range of thermal 
stabilities.  
Using design principles derived from the homotetramers, sets of acidic (A) and 
basic (B) peptides have also been designed. When these peptides are mixed in 
A/B pairs they assemble into A2B2 heterotetramers. The thermal stabilities of these 
heterotetramers depend on the core residues in the constituent peptides: 
heterotetramers with Leu/Ile cores are the most stable; those with Leu/Val cores 
are the least stable; and those with mixed Leu/Ile/Val cores have intermediate 
stabilities. Therefore, unlike the homotetramers, the identities of the core residues 
can be used to modulate the stabilities of the heterotetramers without adversely 
affecting their oligomeric states.  
A selection of the in vitro-characterised heterotetramers have also been 
investigated in E. coli to determine their suitability as PIDs. All three of the 
investigated heterotetramers interact within cells when studied using a 




transcription repression assay based on oligomerisation mutants of the Lac 
repressor. Some of the heterotetramer complexes are also able to form when the 
basic peptides are fused to a small solubility tag, or when they are expressed as 
“minimal” coiled-coil peptides fused only to a six-residue identification tag.  
Furthermore, when the basic components are expressed from an inducible 
promoter, their expression level can be modulated by altering the inducer 
concentration. The expression level of the basic component determines the 
resulting level of transcription repression. Thus, the level of repression can be 
tuned over a reasonable range. Therefore, not only does this work yield a number 
of semi-artificial transcriptional repressors, consisting of a designed PID and an 
engineered DBD, it also identifies further regulatory components that these 
repressors are compatible with.  
Preliminary work has also been carried out to investigate what effect the coiled-coil 
peptides have on the cellular concentrations of the proteins they were fused to. 
Generally, the peptides lead to decreased levels of the fusion proteins. This most 
likely occurs through increased degradation of the protein due to the unfolded 
nature of the peptides when not interacting with their cognate partner.  
Additional coiled-coil tetramer designs have been pursued in vitro. Firstly, the 
effects of placing alanine at g positions have been investigated. Expanding the 
 
Figure 7-1 Graphical summary. Homotetramers have been designed and 
characterised in vitro. A2B2 heterotetramers have been designed and 
characterised both in vitro and in vivo. Their stability can be tuned by varying 
the core residues. Preliminary steps have been made towards the design of 
ABCD heterotetramers and ligand-inducible coiled coils.  




hydrophobic seam of a coiled coil in this way has previously led to the formation of 
parallel 206 and antiparallel 205 tetramers and higher order α-barrels 213. In the work 
described here, the peptides form tetramers, but the orientation of the helices 
remains to be determined. ABCD heterotetramers, where all four peptides are 
different, have also been explored. The ABCD combinations do show heteromeric 
interactions, but extensive cross-interactions are also observed between the 
constituent peptides. Moreover, the designs do not form tetramers.  
Finally, a number of core mutations have been made in existing homo- and 
heterotetramers in an attempt to confer ligand-binding behaviour on these coiled 
coils. While none of the peptides bind the tested small molecules, the globally-
destabilised heterotetramer mutant may provide a starting point for high-
throughput selection studies to identify coiled coils that undergo ligand-induced 
folding or ligand-induced stabilisation. Such coiled coils would be useful as 
inducible protein-protein interaction domains in the design of ATFs.  
7.2 Future work 
7.2.1 Improved coiled coil designs  
As well as the tetramers described above, there are a number of other designs that 
would make useful additions to the suite of coiled coil-based artificial PIDs. For 
example, charge neutral A2B2 heterotetramers could be designed to consist of 
peptides with a net neutral charge instead of highly acidic and basic peptides. As 
discussed in Chapter 5, these may have improved in vivo properties due to reduced 
non-specific interactions with other highly charged cellular components, such as 
negatively charged ribosomes. Designs for such coiled coils may be readily 
achieved using a modified version of the script used to generate the ABCD 
heterotetramer designs described in Chapter 6.  
Furthermore, and also as discussed in Chapter 6, ligand-binding or ligand-
inducible coiled coils present a highly desirable target. High-throughput screening 
assays, such as protein complementation assays or proteolysis-susceptibility 
assays, could be used to select coiled coils that do not fold or are rapidly degraded 
in the absence of ligand but become folded or stabilised in the presence of a small 
molecule. Similar screening strategies could also be used to identify constitutive 
coiled-coil interactions with advantageous in vivo properties such as reduced off-
target interactions or reduced susceptibility to proteases. Additionally, this method 




could be used to select coiled coil-encoding DNA sequences with beneficial 
properties such as efficient transcription. This type of approach has previously 
been used to select constitutively-interacting heterodimeric coiled-coil peptides 
from two libraries of semi-randomised peptides 209. 
Coiled coils that use different switching methods would also be useful in the design 
of inducible protein-protein interactions. For example, coiled coils designed to 
change conformation in response to reversible chemical modifications would 
provide a means of rapidly altering the association state of proteins fused to said 
coiled coil. Phosphorylation is a particularly appealing post-translational 
modification for controlling assembly in this way because phosphorylation and 
dephosphorylation are carried out by enzymes, so both could be readily performed 
in vivo. Furthermore, phosphorylation has previously been used to control both the 
assembly 444 and disassembly 443 of coiled coils. Alternatively, peptides could be 
designed to perform strand displacement or strand exchange. For example, 
displacement has been demonstrated in heterodimers consisting of peptides of 
different lengths 447,448. However, in vivo this type of switching would need to be 
controlled at the transcriptional level and is therefore likely to occur on a slower 
time scale than chemical modifications or small-molecule binding.  
7.2.2 Fully-artificial transcription factors  
The focus of this thesis has been the design of new protein-protein interactions 
and these interactions have been tested using a natural DNA-binding protein. 
Therefore, all of the semi-artificial transcription factors that have been generated 
recognise a natural promoter sequence. This could lead to issues with cross talk. 
Improved ATFs could be designed by combining the de novo coiled-coil domains 
with engineered TALEs as the DBDs. In this way, orthogonal and fully-artificial 
transcription factor/promoter pairs could be designed to minimise off-target 
interactions in the host organism. Alternatively, the DBDs could be designed to 
target the ATF to any promoter of interest in an organism’s genome. 
Furthermore, this thesis has only focused on using protein-protein interactions in 
ATFs. However, there are many other scenarios where both constitutive and 
inducible interaction domains would be of use. For example, constitutive 
interactions could be used to co-localise enzymes of an enzymatic pathway in 
order to increase productivity 449. Inducible interactions could be used in synthetic 
cell-surface receptors to transmit signals to the cell interior.  




7.2.3 More-complex organisms 
As more designs are added to the protein-protein interaction, DNA-binding domain 
and ATF toolkit, increasingly sophisticated characterisation techniques will be 
needed to ensure the new components are suitable for use in organisms. As 
discussed in Chapter 5, these techniques may include quantitative Western 
blotting, pull-down or immunoprecipitation assays and proteomics. Such 
techniques would provide information on whether a component is present in a cell 
in reasonable quantities, whether it has undesirable cross interactions with other 
cellular components, and whether it has global effects on the cell other than those 
intended. These properties are likely to be organism-specific, so the 
characterisation may need to be performed anew as components are taken out of 
E. coli and introduced into increasingly complex organisms such as mammals. This 
may be particularly desirable given the interest in ATFs for treating diseases 
involving aberrant gene expression, most notably cancer.  
There is much left to explore, but what is already apparent is the broad utility and 
versatility of ATFs and their constituent parts. In the future, the same components 
 
Figure 7-2 Future work. Avenues remaining to be explored include 
incorporating switching behaviours into designed protein-protein interaction 
domains; designing fully-artificial transcription factors with engineerable 
DNA-binding domains; improving the in vivo properties of the components; 
and using the components in organisms beyond E. coli. 




used as parts of a synthetic genetic circuit in a bacterium may also find use as a 





Chapter 8: Appendix 
8.1 Peptide sequences 
Sequences, registers, heptads and masses (Da) of all peptides discussed in this 
thesis are displayed in Table 8-1. All peptides are in either c-register or g-register. 
All peptides are N-terminally acetylated and C-terminally amidated. Where present, 
heptads are given as consensus motifs. 
Peptides 6-20 and 26-45 are named for the locations of their charged Glu/Lys 
residues (1, e/g; 2, c/e; 3, g/b; 4, b/c) and the identities of their core residues (LI, 
a=Leu/d=Ile; LV, a=Leu/d=Val; LIA, a=Leu/d=Ile/g=Ala; LVA, a=Leu/d=Val/g=Ala). 
The designed homomeric peptides are further labelled for the order of Glu and Lys 
residues in their linear sequence (EK; KE) and peptide components of heteromeric 
assemblies are labelled as acidic (A, contain Glu at all charged positions) or basic 
(B, contain Lys at all charged positions). 
Other peptides are named for their consensus heptad motif e.g. ELAEIK or using 
a historical name suffixed with identifiers that denote additional mutations to the 
parent sequence e.g. CC-Tet-KE is a version of CC-Tet 208 in which the Glu and 
Lys residues at e/g positions have been swapped.  




























1 CC-Tet Ac – G E LAAIKQE LAAIKKE LAAIKWE LAAIKQ GAG – NH2 g ELAAIK 3374.993 
2 CC-Tet-KE Ac – G K LAAIEQK LAAIEKK LAAIEWK LAAIEQ GAG – NH2 g KLAAIE 3374.993 
3 C-Tet-KE-N-4 Ac – G K LAAIEQK LAAIEKK LAANNWK LAAIEQ GAG – NH2 g KLAAIE 3360.926 
4 CC-Tet-KE-N-4.5 Ac – G K LAAIEQK LAAIEKK LAANNWK LAAIEQ KLAA G – NH2 g KLAAIE 3616.286 
5 CC-Tet-IA Ac – G E LAAIKQE LAAAKKE LAAAKWE LAAIKQ GAG – NH2 g ELAAIK 3290.832 
6 1-LI-EK Ac – G AIKKE LAAIKKE LAAIKWE LAAIKKE LA G – NH2 c ELAAIK 3246.950 
7 1-LI-KE Ac – G AIEQK LAAIEQK LAAIEWK LAAIEQK LA G – NH2 c KLAAIE 3246.820 
8 2-LI-EK Ac - G EIKQQ LAEIKQQ LAEIKWQ LAEIKQQ LA G – NH2 c QLAEIK 3475.027 
9 2-LI-KE Ac – G KIEQQ LAKIEQQ LAKIEWQ LAKIEQQ LA G – NH2 c QLAKIE 3475.027 
10 3-LI-EK Ac – G AIQQE LKAIQQE LKAIQWE LKAIQQE LK G – NH2 c ELKAIE 3475.027 
11 3-LI-KE Ac – G AIQQK LEAIQQK LEAIQWK LEAIQQK LE G – NH2 c KLEAIQ 3475.027 
12 4-LI-EK Ac – G KIQKQ LEKIQKQ LEKIQWQ LEKIQKQ LE G – NH2 c QLEKIQ 3703.364 
13 4-LI-KE Ac – G EIQKQ LKEIQKQ LKEIQWQ LKEIQKQ LK G – NH2 c QLKEIQ 3703.364 
14 1-LV-EK Ac – G AVKQE LAAVKQE LAAVKWE LAAVKQE LA G – NH2 c ELAAVK 3190.712 
15 1-LV-KE Ac – G AVEQK LAAVEQK LAAVEWK LAAVEQK LA G – NH2 c KLAAVE 3190.712 
16 2-LV-EK Ac – G EVKQQ LAEVKQQ LAEVKWQ LAEVKQQ LA G – NH2 c QLAEVK 3418.919 
17 2-LV-KE Ac – G KVEQQ LAKVEQQ LAKVEWQ LAKVEQQ LA G – NH2 c QLAKVE 3418.919 
18 3-LV-EK Ac – G AVQQE LKAVQQE LKAVQWE LKAVQQE LK G – NH2 c ELKAVQ 3418.919 
19 3-LV-KE Ac – G AVQQK LEAVQQK LEAVQWK LEAVQQK LE G – NH2 c KLEAVQ 3418.919 



























21 2-LIA-KE Ac – G KIEQA LAKIEQA LAKIEWA LAKIEQA LA G – NH2 c ALAKIE 3246.820 
22 ELAEIK Ac – G EIKKE LAEIKKE LAEIKWE LAEIKKE LA G – NH2 c ELAEIK 3479.096 
23 ELAEIK-M2-a Ac – G EIKKE VAEASKE AAEHKWE LAEIKKE LA G – NH2 c - 3363.793 
24 ELAEIK-M2-d Ac – G EIKKE LAEVKKA SAEAKWH LAEIKKE LA G – NH2 c - 3346.896 
25 ELAEIK-M2-a-HI Ac – G EIKKE VAEASKE AAEIKWE LAEIKKE LA G – NH2 c - 3339.812 
26 1-LI-A Ac – G AIEKE LAAIEKE LAAIEWE LAAIEKE LA G – NH2 c ELAAIE 3250.715 
27 1-LI-A-g Ac – G E LAAIEKE LAAIEKE LAAIEWE LAAIEK G – NH2 g ELAAIE 3250.715 
28 1-LI-A* Ac – G AIEKE LAAIEKE AAAAEWE LAAIEKE LA G – NH2 c ELAAIE 3166.554 
29 2-LI-A Ac – G EIEKQ LAEIEKQ LAEIEWQ LAEIEKQ LA G – NH2 c QLAEIE 3478.922 
30 3-LI-A Ac – G AIQKE LEAIQKE LEAIQWE LEAIQKE LE G – NH2 c ELEAIQ 3478.922 
31 1-LV-A Ac – G AVEKE LAAVEKE LAAVEWE LAAVEKE LA G – NH2 c ELAAVE 3194.607 
32 2-LV-A Ac – G EVEKQ LAEVEKQ LAEVEWQ LAEVEKQ LA G – NH2 c QLAEVE 3422.814 
33 3-LV-A Ac – G AVQKE LEAVQKE LEAVQWE LEAVQKE LE G – NH2 c ELEAVQ 3422.814 
34 1-LI-B Ac – G AIKQK LAAIKQK LAAIKWK LAAIKQK LA G – NH2 c KLAAIK 3243.054 
35 1-LI-B-g Ac – G K LAAIKQK LAAIKQK LAAIKWK LAAIKQ G – NH2 g KLAAIK 3243.054 
36 1-LI-B* Ac – G AIKQK LAAIKQK AAAAKWK LAAIKQK LA G – NH2 c KLAAIK 3158.893 
37 2-LI-B Ac – G KIKQQ LAKIKQQ LAKIKWQ LAKIKQQ LA G – NH2 c QLAKIK 3471.261 
38 3-LI-B Ac – G AIQQK LKAIQQK LKAIQWK LKAIQQK LK G – NH2 c KLKAIQ 3471.261 
39 1-LV-B Ac – G AVKQK LAAVKQK LAAVKWK LAAVKQK LA G – NH2 c KLAAVK 3186.946 



























41 3-LV-B Ac – G AVQQK LKAVQQK LKAVQWK LKAVQQK LK G – NH2 c KLKAVQ 3415.153 
42 2-LIA-A Ac – G EIEKA LAEIEKA LAEIEWA LAEIEKA LA G – NH2 c ALAEIE 3250.715 
43 2-LVA-A Ac – G EVEKA LAEVEKA LAEVEWA LAEVEKA LA G – NH2 c ALAEVE 3194.607 
44 2-LIA-B Ac – G KIKQA LAKIKQA LAKIKWA LAKIKQA LA G – NH2 c ALAKIK 3243.054 
45 2-LVA-B Ac – G KVKQA LAKVKQA LAKVKWA LAKVKQA LA G – NH2 c ALAKVK 3186.946 
46 ABCD 1 Ac – G AVEQK LAAIEQE LAAIKWK LAAVKQE LA G – NH2 c - 3218.766 
47 ABCD 2 Ac – G AIEQE LAAVKQE LAAVEWK LAAIKQK LA G – NH2 c - 3218.766 
48 ABCD 3 Ac – G AIKQK LAAVKQE LAAIEWE LAAVEQK LA G – NH2 c - 3218.766 
49 ABCD 4 Ac – G AVEQK LAAIKQK LAAVKWE LAAIEQE LA G – NH2 c - 3218.766 
50 ABCD 5 Ac – G AIKQK LAAVKQE LAAVEQK LAAIEQE LA GGSY – NH2 c - 3467.989 
51 ABCD 6 Ac – G AVEQK LAAIKQK LAAIEQE LAAVKQE LA GGSW – NH2 c - 3491.026 
52 ABCD 7 Ac – G AVKQE LAAIEQE LAAVEQK LAAIKQK LA GGDY – NH2 c - 3495.999 
53 ABCD 8 Ac – G AIEQE LAAVEQK LAAIKQK LAAVKQE LA GGDW – NH2 c - 3519.036 
Table 8-1 Sequences of all designed peptides with systematic names, registers, consensus heptads and masses (Da). All peptides were 
C-terminally acetylated (Ac) and N-terminally amidated (NH2). All peptides were designed in either c- or g-resister. All consensus heptads 
are written starting at a g position, regardless of peptide register. 




8.2 Analytical HPLC traces and mass spectra of designed 
peptides 
This section contains representative analytical HPLC traces (left) monitoring 
absorbance at 220 nm (top, black) and 280 nm (bottom, gray) and representative 
mass spectra (right) for each peptide discussed in this thesis. Exp, expected mass 
(Da); obs, observed mass (Da); m/z, mass:charge ratio. Peptides are numbered 






































































































































































8.3 CD data of designed peptides 
This section contains representative circular dichroism (CD) spectra (left or centre) 
and thermal denaturation experiments (right) for all peptides discussed in this 
thesis. Peptide concentrations are indicated in keys. All spectra were measured at 
5 °C except those for peptides 46-53, which were measured at 20 °C. Thermal 
denaturation experiments were performed by heating (5–95 °C) and cooling (95–5 
°C) samples while monitoring MRE222. All measurements were performed in 1X 
PBS (pH 7.4), unless otherwise stated. High tension (HT) plots are shown below 


















Figure 8-2 CD spectroscopy data for CC-Tet-KE.  
 
  











Figure 8-4 CD spectroscopy data for CC-Tet-KE-N-4.5.  
 
  











Figure 8-6 CD spectroscopy data for 1-LI-EK.  
 
  











Figure 8-8 CD spectroscopy data for 2-LI-EK.  
 
  












Figure 8-10 CD spectroscopy data for 3-LI-EK.  
 
  











Figure 8-12 CD spectroscopy data for 4-LI-EK.  
 
  











Figure 8-14 CD spectroscopy data for 1-LV-EK.  
 
  











Figure 8-16 CD spectroscopy data for 2-LV-EK.  
 
  












Figure 8-18 CD spectroscopy data for 3-LV-EK.  
 
  












Figure 8-20 CD spectroscopy data for 2-LIA-EK.  
 
  












Figure 8-22 CD spectroscopy data for ELAEIK.  
 
  












Figure 8-24 CD spectroscopy data for ELAEIK-M2-d.  
 
  












Figure 8-26 CD spectroscopy data for 1-LI-A.  
 
  












Figure 8-28 CD spectroscopy data for 1-LI-A*.  
 
  












Figure 8-30 CD spectroscopy data for 3-LI-A.  
 
  












Figure 8-32 CD spectroscopy data for 2-LV-A.  
 
  












Figure 8-34 CD spectroscopy data for 1-LI-B.  
 
  












Figure 8-36 CD spectroscopy data for 1-LI-B*.  
 
  












Figure 8-38 CD spectroscopy data for 3-LI-B.  
 
  












Figure 8-40 CD spectroscopy data for 2-LV-B.  
 
  












Figure 8-42 CD spectroscopy data for 2-LIA-A.  
 
  











Figure 8-44 CD spectroscopy data for 2-LIA-B.  
 
  




















Figure 8-46 CD spectroscopy data for ABCD peptides: (a) 1; (b) 2; (c) 




















Figure 8-47 CD spectroscopy data for ABCD peptides: (a) 5; (b) 6; (c) 













Figure 8-48 CD spectra for peptide 37 aka 1-LI-B measured at 5 °C 
intervals between 10 and 95 °C.  Peptide concentration 10 µM.  
 
  




8.4 CD Data of designed heteromers 
This section contains representative CD spectra (left or centre) and thermal 
denaturation experiments (right) for all ABAB and ABCD heteromeric coiled coils 
discussed in this thesis. Peptide concentrations are indicated and each peptide in 
the mixture is present at the stated concentration. All ABAB spectra were 
measured at 5 °C and all ABCD spectra were measured at 20 °C. Thermal 
denaturation experiments were performed by heating (5–95 °C) and cooling 
samples (95–5 °C) while monitoring MRE222. All measurements were performed in 
1X PBS. High tension (HT) plots are shown below all CD spectra and have that 
same keys as the associated spectra. 




Figure 8-49 CD spectra (left) and temperature-dependent CD signal 













Figure 8-50 CD spectra (left) and temperature-dependent CD signal 
(right) for heteromer 1-LI-AB-g.   
 
  
Figure 8-51 CD spectra (left) and temperature-dependent CD signal 












Figure 8-52 CD spectra (left) and temperature-dependent CD signal 
(right) for heteromer 2-LI-AB.   
 
  
Figure 8-53 CD spectra (left) and temperature-dependent CD signal 












Figure 8-54 CD spectra (left) and temperature-dependent CD signal 
(right) for heteromer 1-LV-AB.   
 
  
Figure 8-55 CD spectra (left) and temperature-dependent CD signal 












Figure 8-56 CD spectra (left) and temperature-dependent CD signal 
(right) for heteromer 3-LV-AB.   
 
  
Figure 8-57 CD spectra (left) and temperature-dependent CD signal 












Figure 8-58 CD spectra (left) and temperature-dependent CD signal 
(right) for heteromer 1-L1-A/2-LV-B.   
 
  
Figure 8-59 CD spectra (left) and temperature-dependent CD signal 












Figure 8-60 CD spectra (left) and temperature-dependent CD signal 
(right) for heteromer 1-LV-A/1-LI-B.   
 
  
Figure 8-61 CD spectra (left) and temperature-dependent CD signal 












Figure 8-62 CD spectra (left) and temperature-dependent CD signal 
(right) for heteromer 3-LV-A/1-LI-B.   
 
  
Figure 8-63 CD spectra (left) and temperature-dependent CD signal 












Figure 8-64 CD spectra (left) and temperature-dependent CD signal 
(right) for heteromer 2-LV-A/2-LI-B.   
 
  
Figure 8-65 CD spectra (left) and temperature-dependent CD signal 












Figure 8-66 CD spectra (left) and temperature-dependent CD signal 
(right) for heteromer 3-LV-A/3-LI-B.   
 
  
Figure 8-67 CD spectra (left) and temperature-dependent CD signal 











Figure 8-68 CD spectra (left) and temperature-dependent CD signal 
(right) for heteromer 2-LVA-AB.   
 
  















Figure 8-69 CD spectra (top) and HT traces (bottom) for 
heterotetramer 1-LV-AB where each peptide was present at (a) 1 µM or (c) 
5 µM each. Thermal denaturation experiments (top) and temperature 
dependent HT traces (bottom) for heterotetramer 1-LV-AB where each 
peptide was present at 1 (b) or 5 (d) µM each. Measurements were 
performed in 10 mM sodium phosphate buffer in the presence of 0.0 or 1.0 





















Figure 8-70 CD spectra (top) and HT traces (bottom) for (a) 1-LV-A 
and (b) 1-LV-B where each peptide was present at 5 µM. Measurements 
were performed in 10 mM sodium phosphate buffer in the presence of 0.0 or 
1.0 M NaCl.  
 
  








Figure 8-71 CD spectra at 20 °C (left) and temperature-dependent 




Figure 8-72 CD spectra at 20 °C (left) and temperature-dependent 
CD signal (right) for ABCD heteromer 5678.   
 
  
















Figure 8-73 CD spectra at 20 °C for off-target ABCD heteromers 12 
(a), 13 (b), 14 (c), 23 (d), 24 (e) and 34 (f). 
















Figure 8-74 CD spectra at 20 °C for off-target ABCD heteromers 56 
(a), 57 (b), 58 (c), 67 (d), 68 (e) and 78 (f). 















Figure 8-75 CD spectra at 20 °C for off-target ABCD heteromers 123 
(a), 124 (b), 134 (c) and 234 (d). 
 
  















Figure 8-76 CD spectra at 20 °C for off-target ABCD heteromers 567 
(a), 568 (b), 578 (c) and678 (d). 
 
  




8.5 Analytical ultracentrifugation data 
8.5.1 Homomers  
  
Figure 8-77 AUC data for CC-Tet-KE ( v̅ = 0.7696 cm3.g-1). Left: 
sedimentation velocity (SV) continuous c(s) distribution fits (top) and 
residuals (bottom) at 50 krpm returning s = 1.06, s20,w =1.09, f/f0 = 1.33 and 
Mw = 10491 Da (3.11 x monomer mass). Right, top: Sedimentation 
equilibrium (SE) data (circles) fitted to single-ideal species model curves 
(black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm (blue), returning 
Mw = 9561 Da (2.83 x monomer mass, 99 % confidence limits: 9502-9619 
Da). Right, bottom: residuals for the above fit, same colours. Predicted 
molecular weights are also indicated in figure insets. Pred. mass, predicted 
mass; mono. mass, (mean) monomer mass.  
  
Figure 8-78 AUC data for CC-Tet-KE-N-4.5 (v̅ = 0.7673 cm3.g-1). Left: 
SV continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.11, s20,w = 1.14, f/f0 = 1.28 and Mw = 10349 Da (2.86 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 10650 Da (2.95 x monomer mass, 99 % confidence 
limits: 10581-10721 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 





Figure 8-79 AUC data for CC-Tet-IA (v̅ = 0.7595 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 0.83, s20,w = 0.85, f/f0 = 1.30 and Mw = 6485 Da (1.97 x monomer 
mass). Right, top: SE data (circles) fitted to single-ideal species model curves 
(black lines) at 33 krpm (red), 36 krpm (green) and 39 krpm (blue), returning 
Mw = 6188 Da (1.88 x monomer mass, 99 % confidence limits: 6137-6238 
Da). Right, bottom: residuals for the above fit, same colours. Predicted 
molecular weights are also indicated in figure insets. Pred. mass, predicted 
mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-80 AUC data for 1-LI-EK ( v̅  = 0.7669 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.25, s20,w = 1.28, f/f0 = 1.32 and Mw = 12931 Da (3.98 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 12140 Da (3.74 x monomer mass, 99 % confidence 
limits: 12091-12186 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 





Figure 8-81 AUC data for 1-LI-KE ( v̅  = 0.7669 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.23, s20,w = 1.26, f/f0 = 1.23 and Mw = 11328 Da (3.49 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 11310 Da (3.48 x monomer mass, 99 % confidence 
limits: 11253-11361 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-82 AUC data for 2-LI-EK ( v̅  = 0.7545 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.44, s20,w = 1.47, f/f0 = 1.25 and Mw = 13381 Da (3.85 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 13600 Da (3.91 x monomer mass, 99 % confidence 
limits: 13506-13687 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 





Figure 8-83 AUC data for 2-LI-KE ( v̅  = 0.7545 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.46, s20,w = 1.49, f/f0 = 1.29 and Mw = 14405 Da (4.15 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 34 krpm (green) and 38 krpm 
(blue), returning Mw = 13150 Da (3.78 x monomer mass, 99 % confidence 
limits: 13092-13182 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-84 AUC data for 3-LI-EK ( v̅  = 0.7545 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.43, s20,w = 1.47, f/f0 = 1.32 and Mw = 14523 Da (4.18 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 34 krpm (green) and 38 krpm 
(blue), returning Mw = 13420 Da (3.86 x monomer mass, 99 % confidence 
limits: 13338-13437 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 





Figure 8-85 AUC data for 3-LI-KE ( v̅  = 0.7545 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.46, s20,w = 1.49, f/f0 = 1.21 and Mw = 13119 Da (3.78 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 34 krpm (green) and 38 krpm 
(blue), returning Mw = 13220 Da (3.80 x monomer mass, 99 % confidence 
limits: 13190-13284 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-86 AUC data for 4-LI-EK ( v̅  = 0.7594 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.60, s20,w = 1.63 f/f0 = 1.20 and Mw = 15289 Da (4.13 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 15040 Da (4.06 x monomer mass, 99 % confidence 
limits: 14990-15099 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 





Figure 8-87 AUC data for 4-LI-KE ( v̅  = 0.7594 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.55, s20,w = 1.59, f/f0 = 1.24 and Mw = 15433 Da (4.17 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 15140 Da (4.09 x monomer mass, 99 % confidence 
limits: 15074-15200 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-88 AUC data for 1-LV-KE ( v̅  = 0.7595 cm3.g-1). Left: 
sedimentation velocity continuous c(s) distribution fits (top) and residuals 
(bottom) at 50 krpm returning s = 1.03, s20,w = 1.05, f/f0 = 1.25 and Mw = 8410 
Da (2.64 x monomer mass). Right, top: SE data (circles) fitted to single-ideal 
species model curves (black lines) at 33 krpm (red), 36 krpm (green) and 39 
krpm (blue), returning Mw = 7585 Da (2.38 x monomer mass, 99 % 
confidence limits: 7530-7639 Da). Right, bottom: residuals for the above fit, 
same colours. Predicted molecular weights are also indicated in figure insets. 
Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 





Figure 8-89 AUC data for 2-LV-EK ( v̅  = 0.7474 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.13, s20,w = 1.15, f/f0 = 1.32 and Mw = 9662 Da (2.83 x monomer 
mass). Right, top: SE data (circles) fitted to single-ideal species model curves 
(black lines) at 30 krpm (red), 34 krpm (green) and 38 krpm (blue), returning 
Mw = 9285 Da (2.72 x monomer mass, 99 % confidence limits: 9189-9332 
Da). Right, bottom: residuals for the above fit, same colours. Predicted 
molecular weights are also indicated in figure insets. Pred. mass, predicted 
mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-90 AUC data for 2-LV-KE ( v̅  = 0.7474 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.34, s20,w = 1.37, f/f0 = 1.28 and Mw = 11889 Da (3.48 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 11060 Da (3.23 x monomer mass, 99 % confidence 
limits: 11019-11094 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 





Figure 8-91 SV data for 3-LV-KE (v̅ = 0.7474 cm3.g-1). Continuous 
c(s) distribution fits (top) and residuals (bottom) at 50 krpm returning s = 0.51, 
s20,w = 0.52, f/f0 = 1.58 and Mw = 3861 Da (1.13 x monomer mass). Predicted 
molecular weight is also indicated in figure inset. Pred. mass, predicted 





Figure 8-92 AUC data for 2-LIA-EK (v̅ = 0.7669 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.27, s20,w = 1.30, f/f0 = 1.26 and Mw = 12479 Da (3.84 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 34 krpm (green) and 38 krpm 
(blue), returning Mw = 12390 Da (3.82 x monomer mass, 99 % confidence 
limits: 12337-12492 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 
 





Figure 8-93 AUC data for 2-LIA-KE (v̅ = 0.7669 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.34, s20,w = 1.37, f/f0 = 1.25 and Mw = 13277 Da (4.09 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 33 krpm (red), 36 krpm (green) and 39 krpm 
(blue), returning Mw = 12810 Da (3.95 x monomer mass, 99 % confidence 
limits: 12773-12851 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-94 AUC data for ELAEIK ( v̅  = 0.7697 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.40, s20,w = 1.43, f/f0 = 1.28 and Mw = 14924 Da (4.29 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 14060 Da (4.04 x monomer mass, 99 % confidence 
limits: 13992-14121 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 




8.5.2 ABAB homomers 
 
Figure 8-95 SE data for 1-LI-A (v̅ = 0.7591 cm3.g-1). Data (circles) 
fitted to single-ideal species model curves (black lines) at 54 krpm (red), 57 
krpm (green) and 60 krpm (blue), returning Mw = 3591 Da (1.10 x monomer 
mass, 99 % confidence limits: 3577-3605 Da). Bottom: residuals for the 
above fit, same colours. Predicted molecular weight is also indicated in figure 
inset. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-96 AUC data for 2-LI-A ( v̅  = 0.7473 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.30, s20,w = 1.33, f/f0 = 1.25 and Mw = 10955 Da (3.15 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 10270 Da (2.95 x monomer mass, 99 % confidence 
limits: 10212-10331 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 
 






Figure 8-97 AUC data for 3-LI-A ( v̅  = 0.7473 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.47, s20,w = 1.50, f/f0 = 1.24 and Mw = 13029 Da (3.75 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 11420 Da (3.28 x monomer mass, 99 % confidence 
limits: 11382-11466 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 




Figure 8-98 SE data for 1-LI-B (v̅ = 0.7926 cm3.g-1). Data (circles) 
fitted to single-ideal species model curves (black lines) at 54 krpm (red), 57 
krpm (green) and 60 krpm (blue), returning Mw = 3154 Da (0.97 x monomer 
mass, 99 % confidence limits: 3132-3177 Da). Bottom: residuals for the 
above fit, same colours. Predicted molecular weight is also indicated in figure 
inset. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 






Figure 8-99 AUC data for 2-LI-B ( v̅  = 0.7785 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.17, s20,w = 1.20, f/f0 = 1.22 and Mw = 11299 Da (2.36 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 11080 Da (3.19 x monomer mass, 99 % confidence 
limits: 10997-11169 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-100 AUC data for 3-LI-B ( v̅  = 0.7785 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.08, s20,w = 1.11, f/f0 = 1.32 and Mw = 11379 Da (3.28 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 10370 Da (2.99 x monomer mass, 99 % confidence 
limits: 10591-10771 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 






Figure 8-101 SE data for 1-LV-A (v̅ = 0.7516 cm3.g-1). Data (circles) 
fitted to single-ideal species model curves (black lines) at 54 krpm (red), 57 
krpm (green) and 60 krpm (blue), returning Mw = 3335 Da (1.04 x monomer 
mass, 99 % confidence limits: 3325-3345 Da). Bottom: residuals for the 
above fit, same colours. Predicted molecular weight is also indicated in figure 




Figure 8-102 SE data for 2-LV-A (v̅ = 0.7401 cm3.g-1). Data (circles) 
fitted to single-ideal species model curves (black lines) at 54 krpm (red), 57 
krpm (green) and 60 krpm (blue), returning Mw = 3615 Da (1.06 x monomer 
mass, 99 % confidence limits: 3601-3630 Da). Bottom: residuals for the 
above fit, same colours. Predicted molecular weight is also indicated in figure 
inset. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 
 






Figure 8-103 SE data for 3-LV-A (v̅ = 0.7401 cm3.g-1). Data (circles) 
fitted to single-ideal species model curves (black lines) at 54 krpm (red), 57 
krpm (green) and 60 krpm (blue), returning Mw = 3422 Da (1.00 x monomer 
mass, 99 % confidence limits: 3409-3435 Da). Bottom: residuals for the 
above fit, same colours. Predicted molecular weight is also indicated in figure 




Figure 8-104 SE data for 1-LV-B (v̅ = 0.7857 cm3.g-1). Data (circles) 
fitted to single-ideal species model curves (black lines) at 54 krpm (red), 57 
krpm (green) and 60 krpm (blue), returning Mw = 3219 Da (1.01 x monomer 
mass, 99 % confidence limits: 3206-3231 Da). Bottom: residuals for the 
above fit, same colours. Predicted molecular weight is also indicated in figure 
inset. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 
 
 






Figure 8-105 SE data for 2-LV-B (v̅ = 0.7718 cm3.g-1). Data (circles) 
fitted to single-ideal species model curves (black lines) at 54 krpm (red), 57 
krpm (green) and 60 krpm (blue), returning Mw = 3646 Da (1.07 x monomer 
mass, 99 % confidence limits: 3634-3658 Da). Bottom: residuals for the 
above fit, same colours. Predicted molecular weight is also indicated in figure 





Figure 8-106 SE data for 3-LV-B (v̅ = 0.7718 cm3.g-1). Data (circles) 
fitted to single-ideal species model curves (black lines) at 54 krpm (red), 57 
krpm (green) and 60 krpm (blue), returning Mw = 3655 Da (1.07 x monomer 
mass, 95 % confidence limits: 3636-3675 Da). Bottom: residuals for the 
above fit, same colours. Predicted molecular weight is also indicated in figure 
inset. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 
 






Figure 8-107 SE data for 1-LI-A* (v̅ = 0.7481 cm3.g-1). Data (circles) 
fitted to single-ideal species model curves (black lines) at 54 krpm (red), 57 
krpm (green) and 60 krpm (blue), returning Mw = 3289 Da (1.04 x monomer 
mass, 99 % confidence limits: 3279-3300 Da). Bottom: residuals for the 
above fit, same colours. Predicted molecular weight is also indicated in figure 





Figure 8-108 SE data for 1-LI-B* (v̅ = 0.7825 cm3.g-1). Data (circles) 
fitted to single-ideal species model curves (black lines) at 54 krpm (red), 57 
krpm (green) and 60 krpm (blue), returning Mw = 3364 Da (1.06 x monomer 
mass, 99 % confidence limits: 3353-3376 Da). Bottom: residuals for the 
above fit, same colours. Predicted molecular weight is also indicated in figure 
inset. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 
 





Figure 8-109 AUC data for 2-LIA-A ( v̅  = 0.7591 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.47, s20,w = 1.50, f/f0 = 1.24 and Mw = 14245 kDa (4.38 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 13520 Da (4.16 x monomer mass, 99 % confidence 
limits: 13466-13582 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-110 AUC data for 2-LVA-A ( v̅  = 0.7516 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.42, s20,w = 1.46, f/f0 = 1.29 and Mw = 13605 Da (4.26 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 34 krpm (green) and 38 krpm 
(blue), returning Mw = 12250 Da (3.83 x monomer mass, 99 % confidence 
limits: 12190-12316 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 





Figure 8-111 AUC data for 2-LIA-B ( v̅  = 0.7926 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.31, s20,w = 1.35, f/f0 = 1.19 and Mw = 14542 Da (4.48 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 14680 Da (4.53 x monomer mass, 99 % confidence 
limits: 14608-14759 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-112 AUC data for 2-LVA-B ( v̅  = 0.7857 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.13, s20,w = 1.16, f/f0 = 1.32 and Mw = 12749 Da (4.00 x 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 34 krpm (green) and 38 krpm 
(blue), returning Mw = 14110 Da (4.43 x monomer mass, 99 % confidence 
limits: 14044-14170 Da). Right, bottom: residuals for the above fit, same 
colours. Predicted molecular weights are also indicated in figure insets. Pred. 
mass, predicted mass; mono. mass, (mean) monomer mass. 




8.5.3 ABAB heteromers 
  
Figure 8-113 AUC data for 1-LI-AB ( v̅  = 0.7780 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.29, s20,w = 1.33, f/f0 = 1.20 and Mw = 12772 Da (3.93 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 13190 Da (4.06 x mean monomer mass, 99 % 
confidence limits: 13107-13276 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-114 AUC data for 1-LI-AB-g (v̅ = 0.7780 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.60, s20,w = 1.63, f/f0 = 1.20 and Mw = 13698 Da (4.22 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 12820 Da (3.95 x mean monomer mass, 99 % 
confidence limits: 12757-12892 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 





Figure 8-115 AUC data for 2-LI-AB ( v̅  = 0.7649 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.39, s20,w = 1.42, f/f0 = 1.25 and Mw = 13697 Da (3.94 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 13640 Da (3.93 x mean monomer mass, 99 % 
confidence limits: 13583-13703 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-116 AUC data for 3-LI-AB ( v̅  = 0.7649 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning a major product with s = 1.51, s20,w = 1.55, f/f0 = 1.16 and Mw = 
14025 Da (4.04 x mean monomer mass) and a minor product with s = 2.42, 
s20,w = 2.48, f/f0 = 1.16 and Mw = 28384 Da (8.17 x monomer mass). Right, 
top: SE data (circles) fitted to single-ideal species model curves (black lines) 
at 30 krpm (red), 33 krpm (green) and 36 krpm (blue), returning Mw = 14180 
Da (4.08 x mean monomer mass, 99 % confidence limits: 14118-14252 Da). 
Right, bottom: residuals for the above fit, same colours. Predicted molecular 
weights are also indicated in figure insets. Pred. mass, predicted mass; 
mono. mass, (mean) monomer mass. 





Figure 8-117 AUC data for 1-LV-AB ( v̅  = 0.7708 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.25, s20,w = 1.28, f/f0 = 1.27 and Mw = 12589 Da (3.95 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 34 krpm (green) and 38 krpm 
(blue), returning Mw = 12110 Da (3.80 x mean monomer mass, 99 % 
confidence limits: 12058-12154 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-118 AUC data for 2-LV-AB ( v̅  = 0.7580 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.39, s20,w = 1.42, f/f0 = 1.28 and Mw = 13552 Da (3.96 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 27 krpm (red), 30 krpm (green) and 33 krpm 
(blue), returning Mw = 13290 Da (3.89 x mean monomer mass, 99 % 
confidence limits: 13183-13396 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 





Figure 8-119 AUC data for 3-LV-AB ( v̅  = 0.7580 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.43, s20,w = 1.46, f/f0 = 1.29 and Mw = 14363 Da (4.20 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 12910 Da (3.78 x mean monomer mass, 99 % 
confidence limits: 12840-12982 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-120 AUC data for 1-LV-AB in 10 mM sodium phosphate (pH 
7.4) in the presence of 0.0 M NaCl (v̅ = 0.7708 cm3.g-1). Left: SV continuous 
c(s) distribution fits (top) and residuals (bottom) at 50 krpm returning s = 1.38, 
s20,w = 1.39, f/f0 = 1.20 and Mw = 13080 Da (4.10 x mean monomer mass). 
Right, top: SE data (circles) fitted to single-ideal species model curves (black 
lines) at 30 krpm (red), 33 krpm (green) and 36 krpm (blue), returning Mw = 
12730 Da (3.99 mean monomer mass, 99 % confidence limits: 12664-12788 
Da). Right, bottom: residuals for the above fit, same colours. Predicted 
molecular weights are also indicated in figure insets. Pred. mass, predicted 
mass; mono. mass, (mean) monomer mass. 





Figure 8-121 AUC data for 1-LV-AB in 10 mM sodium phosphate (pH 
7.4) in the presence of 1.0 M NaCl (v̅ = 0.7708 cm3.g-1). Left: SV continuous 
c(s) distribution fits (top) and residuals (bottom) at 50 krpm returning s = 
0.992, s20,w = 1.27, f/f0 = 1.24 and Mw = 11979 Da (3.75 x mean monomer 
mass). Right, top: SE data (circles) fitted to single-ideal species model curves 
(black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm (blue), returning 
Mw = 11650 Da (3.65 mean monomer mass, 99 % confidence limits: 11592-
11715 Da). Right, bottom: residuals for the above fit, same colours. Predicted 
molecular weights are also indicated in figure insets. Pred. mass, predicted 
mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-122 AUC data for 1-LI-A/1-LV-B (v̅ = 0.7745 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.29, s20,w = 1.32, f/f0 = 1.22 and Mw = 12737 Da (3.96 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 34 krpm (green) and 38 krpm 
(blue), returning Mw = 12150 Da (3.77 x mean monomer mass, 99 % 
confidence limits: 12091-12213 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 





Figure 8-123 AUC data for 1-LV-A/1-LI-B (v̅ = 0.7745 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.28, s20,w = 1.31, f/f0 = 1.21 and Mw = 12530 Da (3.89 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 34 krpm (green) and 38 krpm 
(blue), returning Mw = 12530 Da (3.89 x mean monomer mass, 99 % 
confidence limits: 12492-12592 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-124 AUC data for 2-LI-A/2-LV-B (v̅ = 0.7615 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.38, s20,w = 1.41, f/f0 = 1.29 and Mw = 13931 Da (4.04 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 34 krpm (green) and 38 krpm 
(blue), returning Mw = 12600 Da (3.66 x mean monomer mass, 99 % 
confidence limits: 12529-12681 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 





Figure 8-125 AUC data for 2-LV-A/2-LI-B (v̅ = 0.7615 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.38, s20,w = 1.42, f/f0 = 1.26 and Mw = 13594 Da (3.94 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 34 krpm (green) and 38 krpm 
(blue), returning Mw = 12890 Da (3.74 x mean monomer mass, 99 % 
confidence limits: 12827-12948 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-126 AUC data for 3-LI-A/3-LV-B (v̅ = 0.7615 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.43, s20,w = 1.47, f/f0 = 1.23 and Mw = 13733 Da (3.98 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 13840 Da (4.02 x mean monomer mass, 99 % 
confidence limits: 13779-13899 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 





Figure 8-127 AUC data for 3-LV-A/3-LI-B ( v̅  = 0.7615 cm3.g-1). SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.44, s20,w = 1.47, f/f0 = 1.23 and Mw = 13843 Da (4.02 x mean 
monomer mass). Predicted molecular weight is also indicated in figure inset. 





Figure 8-128 AUC data for 1-LI-A/2-LV-B (v̅ = 0.7677 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.34, s20,w = 1.38, f/f0 = 1.23 and Mw = 13025 Da (3.91 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 12650 Da (3.80 x mean monomer mass, 99 % 
confidence limits: 12589-12717 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 
 





Figure 8-129 AUC data for 1-LI-A/3-LV-B (v̅ = 0.7677 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.32, s20,w = 1.35, f/f0 = 1.27and Mw = 13295 Da (3.99 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 13300 Da (3.99 x mean monomer mass, 99 % 
confidence limits: 13253-13356 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-130 AUC data for 2-LV-A/1-LI-B (v̅ = 0.7615 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.32, s20,w = 1.35, f/f0 = 1.26 and Mw = 13128 Da (3.94 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 27 krpm (red), 30 krpm (green) and 33 krpm 
(blue), returning Mw = 13400 Da (4.02 x mean monomer mass, 99 % 
confidence limits: 13280-13517 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 





Figure 8-131 AUC data for 3-LV-A/1-LI-B (v̅ = 0.7677 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.34, s20,w = 1.37 f/f0 = 1.21 and Mw = 12723 Da (3.82 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 12610 Da (3.78 x mean monomer mass, 99 % 
confidence limits: 12558-12659 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-132 AUC data for 2-LIA-AB (v̅ = 0.7780 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.28, s20,w = 1.32, f/f0 = 1.25 and Mw = 13445 Da (4.14 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 12810 Da (3.95 x mean monomer mass, 99 % 
confidence limits: 12757-12872 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 





Figure 8-133 AUC data for 2-LVA-AB (v̅ = 0.7708 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.37, s20,w = 1.40, f/f0 = 1.19 and Mw = 12945 Da (4.06 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 34 krpm (green) and 38 krpm 
(blue), returning Mw = 12360 Da (3.87 x mean monomer mass, 99 % 
confidence limits: 12300-12418 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 




Figure 8-134 SV data for 1-LI-AB* (v̅ = 0.7675 cm3.g-1). Continuous 
c(s) distribution fits (top) and residuals (bottom) at 50 krpm returning s = 0.56, 
s20,w = 0.58, f/f0 = 1.41 and Mw = 4335 Da (1.37 x mean monomer mass). 
Predicted molecular weight is also indicated in figure inset. Pred. mass, 
predicted mass; mono. mass, (mean) monomer mass. 




8.5.4 ABCD heteromers 
  
Figure 8-135 AUC data for 1234 ( v̅  = 0.7665 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.05, s20,w = 1.08, f/f0 = 1.30 and Mw = 9743 Da (3.03 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 34 krpm (green) and 38 krpm 
(blue), returning Mw = 9127 Da (2.84 x mean monomer mass, 99 % 
confidence limits: 9078-9177 Da). Right, bottom: residuals for the above fit, 
same colours. Predicted molecular weights are also indicated in figure insets. 
Pred. mass, predicted mass; mono. mass, (mean) monomer mass. 
 
  
Figure 8-136 AUC data for 5678 ( v̅  = 0.7555 cm3.g-1). Left: SV 
continuous c(s) distribution fits (top) and residuals (bottom) at 50 krpm 
returning s = 1.13, s20,w = 1.15, f/f0 = 1.38 and Mw = 10884 Da (3.12 x mean 
monomer mass). Right, top: SE data (circles) fitted to single-ideal species 
model curves (black lines) at 30 krpm (red), 33 krpm (green) and 36 krpm 
(blue), returning Mw = 10170 Da (2.91 x mean monomer mass, 99 % 
confidence limits: 10122-10222 Da). Right, bottom: residuals for the above 
fit, same colours. Predicted molecular weights are also indicated in figure 
insets. Pred. mass, predicted mass; mono. mass, (mean) monomer mass.  




8.6 X-ray crystallography conditions, data collection statistics 
and refinement statistics 
 
Peptide Buffer pH Salt Precipitant 
2-LI-EK 0.1 M PCTP 7.0 - 
25 % (w/v) PEG 
1500 
3-LI-EK 
0.1 M Sodium 
HEPES 
7.5 
0.2 M Sodium 
citrate tribasic 
dihydrate 
20 % (v/v) 2-
propanol 
ELAEIK 
0.08 M sodium 
cacodylate 
6.5 
0.16 M calcium 
acetate 
14.4 % w/v PEG 
8000, 20 % v/v 
glycerol 
Table 8-2 Crystallisation buffer conditions for peptide X-ray crystal 
structures. PEG, polyethylene glycol; HEPES, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid. PCTP: sodium propionate, sodium 
cacodylate trihydrate, bis-tris propane. 
  





Wavelength (Å) 0.9763 
Beamline (Diamond, UK) i03 
Space Group C222 
Cell Dimensions 
a, b, c (Å) 47.56, 50.84, 43.94 
α, β, γ (°) 90, 90, 90 
Resolution (Å) 43.94–1.70 (1.76–1.70) 
Rmerge 0.080 (0.303) 
Rmeas 0.091 (0.347) 
I/σI 12.8 (1.9) 
CC ½ (%) 99.0 (97.8) 
Completeness (%) 99.6 (100) 
Redundancy 7.9 (7.7) 
Wilson B Factor (Å2) 19.72 
Refinement 








Main chain/protein 21.698/ 27.883 
Water/ligand 41.816/53.858 
R.m.s.d 
Bond lengths (Å) 0.005 





Table 8-3 Data collection and refinement statistics for peptide 2-LI-EK. 
Overall data are shown with outer shell data given in parentheses.  
  





Wavelength (Å) 0.9795 
Beamline (Diamond, UK) i04 
Space Group P1211 
Cell Dimensions 
a, b, c (Å) 29.46, 48.55, 36.57 
α, β, γ (°) 90.00, 96.19, 90.00 
Resolution (Å) 48.55–1.11 (1.12–1.11) 
Rmerge 0.051 (0.908) 
Rmeas 0.062 (1.127) 
I/σI 12.7 (1.9) 
CC ½ (%) 99.8 (62.9) 
Completeness (%) 94.5 (90.6) 
Redundancy 6.1 (5.3) 
Wilson B Factor (Å2) 12.88 
Refinement 








Main chain/protein 15.982/18.938 
Water 36.699 
R.m.s.d 
Bond lengths (Å) 0.005 





Table 8-4 Data collection and refinement statistics for peptide 3-LI-EK. 
Overall data are shown with outer shell data given in parentheses.  
  





Wavelength (Å) 0.9282 
Beamline (Diamond, UK) i04-1 
Space Group P21212 
Cell Dimensions 
a, b, c (Å) 35.110, 40.040, 44.590 
α, β, γ (°) 90, 90, 90 
Resolution (Å) 29.79–1.44 (1.49–1.44) 
Rmerge 0.068 (0.862) 
Rmeas 0.080 (1.021) 
I/σI 11.4 (1.4) 
CC ½ (%) 0.999 (0.99) 
Completeness (%) 96.0.7 (96.4) 
Redundancy 6.0 (6.3) 
Wilson B Factor (Å2) 16.79 
Refinement 








Main chain/protein 20.6015/34.8105 
Water 40.515/53.512 
R.m.s.d 
Bond lengths (Å) 0.009 





Table 8-5 Data collection and refinement statistics for peptide ELAEIK. 
Overall data are shown with outer shell data given in parentheses.  
  




8.7 Plasmid maps 
All plasmids included in this work are listed in Table 8-6. Selected plasmid maps 
are shown in Figures 8-137 to 8-155. Plasmid maps were generated using 
SnapGene Viewer.  
No. Name Size (bp) 
Resistance 
gene 
1 pVRb-LacUV5-SFGFP 4318 KanR 
2 pVRb-O1O1-LacUV5-SFGFP 4404 KanR 
3 pBAD-LacI-WT 5152 AmpR 
4 pBAD-LacI-L251 5092 AmpR 
5 pBAD-LacI-L251A-WTtet 5152 AmpR 
6 pVRc-LacI-L251A 5943 CmR 
7 pBAD-LacI-L251A 5092 AmpR 
8 pBAD-LacI-ΔHTH 4951 AmpR 
9 pBAD-LacI-ΔHTH-L251A 4951 AmpR 
10 pBAD-6H-SUMO 4324 AmpR 
11 pBAD-6H-T7-Xpress 4099 AmpR 
12 pBAD-6H 4030 AmpR 
13 pBAD-LacI-L251A-ccDi 5178 AmpR 
14 pVRc-LacI-L251A-A1 6029 CmR 
15 pVRc-LacI-L251A-A2 6029 CmR 
16 pVRc-LacI-L251A-A3 6029 CmR 
17 pVRc-LacI-L251A-A1* 6029 CmR 
18 pBAD-LacI-L251A-A1 5178 AmpR 
19 pVRc-LacI-L251A-B1 6029 CmR 
20 pBAD-LacI-L251A-B1 5178 AmpR 
21 pBAD-LacI-L251A-B2 5178 AmpR 
22 pBAD-LacI-L251A-B3 5178 AmpR 
23 pBAD-LacI-L251A-B1* 5178 AmpR 
24 pBAD-LacI-ΔHTH-B1 5037 AmpR 
25 pBAD-LacI-ΔHTH-L251A-B1 5037 AmpR 
26 pBAD-6H-SUMO-B1 4410 AmpR 
27 pBAD-6H-SUMO-B2 4410 AmpR 
28 pBAD-6H-SUMO-B3 4410 AmpR 
29 pBAD-6H-T7-Xpress-B1 4185 AmpR 
30 pBAD-6H-B1 4116 AmpR 
31 pBAD-6H-B2 4116 AmpR 
32 pBAD-6H-B3 4116 AmpR 




33 pBAD-LacI-L251A-Y282A-Wttet 5152 AmpR 
34 pBAD-LacI-L251A-Y282D-Wttet 5152 AmpR 
35 pBAD-LacI-L251A-Y282A 5092 AmpR 
36 pBAD-LacI-L251A-Y282D 5092 AmpR 
37 pVRc-LacI-L251A-Y282A 5943 CmR 
38 pBAD-LacI-L251A-Y282A-ccDi 5178 AmpR 
39 pBAD-LacI-L251A-Y282D-ccDi 5178 AmpR 
40 pVRc-LacI-L251A-Y282A-A1 6029 CmR 
41 pBAD-LacI-L251A-Y282A-B1 5178 AmpR 
42 pBAD-pro1-LacI-L251A 4046 AmpR 
43 pBAD-pro1-LacI-L251A-ccDi 4132 AmpR 
44 pVRc-pro1-LacI-L251A 4897 CmR 
45 pVRc-pro1-LacI-L251A-A1 4983 CmR 
46 pVRc-pro1-LacI-L251A-Y282A 4897 CmR 
47 pVRc-pro1-LacI-L251A-Y282A-A1 4983 CmR 
48 pBAD-pro5-LacI-L251A 4046 AmpR 
49 pBAD-pro5-LacI-L251A-ccDi 4132 AmpR 
50 pE-SUMOpro-Kan-LbCpf1 9285 KanR 
Table 8-6 Names, sizes and antibiotic resistance markers of all plasmids 
discussed in this thesis. Plasmid sizes are in bp. KanR encodes an 
aminoglycoside phosphotransferase for resistance to kanamycin (an inhibitor 
of ribosomal synthesis in gram negative bacteria, binds 30S ribosomal 
subunit). CmR encodes chloramphenicol acetyltransferase for resistance to 
chloramphenicol (an inhibitor of ribosomal synthesis in gram negative 
bacteria, binds 50S ribosomal subunit). AmpR encodes β-lactamase for 
resistance to ampicillin (an inhibitor of cell wall biogenesis in gram negative 
bacteria).  
  








Figure 8-137 Map of plasmid pVRb-LacUV5-SFGFP.  
 
 











Figure 8-139 Map for plasmids pBAD-LacI-WT (carries wild type lac 
repressor gene) and pBAD-LacI-L251A-WTtet (carries an L251A substitution 
in the Lac repressor protein). Residue 251 is labelled.  
 
 
Figure 8-140 Map of plasmid pBAD-LacI-L251A. Residue 251 is 
labelled. 






Figure 8-141 Map of plasmid pVRc-LacI-L251A. Residue 251 is 
labelled. 
 
Figure 8-142 Map of plasmids pBAD-LacI-L251A-A1, pBAD-LacI-
L251A-B1, pBAD-LacI-L251A-B2, pBAD-LacI-L251A-B3, pBAD-LacI-
L251A-B1* and pBAD-LacI-L251A-ccDi where “peptide” represents the 
position of the genes for A1, B1, B2, B3, B1* and ccDi, respectively. Residue 
251 is labelled. 





Figure 8-143 Map of plasmids pVRc-LacI-L251A-A1, pVRc-LacI-
L251A-A2, pVRc-LacI-L251A-A3, pVRc-LacI-L251A-A1* and pVRc-LacI-
L251A-B1 were “peptide” represents the position of the genes for A1, A2, A3, 
A1* and B1, respectively. Residue 251 is labelled. 
 
Figure 8-144 Map of plasmids pBAD-LacI-ΔHTH and pBAD-LacI-
ΔHTH-L251A. Residue 251 is labelled. 
 





Figure 8-145 Map of plasmids pBAD-LacI-ΔHTH-B1 and pBAD-LacI-
ΔHTH-L251A-B1. Residue 251 is labelled. 
 
 
Figure 8-146 Map of plasmid pBAD-6H-T7-Xpress.  
 











Figure 8-148 Map of plasmid pBAD-6H.  
 





Figure 8-149 Map of plasmids pBAD-6H-B1, pBAD-6H-B2 and pBAD-






Figure 8-150 Map of plasmid pBAD-6H-SUMO. 
 





Figure 8-151 Map of plasmids pBAD-6H-SUMO-B1, pBAD-6H-SUMO-
B2 and pBAD-6H-SUMO-B3 where “peptide” represents the position of the 




Figure 8-152 Map of plasmids pBAD-pro1-LacI-L251A and pBAD-
pro5-LacI-L251A where “pro” represents the position of the constitutive 
promoters pro1 and pro5, respectively. 
 





Figure 8-153 Map of plasmids pBAD-pro1-LacI-L251A-ccDi and 
pBAD-pro5-LacI-L251A-ccDi where “pro” represents the position of the 




Figure 8-154 Map of plasmids pVRc-pro1-LacI-L251A and pVRc-pro1-
LacI-L251A-Y282A. Residues 251 and 282 are labelled. 
 





Figure 8-155 Map of plasmids pVRc-pro1-LacI-L251A-A1 and pVRc-
pro1-LacI-L251A-Y282A-A1. Residues 251 and 282 are labelled.  




8.8 Proteins and linkers 
 
Protein Size (kDa) 
LacI (WT) 42.3 
LacI-Trunc 39.8 
LacI-L251A (LacI*-WTtet) 42.2 
LacI-L251A-Trunc (LacI*) 39.7 
LacI-L251A-A1 (LacI*-A1) 42.9 
LacI-L251A-A2 (LacI*-A2) 43.0 
LacI-L251A-A3 (LacI*-A3) 43.0 
LacI-L251A-A1* (LacI*-A1*) 42.8 
LacI-L251A-B1 (LacI*-B1) 42.9 
LacI-L251A-B2 (LacI*-B2) 43.0 
LacI-L251A-B3 (LacI*-B3) 43.0 
LacI-L251A-B1* (LacI*-B1*) 42.8 
LacI-L251A-ccDi (LacI*-ccDi) 42.9 
LacI-ΔHTH-Trunc (LacI-ΔHTH) 34.7 
LacI-ΔHTH-L251A-Trunc (LacI*-ΔHTH) 34.6 
LacI-ΔHTH-B1 (LacI-ΔHTH-B1) 37.8 
LacI-ΔHTH-L251A-B1 (LacI*-ΔHTH-B1) 37.7 
6H-SUMO (SUMO) 13.1 
6H-SUMO-B1 (SUMO-B1) 16.2 
6H-SUMO-B2 (SUMO-B2) 16.4 





6H-T7-Xpress (6H-Tags) 4.3 
6H-T7-Xpress-B1 (6H-Tags-B1) 7.5 
LacI-L251A-Y282A (LacIAA-WTtet) 42.1 
LacI-L251A-Y282D (LacIAD-WTtet) 42.2 
LacI-L251A-Y282A-Trunc (LacIAA) 39.6 
LacI-L251A-Y282D-Trunc (LacIAD) 39.7 
LacI-L251A-Y282A-ccDi (LacIAA-ccDi) 42.8 
LacI-L251A-Y282D-ccDi (LacIAD-ccDi) 42.8 
LacI-L251A-Y282A-A1 (LacIAA-A1) 42.8 
LacI-L251A-Y282A-B1 (LacIAA-B1) 42.8 
Table 8-7 Names and masses (kDa) of all proteins discussed in this thesis.  
  


















Figure 8-156 Representative C-terminal sequences demonstrating 
protein linker sequences. (a) Wild type Lac repressor (where linker and coiled 
coil regions were assigned by inspection of the crystal structure, PDB ID: 
1TLF 315). (b) C-terminally truncated Lac repressor. (c) C-terminally truncated 
Lac repressor fused to a de novo peptide. (d) SUMO. (e) SUMO fused to a 
de novo peptide. (f) 6His tag. (g) 6His tag fused to a de novo peptide. The 
sequence for de novo peptide B1 (aka 1-LI-B) is shown as an example. Six 
residues of each fusion partner (LacI, SUMO or 6H) are shown. Ellipses 
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